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Abstract——In contrast to nitric oxide, which has
well established and important roles in the regulation
of blood flow and thrombosis, neurotransmission, the
normal functioning of the genitourinary system, and
the inflammation responseandhostdefense, its oxidized
metabolites nitrite and nitrate have, until recently, been
considered to be relatively inactive. However, this view
has been radically revised over the past decade and
more.Much evidence has nowaccumulated demonstrat-
ing that nitrite serves as a storage form of nitric oxide,
releasing nitric oxide preferentially under acidic and/or
hypoxic conditions but also occurringunderphysiologic
conditions: a phenomenon that is catalyzed by a number
of distinct mammalian nitrite reductases. Importantly,
preclinical studies demonstrate that reduction of nitrite
to nitric oxide results in a number of beneficial effects,
including vasodilatation of blood vessels and lowering
of blood pressure, as well as cytoprotective effects that
limit the extent of damage caused by an ischemia/
reperfusion insult, with this latter issue having been
translated more recently to the clinical setting. In
addition, researchhasdemonstrated that theothermain
metabolite of the oxidation of nitric oxide (i.e., nitrate)
can also be sequentially reduced through processing
in vivo to nitrite and then nitrite to nitric oxide to exert
a range of beneficial effects—most notably lowering
of blood pressure, a phenomenon that has also been
confirmed recently to be an effective method for blood
pressure lowering in patients with hypertension. This
review will provide a detailed description of the
pathways involved in the bioactivation of both nitrate
and nitrite in vivo, their functional effects in preclinical
models, and their mechanisms of action, as well as a
discussion of translational exploration of this pathway
indiverse disease states characterized bydeficiencies in
bioavailable nitric oxide.
Significance Statement——The past 15 years has
seen a major revision in our understanding of the
pathways for nitric oxide synthesis in the body with
the discovery of the noncanonical pathway for nitric
oxide generation known as the nitrate-nitrite-nitric
oxide pathway. This review describes the molecular
components of this pathway, its role in physiology,
potential therapeutics of targeting this pathway, and
their impact in experimental models, as well as the
clinical translation (past and future) and potential
side effects.
I. Introduction
Nitric oxide (·NO) was discovered by the British
chemist Joseph Priestley simultaneous with his discov-
ery of oxygen in 1776. For the next 200 years, ·NO was
largely thought of as an unwanted, atmospheric pollut-
ant (Spicer, 1977). However, the discovery of mamma-
lian ·NO production and its protean effects on biologic
systems profoundly changed this view. The magnitude
of the importance of this shift in view is reflected by the
award of the Nobel Prize in Physiology or Medicine in
1998 to Furchgott, Ignarro, and Murad, which is shared
for their seminal roles in the discovery “concerning NO
as a signaling molecule in the cardiovascular system”
(https://www.nobelprize.org/prizes/medicine/1998/
summary). A PubMed search of the term ·NO identifies
one publication in 1816, which describes the unfortu-
nate event of poisoning with ·NO of quicksilver, rising to
a colossal 6670 publications in 2017, with the highest
number to date occurring in 2015, with 7277. These
numbers clearly demonstrate that interest in this
molecule and its biologic function really started to heat
up after the seminal 1980 paper describing “The oblig-
atory role of the endothelium…” and increasing expo-
nentially after the Nobel Prize award. But perhaps more
pertinently for this review, by the early 2000s, interest in
·NO, although still high, had plateaued until the more
recent 5–10 years, in which it is clear that there has been
a sudden boost in interest.We suggest that this reignited
interest comes in part from discoveries demonstrating
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the significant biologic activity of the nitrate-nitrite-
·NO pathway, which we now describe as the noncanon-
ical pathway for in vivo ·NO generation. Moreover, it
seems to us that interest in ·NO, by virtue of these
discoveries, is not going to abate any time soon (Fig. 1).
A. Chemistry of ·NO and Its Metabolism to Nitrite
and Nitrate
·NO is a small, diatomic, amphipathic, free-radical
molecule that is freely diffusible and membrane-
permeable. Although one of the simplest biologic mole-
cules, ·NO has relevant functions in almost every human
physiologic system, including critical roles in neurotrans-
mission, gastrointestinal (GI) physiology, genitourinary
function, innate immunity, and the cardiovascular (CV)
system (Moncada and Higgs, 1993).
There are three core properties of ·NO that deter-
mine its physical and chemical interactions and enable
generation of a range of ·NO and other nitrogen species
(Fig. 2): it is electrically neutral, it is small, and it has an
unpaired electron in a nonbonding molecular orbital.
The fundamental chemistry of ·NO is unique among all
other small-molecule signaling agents. Since ·NO
possesses an unpaired electron (i.e., it is paramagnetic),
it readily reacts with many other species that are also
paramagnetic. For example, ·NO reacts with dioxygen
(O2), superoxide (·O2
2), and nitrogen dioxide (NO2), as
well as oxidizing carbon/nitrogen-centered radicals that
would otherwise oxidize biologic molecules, potentially
causing an “oxidative stress” (vide infra). Indeed, the
ability of ·NO to react with and quench oxidizing radical
species is the basis of its antioxidant properties.
·NO also reacts with transition metals and, therefore,
in biologic systems, has numerous possible targets, i.e.,
molecules containing an iron heme moiety. The co-
ordination chemistry of ·NO is unique compared with
other small, diatomic molecules (e.g., O2, CO) in that it
can react with both ferric [Fe(III)] and ferrous [Fe(II)]
heme proteins (that contain an open coordination site).
Reaction with Fe(III)-hemes often results in reduction
to Fe(II)-hemes, with consequent generation of nitrite
(Fukuto et al., 2000). The coordination of ·NO with
Fe(II)-heme typically leads to the formation of a rela-
tively stable Fe(II)-NO complex. The primary biologic
target for ·NO is, indeed, the Fe(II)-heme protein soluble
guanylyl cyclase (Hobbs and Stasch, 2010) (GC-1, or
more commonly known as sGC [Alexander et al., 2019]).
Coordination of ·NO to the Fe(II)-heme of GC-1 results in
activation of the enzyme triggering generation of cyclic
GMP (cGMP). Importantly, the coordination chemistry
of ·NO with Fe(II)-hemes is unique among all small
diatomics; thus, only ·NO is capable of significantly
activatingGC-1 via heme coordination. ·NO can also react
with O2 bound to Fe(II)-heme [Fe(II)-hemeO2], such as
that found in oxyhemoglobin [oxyHb, Fe(II)HbO2] or
oxymyoglobin [oxyMb, Fe(II)MbO2], to give ferric Hb or
ferric myoglobin (Mb) [Fe(III)Hb, Fe(III)Mb, respectively]
and nitrate, a reaction described first by Hermann (1865),
cited in Gladwin et al. (2005) (eq. 1.1). Oxidative
termination of NO activity with Hb is as follows:
oxyHb nitric oxide metHb nitrate
FeðIIÞHbO2 1 NO   ⇒ FeðIIIÞHb 1 NO32 :
ð1:1Þ
It is now understood that the reaction of ·NOwith Fe(II)
HbO2 is relatively fast and provides a sink (6–8  107
Fig. 1. Number of publications per year for (upper) ×NO and (lower)
nitrate and nitrite. Figures highlight only some of the key observations in
the fields, and this is not an exhaustive list. Please see the text for greater
detail. EDRF, endothelium derived relaxing factor.
Fig. 2. Redox relationship of NO and other nitrogen species.
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M21 s21) for ·NO (Feelisch and Noack, 1987; Eich et al.,
1996; Herold et al., 2001). Since this reaction is so fast,
there were originally concerns that there was little
chance of ·NO expressing functional activity in vivo
(Lancaster, 1994); however, the discovery of a cell-free
layer of blood flowing adjacent to the endothelium (Liao
et al., 1999) and the recognition that the encapsulation
of Hb within the erythrocyte limits the speed of the
reaction because of the need for diffusion through the
erythrocyte membrane (Liu et al., 1998; Vaughn et al.,
1998, 2000;Han et al., 2002) have allayed these concerns,
for the most part.
Like all biologic molecules, ·NO moves only insomuch
that the probability of random diffusion is greater for
movement into a compartment with a lower concentra-
tion, resulting in net movement along a concentration
gradient. Hence, ·NOmoleculesmove away froma specific
point of generation. Since ·NO is electrically neutral, it
has a high diffusion coefficient [1027 cm2s21 (Vanderkooi
et al., 1994)] (Malinski et al., 1993) and may travel far
(100–200 mm) in a short time frame (Lancaster, 1994,
1997); however, because of its numerous interactions with
a number of diverse molecules (i.e., something to which it
can chemically react), this can greatly reduce its sphere
of biologic action (Lancaster, 1997).
·NO does not dimerize in gas or in solution and is
poorly soluble in water (1.57 mmol dm23 at 35°C)
(Hughes, 2008) and does not react with water (i.e.,
·NO is not electrophilic). ·NO is lipophilic, which allows
it to freely enter and accumulate in cell membranes.
Although ·NO has been characterized as a “highly
reactive” molecule, it is inherently stable in the pure
form. However, it can react readily with specific species,
such as those that also possess an unpaired electron. As
discussed previously, the unpaired electron of ·NO
makes it reactive with other paramagnetic species,
including O2, NO2 (Bonner and Hughes, 1988; Ignarro
et al., 1993), superoxide (Blough and Zafiriou, 1985),
and other “radicals,” such as those involved in delete-
rious oxidative events (Rubbo et al., 1996). In spite of
the fact that ·NO possesses an unpaired electron (and is
considered to be a “radical” species), it is important to
note that it is not an oxidizing radical (i.e., it does not
readily take electrons or abstract H-atoms) and, there-
fore, is distinct from other known radical oxidants, such
as NO2 or hydroxyl radical (HO·). Indeed, besides
coordination to metals, ·NO tends to react only with
other radicals that already exist or have been preformed
in solution (e.g., O2, superoxide, NO2, etc.). The reaction
of ·NO with O2 initially leads to the formation of NO2,
which is also a radical that is a relatively strong oxidant
and, like ·NO, will also react with other radicals such
as ·NO. The reaction of ·NO and NO2 results in the
formation of N2O3 (a nonradical species). In a purely
aqueous system,N2O3 can react withwater to give nitrite.
This series of chemical reactions is shown below (eq. 1.2).
Oxidation of NO in aqueous solutions is as follows:
dioxygen nitric oxide nitrogen dioxide
O2 1 2NO ⇒ 2NO2
nitrogen dioxide nitric oxide dinitrogen trioxide
NO2 1 NO ⇒ N2O3
dinitrogen trioxide
N2O3 1
water
H2O ⇒
nitrite
2NO22 1 2H1 :
ð1:2Þ
At biologically relevant levels of ·NO, this process is
very slow, as the overall reaction kinetics are second
order with respect to ·NO, making the O2-dependent
oxidation of ·NO to nitrite of limited importance (Li and
Lancaster, 2012). In pure aqueous solutions, ·NO is
slowly converted to nitrite, although there is evidence in
humans of a nitrite synthase function of the multifunc-
tion copper-containing protein caeruloplasmin facilitat-
ing this reaction (Shiva et al., 2006). The importance of
this reaction in vivo for termination of ·NO activity and
regulating basal ·NO levels is currently unclear. The
same reactivity of ·NO for transition metals has spurred
interest in developing transition metal–based scavengers
of ·NO, such as ruthenium complexes that are being
developed for use in situations in which large amounts
of inducible ·NO synthase (iNOS)-derived ·NO may be
detrimental, such as in tumor growth (Flitney et al., 2011).
In addition, and of particular relevance to this review,
is the potential for reduction of nitrite by deoxyHb
[Fe(II)Hb] to give ·NO (Cosby et al., 2003; Huang
et al., 2005b; Grubina et al., 2007), described below
(eq. 1.3). The reaction of NO22 with deoxyHb is as
follows:
However, how ·NO derived from nitrite reduction
within the erythrocyte in the presence of an excess of
oxyHb (even in relative hypoxia), a rapid ·NO scaven-
ger, escapes the erythrocyte is not clear. Some have
suggested that ·NO bioactivity is exported from eryth-
rocytes as dinitrogen trioxide after a nitrite anhydrase
reaction involving Hb (eqs. 1.4–1.6) and that, once
deoxyHb
FeðIIÞHb 1
nitrite
NO22 1
protons
2H1 5
metHb
FeðIIIÞHb 1
nitric oxide
NO
water
1H2O :
ð1:3Þ
696 Kapil et al.
outside, the erythrocyte can dissociate to ·NO and
nitrogen dioxide (Basu et al., 2007; Hopmann et al.,
2011). It should be noted that ·NO made via these
reactions represents a disproportionation (one species is
oxidized, whereas the other is reduced) and not an
overall reduction reaction. NO22 acidification to form
HNO2 is as follows:
nitrite
NO22 1
 
proton
H1 ⇔
nitrous acid
HNO2 :
ð1:4Þ
Dehydration of HNO2 is
nitrous acid
2 HNO2 ⇔
water
H2O 1
dinitrogen trioxide
N2O3 :
ð1:5Þ
N2O3 dissociation to NO is
dinitrogen trioxide
N2O3 ⇔
nitric oxide
NO 1
nitrogen dioxide
NO2 :
ð1:6Þ
Since the early proposals that Hb may be a site for
nitrite reduction, a number of other nitrite reductases
have been identified, and these and the chemistry in-
volved are discussed in more detail in this review.
It is worthwhile to briefly discuss the potential for
nitrite to be generated via the reactions of ·NO with
O2-derived species such as superoxide. Although it was
previously thought that the reaction of ·NOwith superoxide
was of toxicological/pathophysiological concern, since the
product, peroxynitrite (ONOO2), is a potential oxidant, this
idea has not been well supported. The generation of
peroxynitrite from this reaction may simply serve to limit
the signaling associated with ·NO and/or superoxide. How-
ever, it is also worth considering that the ·NO/superoxide
reaction can serve as a source of nitrite since peroxynitrite
in the presence of excess ·NO or superoxide will lead to the
formation of nitrite (Jourd’heuil et al., 2001).
Thus, unless ·NO and superoxide were generated at
the same time, same flux, and in the same place in a cell
(a highly unlikely scenario), nitrite generation will be
the primary fate of this reaction. This also indicates that
the spatial and temporal aspects of nitrite generation
(via the ·NO/superoxide reaction) can be governed by
the place and time of reactive oxygen species (ROS)
[superoxide via xanthine oxidoreductase (XOR), for
example] and ·NO generation. Moreover, it has been
reported that ·NO can be metabolized by cells to give
nitrite (Thomas et al., 2001) (although the chemical
reactions responsible for the cellular conversion of
·NO to nitrite have not been established). Finally, just
as the formation of nitrite from ·NO can be dependent
on the timely and localized generation of ROS, the
reverse process (formation of ·NO from nitrite) can also
be dependent on O2 and O2-derived species as well
(Wink, 2003).
II. Inorganic Nitrite and Nitrate
A. Historical Uses of Inorganic Nitrite
The use of nitrovasodilators by Lauder Brunton and
Murrell led to the exploration of related chemicals that
included salts of inorganic nitrite. Below are the words
that Reichert used to start his detailed monograph on
the actions of potassium nitrite to explain why he was
using a related substance to amyl nitrite (Reichert and
Mitchell, 1880):
“The very great value of amyl nitrite in warding off
impending paroxysms of epileptic convulsions, angina
pectoris, and asthma, has been so generally recognized
by the profession, that the discovery of a new salt whose
physiological action is identical with… that of amyl
nitrite, but whose effects would be more permanent and
therefore suitable for maintaining a continuous systemic
influence, we would have an addition to our materia
medicawhichwould fill a very apparent therapeutic void.”
The experiments that Reichert was describing in this
work demonstrated that, in dogs and cats, potassium
nitrite caused profound hypotension, leading to death,
and perhaps more importantly, that in humans potas-
sium nitrite had a synonymous effect to the organic
amyl nitrite (Reichert and Mitchell, 1880). These obser-
vations were followed by a detailed comparative analysis
of the effects of sodium nitrite and organic nitrites,
including amyl nitrite and glyceryl trinitrate (GTN). In
normotensive subjects, the blood pressure (BP)-lowering
effects of organic nitrites and nitrates were observed for
up to 30 minutes postadministration, but a similar level
of BP reduction was maintained for up to 60 minutes
after inorganic nitrite dosing, indicating some differ-
ences in biologic activity between the two compound
classes. The effects of sodium nitrite weremuch larger in
patients with significant hypertension (see Fig. 3), with
maximal systolic BP (SBP) reductions up to 50 mm Hg
Fig. 3. Oral inorganic nitrite and acute BP response (Matthew, 1909).
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(Matthew, 1909; Wallace and Ringer, 1909). It was after
this, in the early part of the 20th century, that inorganic
nitrite was used for the treatment of BP appearing in
materiae medicae and being produced by several phar-
maceutical suppliers for the treatment of patients with
hypertension (Butler and Feelisch, 2008). This occurred
despite an absence of a clear understanding of the
mechanisms involved. However, the use of nitrite salts
for BPmanagement never really took off, and this relates
to concerns regarding the reactions between nitrite and
oxyHb generating metHB (eq. 1.3). If metHB levels
rise .10%, the fraction of bound oxygen to Hb becomes
insufficient for metabolic demand, thus provoking symp-
tomatic hypoxemia despite adequate oxygenation (Skold
et al., 2011). Indeed, concerns relating to this continue
to be raised in relation to the use of both organic and
inorganic nitrites in clinical practice (Pierce andNielsen,
1989; Finan et al., 1998; Modarai et al., 2002).
B. Historical Uses of Inorganic Nitrate
Inorganic nitrate has been used in traditional Chi-
nese medicine to treat cardiovascular disease (CVD) for
over a millennium. The following passage is a trans-
lation from an 8th century CEmanuscript discovered in
the Mogao caves in Gansu Province, China (Butler and
Moffett, 2005):
“Putting under the tongue to cause heart qi to flow
freely for treating symptoms such as struck by evil,
acute heart pains and cold in the hands and feet which
can kill a patient in an instant. Look at the patient’s
fingers and those with greenish-black nails are such
cases. Take saltpeter [xiaoshi, potassium nitrate] (five
measures of a bi spoon) and realgar [xiongshi, arsenic
sulphide] (one measure of a bi spoon) and combine the
two into a fine powder. Lift the patient’s tongue and
sprinkle one measure of a bi spoon under the tongue. If
saliva is produced, have the patient swallow it. This is a
certain cure.”
Interestingly, the comment regarding the production
of saliva and the importance of swallowing appears to
relate to knowledge of the bioactivation of inorganic
nitrate by the oral microbiota (see below). Although it is
difficult to tell whether there was widespread use of
inorganic nitrate in traditional Chinese medicine over
the proceeding centuries, it was much later, in the early
20th century, that Western physicians explored the
utility of the same chemicals. Edward Stieglitz produced
a body of work in Chicago with bismuth subnitrate
[chemical formula: Bi5O(OH)9(NO3)4]. At that time,
bismuth subnitrate was being used as an established
and recommended treatment of peptic ulcer disease and
diarrhea, with the caveat and caution against prolonged
use because of the risk of hypotension (Frick, 1924).
Stieglitz was aware of evidence from bacteriologists that
enteric bacteria could convert nitrate to nitrite (Salen,
1925; Zobell, 1932). He thus proposed the following
(Stieglitz, 1927):
“The idea to use bismuth subnitrate as an auxiliary to
break the vicious circle of vascular fatigue arose from
the observation of three cases of nitrate poisoning result-
ing from the liberal use of bismuth subnitrate in severe
diarrhoeas… Therefore, theoretically, small frequent
doses should lead to the liberation of small amounts of
nitrite, uniformly and continuously absorbed. The effect
of this is quite different from the violent, very transient
vasodilatory effect of other forms of nitrite, such as
nitroglycerol, amyl nitrite and sodium nitrite. The action
to be expected is a gradually increasing vascular re-
laxation, with localized physiological rest to the arterio-
lar musculature.”
He reported, in almost 1000 patients, sustained hy-
potensive effects of bismuth subnitrate (Stieglitz, 1927,
1928, 1930, 1932). Furthermore, he determined that,
although the basal level of nitrite in blood was 110–
220 nmol/l, this was increased after an inorganic nitrate
load and that, although nitrite was not a normal con-
stituent of fresh urine, it could be detected after an oral
inorganic nitrate load (Stieglitz and Palmer, 1934, 1936,
1937). Lastly, he expended much effort exploring the
nitrate-reducing activity of bacteria in vitro, resulting
with his hypothesis that bacterial nitrate reduction
might be responsible for significant physiologic effects
in vivo (Stieglitz and Palmer, 1936). There was not
widespread uptake of this therapy, in part because of
concerns regarding methemoglobinemia (Comly, 1945;
Walton, 1951) and the prevailing view that nitrate was
an inert end product of oxidative ·NOmetabolism (Bonner
and Hughes, 1988; Ignarro et al., 1993). However, of
course, all of this changed in the late 2000s with the
realization that nitrate via the noncanonical pathway
offers an alternative approach to ·NO delivery and po-
tential BP lowering.
III. Sources and Pharmacokinetics of Nitrate
There are twomajor sources of nitrate in humans, i.e.,
through the oxidation of ·NO and directly from exoge-
nously derived (environment and diet) sources.
A. Endogenously Derived Nitrate
Assessments of the contribution of endogenously de-
rived nitrate to daily bodily exposure has suggested that
;25% of bodily nitrate comes from endogenous sources
(Green et al., 1981). Plasma nitrate levels in healthy,
fasted persons have been shown to be in the order of 20–
40 mmol/l (Gladwin et al., 2000; Lundberg and Govoni,
2004;Webb et al., 2008b). In long-term nitrogen balance
studies lasting 3 months, in healthy participants given
,180 mmol nitrate daily, endogenous nitrate biosynthe-
sis estimated from 24-hour urine collection was between
0.5 and 1 mmol daily (Green et al., 1981), although with
the contribution of iNOS in inflammatory states, this can
be much higher (Stichtenoth et al., 1994).
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B. Exogenous Sources of Nitrate
Humans are exposed to exogenously derived nitrate
on a daily basis. There are two primary sources: drink-
ing water and diet.
1. Dietary Intake. The predominant dietary source
of nitrate comes from vegetable intake. Using theWorld
Health Organization (WHO) recommended intake of
mixed vegetables of 400 g daily as a guide would lead
to a total daily nitrate intake of ;2.5 mmol, although in
reality, most people consume less than this, with esti-
mates at 1.5–2mmol (or 93–124mg) nitrate daily (World
Cancer Research Fund/American Institute for Cancer
Research, 2007; European Food Safety Authority, 2008).
However, in vegetable-rich diets, such as the proposed
diet based upon the Dietary Approaches to Stop Hyper-
tension (DASH) study, estimates suggest that intake
levels can easily be increased to somewhere in the region
of 6–20 mmol daily (Hord et al., 2009). Other dietary
patterns, such as the traditional Japanese diet, may also
have significantly higher nitrate intakes (Sobko et al.,
2010) compared with European or United States diets.
This variation in intake is driven by the differences in
nitrate levels found in vegetables. In general, large green
leafy vegetables contain the largest amounts of nitrate
per gram (European Food Safety Authority, 2008), and
this source is thought to be responsible for the elevated
amounts consumed within the traditional Japanese diet.
Importantly, because of concerns associatedwith toxicity
(see later), the WHO has set an acceptable daily intake
(ADI) recommendation for dietary nitrate at 3.7 mg/kg
daily, which equates to ;4 mmol nitrate daily for an
average 70-kg person (European Food Safety Authority,
2008).
2. Water Supplies. Because of historical concerns
regarding toxicity from nitrate in drinking water sup-
plies, mostly concerning the risk of infantile methemo-
globinemia (see later), there exists regulatory control of
the nitrate level in water at ,50 mg/l (U.S. Public
Health Service, 1962). The levels of nitrate in drinking
water derived from surface water do not exceed 10 mg/l
inmost countries. In such conditions, the contribution of
drinking water to nitrate intake is usually less than
14% (World Health Organization, 2011), and therefore,
vegetables are the main source of nitrate intake (Chilvers
et al., 1984; European Centre for Ecotoxicology and
Toxicology of Chemicals, 1988).
In some particularly agricultural areas, however, con-
centrations of nitrate in drinking water are higher be-
cause of runoff and the discharge of sewage effluent
and certain industrial wastes. In 15 European
countries, evidence was shown indicating that the
percentage of the population exposed to nitrate levels
in drinking water above 50 mg/l ranged from 0.5%
to 10% (European Centre for Ecotoxicology and Tox-
icology of Chemicals, 1988). Individual wells in agri-
cultural areas throughout the world often contain
drinking water with nitrate levels exceeding 50 mg/l
(World Health Organization, 2011), and in such circum-
stances, drinking water will be the major source of total
nitrate intake, especially for bottle-fed infants (World
Health Organization, 2011).
C. Pharmacokinetics of Nitrate
After the oral ingestion of nitrate, it is rapidly
absorbed across the upper GI tract (Hawksworth
and Hill, 1971; Witter et al., 1979; Miyoshi et al.,
2003) and does not undergo transformation with first-
pass metabolism, thereby having almost 100% bio-
availability (van Velzen et al., 2008). It is not clear
how nitrate is able to cross the upper GI tract, and no
putative mechanism or transporter has been identi-
fied to date.
After ingestion of a single inorganic nitrate load as a
salt or in dietary form (i.e., vegetable), significant ele-
vation in circulating plasma nitrate levels can be
detected within 15 minutes, with peak levels achieved
by 30–60 minutes postdose (McKnight et al., 1997;
Lundberg and Govoni, 2004; van Velzen et al., 2008;
Webb et al., 2008b). The effective half-life for nitrate in
the plasma after consumption of different vegetable
sources is ;6 hours (van Velzen et al., 2008), with a
slow reduction over time and significant elevation in
circulating plasma nitrate levels even 24 hours post–
single-dose administration (Webb et al., 2008b; Kapil
et al., 2010).
The fate of nitrate in the plasma is 2-fold. Studies
with radiolabeled [15N]nitrate reveal that two-thirds
is excreted in the urine. Peak excretion of nitrate
occurs ;6 hours after supplementation with small
amounts and has been accounted for in sweat (up to
10%) or feces (,1%) (Green et al., 1981; Wagner et al.,
1983, 1984; Bartholomew and Hill, 1984; Packer
et al., 1989; Pannala et al., 2003). Nitrate is freely
filtered at the glomerulus, and clearance from the
plasma has been estimated as ;20 ml/min in healthy
subjects (Wennmalm et al., 1993). This relatively low rate
of clearance (taking into consideration that a normal
glomerular filtration rate is between 100 and 125ml/min)
suggests that much of the filtered nitrate is reabsorbed
and explains its relatively long half-life (Kahn et al., 1975;
Rahma et al., 2001).
As such, renal reabsorption of nitrate increases with
increasing filtered nitrate level, with no clear transport
limit (Godfrey and Majid, 1998). In clearance experi-
ments, both mannitol and furosemide inhibited tubular
reabsorption of nitrate, suggesting that nitrate reab-
sorption occurs across the whole tubule. Further stop-
flow experiments also suggest that nitrate is avidly
reabsorbed at the same location as sodium in the distal
tubule, suggesting cotransport (Rahma et al., 2001),
although the transporters for such action have not been
identified, and this remains one of the major unknowns
in the field.
Nitrate-Nitrite-Nitric Oxide Pathway 699
D. Enterosalivary Circulation and Oral Reduction
of Nitrate
The remaining (;25%) of nitrate that is not excreted
by the kidneys is selectively taken up by the salivary
glands (Spiegelhalder et al., 1976; Tannenbaum et al.,
1976; Kortboyer et al., 1994) via the two-nitrate/one-
proton electrogenic cotransporter sialin (Qin et al., 2012).
This reuptake of nitrate is often described as the enter-
osalivary circulation of nitrate (Duncan et al., 1995).
Salivary nitrate levels at baseline are .10-fold higher
than circulating plasmanitrate levels (Spiegelhalder et al.,
1976; Lundberg and Govoni, 2004), indicating a concen-
tration of nitrate within the oral cavity. This circuit of
nitrate is a relatively quick process; within 20–60minutes
post–inorganic nitrate load, an elevation in salivary ni-
trate levels is detectable (Harada et al., 1974; Ishiwata,
1976b; McKnight et al., 1997).
These early studies demonstrated that in addition to
these rises in salivary nitrate with oral nitrate dosing,
rises in the chemically related but distinct anion nitrite
occur hand in hand. It is noteworthy that the primary
aim of these investigations was to determine whether
nitrate ingestion might result in sufficient nitrite gener-
ation to lead to formation ofN-nitroso compounds linked
to carcinogenesis (Harada et al., 1974; Tannenbaum
et al., 1974, 1976; Eisenbrand et al., 1980). Studies have
shown that there is no nitrite in saliva taken directly
from salivary gland ducts, as opposed to mixed saliva in
the oral cavity, indicating that conversion of nitrate to
nitrite within the oral cavity, and not within the salivary
glands, was responsible for salivary nitrite levels. It was
in 1975 that it was first suggested that the appearance
of nitrite within the saliva may be due to the activity
of nitrate-reducing bacteria within the oral cavity
(Ishiwata et al., 1975d). It was known at that time that
bacteria existing in the lower GI tract (Salen, 1925;
Zobell, 1932; Stieglitz and Palmer, 1936) could use ni-
trate as a terminal electron donor in respiration instead
of oxygen and, thereby, reduce nitrate to nitrite (Moreno-
Vivián et al., 1999; Lundberg et al., 2004). In addition,
consumption of nitrate and corresponding formation of
nitrite in human saliva in vitro at 37°C had been shown
to be prevented by heating the saliva to 100°C or by
passing the saliva first through a filter (Goaz and
Biswell, 1961; Ishiwata et al., 1975a). If the filter
residue was returned to the saliva filtrate, the changes
in salivary nitrate and nitrite levels were restored,
suggesting a denaturable, biologic element in the residue
fraction that was necessary for nitrate reduction (Goaz
andBiswell, 1961; Ishiwata et al., 1975a). Further studies
using commercially available antibacterial mouthwash or
systemic antibiotics resulted in up to 90% reduction in
salivary nitrite levels after an inorganic dietary load,
supporting the view that bacterial conversion of nitrate
was responsible for salivary nitrite (Tannenbaum et al.,
1976; Dougall et al., 1995; Duncan et al., 1995).
Sasaki and Matano (1979) used a filter-paper tech-
nique to identify particular areas of the oral cavity that
were responsible for nitrate reduction. They impreg-
nated small 1.5-cm2 pieces of filter paper with potas-
sium nitrate and placed them on particular areas of the
oral cavity for 90 seconds. On removal, they agitated the
paper squares with distilled water and determined
nitrite accumulation colorimetrically. Their investiga-
tions revealed that significant nitrate reduction was
localized to only the posterior, dorsal aspect of the tongue,
an observation that has since been confirmed in rodents
(Duncan et al., 1995). Incubation of rat tongue sections
with nitrate solution ex vivo revealed abundant nitrate
reduction completely attenuated by prior boiling (Duncan
et al., 1995; Li et al., 1997). In addition, oral nitrate-
reduction activity was found to be completely absent in
any part of the oral cavity of rats raised in a germ-free
environment (Duncan et al., 1995). Histologic exami-
nations of these sections demonstrated the presence of
abundant bacteria in the deep, interpapillary sulci
(crypts) in the posterior third of the tongue and rela-
tively less elsewhere, which coincided with the distri-
bution of nitrate reductase activity across the tongue
(Fig. 4) (Sasaki and Matano, 1979; Sasaki et al., 1981;
Duncan et al., 1995; Li et al., 1997).
The first bacterial species identified capable of facili-
tating oral nitrate reduction, Bacillus coagulans, was
found by incubating saliva samples on nitrate-containing
blood agar under anaerobic conditions (Maruyuma et al.,
1976). Studies with samples of rat tongue or human
saliva, using standard culture and colony isolation,
coupled predominantly with species identification by
biochemical means, have implicated Veillonella, Lacto-
bacillus, Micrococcus, Corynebacterium, Propionibacte-
rium, Neisseria, Actinomyces, commensal Staphylococcus,
and Rothia spp. as playing significant roles in oral
nitrate reduction (Murumatsu et al., 1979; Doel et al.,
2005). Importantly, these observations have been lim-
ited to only those bacteria that can be cultured. More
recent use of biofilm modeling has revealed two addi-
tional species with nitrate reductase activity (Hyde
et al., 2014); however, even this model only supported
culture of ;100 different species-level taxa. Impor-
tantly, nonculturable organisms, detected using culture-
independent molecular analyses, make up a significant
proportion of the total oral microbiome (Dewhirst et al.,
2010). The human microbiome project, utilizing next-
generation sequencing methods, has shown that culture-
independent analyses of the bacterial genome targeting
the 16S rRNA gene identify 700 bacterial species resi-
dent in the human oral cavity, with a predicted total
species richness of ;1000 (Dewhirst et al., 2010). With
the advent of these next-generation sequencing tech-
niques and the human oral microbiome project, further
novel nitrate reductase–containing species are being
identified, although the relative importance of any of
these to overall oral nitrate reduction has been difficult
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Fig. 4. Oral microbiome and nitrate reduction. Reprinted by permission from Springer: (Nature), Nature Medicine, Chemical generation of nitric oxide
in the mouth from the enterosalivary circulation of dietary nitrate Duncan et al. (1995). (A) Micrograph showing the dorsal epithelial surface of the
posterior third of the rat tongue. A convoluted surface with deep interpapillary clefts is seen and large numbers of microorganisms are present (dark
areas). (B) Three-dimensional plot of nitrate reduction on the surface of (left) conventional (n 5 7) and (right) germ-free (n 5 2) rat tongues. Nitrate
reduction (measured as micromoles nitrite per hour) is mainly confined to the posterior third of the tongue in conventional rats but is absent in those
raised in a germ-free environment. (C and D) Sections 1 to 3 correspond to the anterior two-thirds of the tongue and 4 to 5 to the posterior third.
Comparison between nitrate reduction and the microbial population over the surface of the rat tongue (n 5 5). The distribution of nitrate reduction
(micromoles nitrite per hour) relates to the distribution of microorganisms.
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to determine given the interdependency of microbial
ecology (Hajishengallis et al., 2012).
Observations have also suggested that within the oral
cavity, nitrate reduction is not, as previously thought,
restricted to the anaerobic crypt environment at the
dorsal surface of the tongue. Recent demonstrations
show that bacteria residing on the teeth, on the cheek
surface, and even in human dental plaque are capable of
nitrate reduction (Schreiber et al., 2010). However,
again, the relative contribution from this site versus
the others is uncertain. In addition, there is some evi-
dence that long-term dietary nitrate supplementation
actually changes oral microbial ecology and may lead to
further improvement in the processing of nitrate to
nitrite (Hyde et al., 2014; Velmurugan et al., 2016;
Vanhatalo et al., 2018; Burleigh et al., 2019). Feeding
healthy pigs nitrate led to a change in the diversity of
the oral microbiota (Trevisi et al., 2011), decreasing the
Shannon index (a measure of the number of different
types of bacteria and their relative abundance), sug-
gesting that persistent (2-week) dietary nitrate treat-
ment causes either a reduction in the richness of the
community or triggers numbers of certain species to
rise, thus reducing evenness. This effect was associated
with acute increases in oral nitrate reduction followed
by decreases with high doses of nitrate, although the
identity of the species involved was not determined. In
addition, in patients with hypercholesterolemia ran-
domized to dietary nitrate for 6 weeks or control, there
was a significant shift in 78 oral microbial taxa only
after nitrate treatment, with Rothia and Neiserria spp.
representing the greatest change (Velmurugan et al.,
2016). Further studies have confirmed these increases
in Rothia and Neiserria spp. in a healthy volunteer
cohort after dietary nitrate supplementation for 10 days
and have also noted reductions in Prevotella spp. and
Veillonella spp. (Vanhatalo et al., 2018). However,
whether these changes in oral microbiome in response
to inorganic nitrate supplementation lead to further
beneficial functional changes is not clear, as there is
conflicting evidence of whether abundance of nitrate-
reducing bacteria in the oral microbiome correlates to
baseline plasma nitrite (Burleigh et al., 2018; Vanhatalo
et al., 2018). Additionally, vascular responses to an acute
dietary nitrate load were not different in healthy volun-
teers with increased nitrate-reducing bacteria identified
in their oral microbiome (Burleigh et al., 2019).
Interestingly, there appear to be sex differences in the
nitrate-nitrite-·NO pathway, at least in part relating to
oral microbial conversion of salivary nitrate to nitrite.
The first hint of such an effect was demonstrated in a
post hoc analysis of one of our first nitrate supplemen-
tation studies in healthy volunteers. Healthy women,
in comparison with healthy men, had higher baseline
plasma nitrite levels despite similar plasma nitrate
levels and also greaterfold increases in plasma nitrite
after a fixed dose of inorganic nitrate (Kapil et al., 2010).
Prospective evaluation confirms these baseline differ-
ences in plasma nitrite levels despite similar plasma
nitrate levels and that this is represented in other biologic
matrices additionally, namely in saliva and urine (Kapil
et al., 2018). In addition, investigation of the enterosali-
vary pathway reveals that women have greater capacity
for oral nitrate reduction compared with men. That is, for
a fixed concentration of nitrate in the oral cavity, there is
greater molar conversion to nitrite (Kapil et al., 2018).
Despite these robust differences, there were no clear dif-
ferences in oral microbial community diversity or struc-
ture (by 16s RNA profiling) overall or when restricted
to taxa known to contain nitrate reductase genes
(Kapil et al., 2018). A possible explanation is that
bacterial nitrate reductase expression is influenced
by sex hormones, although this has not been evalu-
ated to date. Importantly, these differences in pro-
cessing of nitrate to nitrite do not lead to divergence
in response to inorganic nitrate supplementation, at
least in CV responses such as BP and endothelial
function (Kapil et al., 2018).
E. Nitrate Reductases
1. Prokaryotic Nitrate Reductases. The nitrogen
cycle details the chemical transformations that recycle
nitrogen between the atmosphere, biosphere, and hy-
drosphere. The most reduced form of nitrogen is am-
monia, the oxidized form of nitrogen, whereas the most
oxidized form is nitrate. Microbes drive the nitrogen
cycle, as they use an assortment of redox reactions to
metabolize nitrogen for energy transduction, detoxifica-
tion, or assimilation (Stein and Klotz, 2016). These
microbial reactions are essential to most Terran life, as
they are essential tomaintain bioavailability of nitrogen.
Many bacteria readily reduce nitrate to nitrite via
nitrate reductases. All prokaryotic nitrate reductases are
molybdenum-dependent enzymes. They are traditionally
separated into three major groups: membrane-bound
periplasmic nitrate reductase (Nap), membrane-bound
respiratory nitrate reductase (Nar), and the cytoplasmic,
assimilatory nitrate reductase (Nas) (Sparacino-Watkins
et al., 2014). Nitrate is retained in soils, sediments, and
water, providing a biologically useful pool for many bac-
teria. Enzymatic reduction to nitrite generates enormous
energy (Moreno-Vivián et al., 1999), which the organisms
use to maintain homeostatic processes and life.
2. Mammalian Nitrate Reductase Activity. Despite
the fact that it is accepted that mammals, in the main,
lack the enzymes capable of undertakingnitrate reduction
to nitrite and are therefore reliant on functioning oral
microflora, there is some evidence that mammalian ni-
trate reductases may have a role. Although antibacterial
mouthwash treatment in humans totally abrogated
ex vivo nitrate reduction in saliva incubated with
1 mmol/l nitrate solution and prevented any increase
in saliva nitrite levels in vivo, there was still a small
increase in plasma nitrite level after an inorganic
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nitrate load (Govoni et al., 2008). Although there could
be nitrate reduction from lower GI commensals, an alter-
native explanation of mammalian nitrate reduction has
also been postulated that is particularly focused on XOR.
XOR demonstrates nitrate-reduction activity in vitro
under anoxic conditions that can be abrogated by XOR
inhibition (Li et al., 2003). Furthermore, in normoxic
wild-type rats, increases in plasma nitrite are partially
abrogated after nitrate supplementation by XOR inhibi-
tion (Jansson et al., 2008). Similar results were demon-
strated in endothelial ·NO synthase (eNOS)-deficient and
germ-free mice, thereby excluding bacterial nitrate re-
duction and vascular ·NO synthase (NOS) activation as
the source of nitrite (Jansson et al., 2008). Germ-free mice
exhibited greater tissue levels of XOR, suggesting that
this may represent a functional compensatory response to
uphold nitrate production in the absence of a commensal
microflora (Huang et al., 2010). These studies seem to
confirm much earlier studies on ex vivo mammalian
liver/muscle homogenates suggesting that XOR may
exhibit nitrate-reducing capability (Bernheim and Dixon,
1928; Ward et al., 1985, 1986). In contrast, very recently,
Moretti et al. (2019) have published findings suggesting a
lack ofmammalian nitrate reductase activity in germ-free
mice in a separate study, indicating someheterogeneity in
studies with animals rendered “germ-free.” Irrespective,
the presence and importance of putative nitrate reduc-
tases in human physiology is yet to be firmly established.
IV. Sources and Pharmacokinetics of Nitrite
Plasma nitrite levels in the circulation are much lower
than nitrate, with measurements from several different
research groups falling in the 0.2–0.5mmol/l range under
basal, fasting conditions (Grau et al., 2007). Nitrite also
has amuch shorter half-life than nitrate, estimated to be
between ;15 and 45 minutes in the circulation (Dejam
et al., 2007; Hunault et al., 2009). In addition, nitrite
levels measured in the plasma are likely to reflect mul-
tiple different sources. Nitrite that is generated from the
metabolism of ·NO, in the oral cavity or from dietary
sources, undergoes absorption and both enzymatic and
nonenzymatic conversion to ·NO (Fig. 5).
A. Endogenously Derived Nitrite from the
Enterosalivary Circuit
Elevation of systemic nitrite levels after ingestion of
inorganic nitrate has been demonstrated to occur across
a range of species as well as in humans. For example,
provision of 1 g/l (16.2 mmol/l) inorganic nitrate in the
drinking water to C57BL6 mice increases steady-state
plasma nitrite levels by ;50% (from ;0.8 to 1.2 mmol/l)
and increases tissue levels (for example, heart tissue) by
500% (from ;3 to 18 mmol/l), highlighting that plasma
nitrite levels may not be indicative of tissue-specific
levels or changes in levels (Bryan et al., 2007). Interest-
ingly, supplementation of drinking water in Sprague-
Dawley rats with much lower amounts of nitrate (to
provide total daily nitrate intake of 0.1 and 1 mmol/kg)
for 7 days increased plasma nitrite levels from 0.4 to
0.6 and 2.6 mmol/l, respectively (Jansson et al., 2007).
The differences reflected in these two studies reveal
that the pharmacokinetics and handling of nitrate may
be species-dependent.
Thus, studies in humans have been important to
determine the impact of nitrate supplementation on
systemic nitrite levels. In these studies, systemic nitrite
levels have largely been examined in saliva, plasma,
and urine only because, understandably, it is difficult to
get tissue samples in healthy-subject studies. Although
Stieglitz had shown more than 70 years ago that inor-
ganic nitrate supplementation acutely (within 1 hour)
Fig. 5. NO cycle in humans. Colored arrows indicate oxidation and reduction.
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and chronically (up to 14 days) elevated blood nitrite
levels (Stieglitz and Palmer, 1936), it is only more
recently that researchers have studied systemic nitrite
elevations after inorganic nitrate supplementation in
depth, trying to elucidate whether sufficient nitrate-
derived nitrite from the oral cavity reaches the circula-
tion in humans. One of the first explorations of this
phenomenon was conducted in healthy subjects who
were supplemented with ;120 mmol/kg NaNO3 (equiv-
alent to ;8 mmol NaNO3 and 496 mg of nitrate for a
70-kg person) in a single dose (Lundberg and Govoni,
2004). Salivary, plasma, and urinary NOx levels were
assayed for up to 3 hours postingestion. In contrast to
the very rapid appearance of nitrate in the plasma
(within 15 minutes, as previously discussed above) and
early plateau phase (within 1 hour), plasma nitrite
levels were only significantly detected above basal
valuesafter30minutesandwere still risingat90minutes.
In this experiment, some subjects were asked to refrain
from swallowing their saliva (by spitting all saliva out)
to interrupt the enterosalivary circulation. In these sub-
jects, although there was no difference in plasma nitrate
levels compared with control (swallowing saliva), plasma
nitrite levels did not rise. However, following resumption
of swallowing saliva after 1 hour, plasma nitrite levels
started to rise again (Lundberg and Govoni, 2004).
In 2006, Weitzberg and Lundberg also demonstrated
that plasma nitrite levels were significantly higher
(2196 105 nmol/l) after 3 days of supplementation with
0.1mmol/kg NaNO3 (;7mmol and 434mg nitrate) com-
paredwith after 3 days ofmatched placebo (0.1mmol/kg
sodiumchloride,NaCl) supplementation (138638nmol/l)
(Larsen et al., 2006). The ;1.5-fold increases in plasma
nitrite levels from baseline after supplementation with
0.1 mmol/kg in humans was similar to that observed in
rats described above (Jansson et al., 2007). Similarly, we
have demonstrated dose-dependent effects after the in-
gestion of nitrate in both inorganic salt and the dietary
form of beetroot juice (Webb et al., 2008b; Kapil et al.,
2010). Although beetroot is purple-red, it is a green
leafy vegetable and contains significant nitrate levels
(Santamaria, 2006). Ingestion of 500 ml of beetroot
juice [mean (nitrate)5 45.0mmol/l] provided;22.5mmol
(;1395 mg nitrate) and was associated with an elevation
of plasma nitrite levels from 0.4 to 0.6 mmol/l. Plasma
nitrite levels were slower to rise than plasma nitrate
levels, with peak plasma nitrite levels apparent 3 hours
after ingestion, compared with peak plasma nitrate levels
at 60–90minutes (Webb et al., 2008b). There were similar
effects when a matched dose of nitrate salts (24 mmol
potassium nitrate) was used (Kapil et al., 2010). In
addition, interruption of the enterosalivary circulation
by avoidance of swallowing saliva prevented the rises in
plasma nitrite but not plasma nitrate levels, confirming
the critical importance of oral nitrate reduction in modu-
lating systemic nitrite levels after inorganic nitrate
ingestion (Webb et al., 2008b).
Further evidence for the importance of the oral micro-
flora in facilitating this process is taken from studies
that have sought to suppress the bacteria responsible
for nitrate reduction. Prior treatment with a chlorhex-
idine antisepticmouthwash in animals and humans has
been shown to prevent the increases in plasma nitrite
levels associated with nitrate ingestion (Govoni et al.,
2008; Petersson et al., 2009; Jädert et al., 2012).
In summary, ;1 hour after an inorganic nitrate load,
plasmanitrite levels rise in a slow and sustainedmanner
in humans, peaking in the circulation after 2.5–3 hours,
reflecting the ingestion and enterosalivary processing of
inorganic nitrate (Lundberg and Govoni, 2004; Webb
et al., 2008b; Kapil et al., 2010).
B. Endogenously Derived Nitrite from NOS Activity
Nitrite is formed by oxidation of ·NO as previously
described above and has been suggested to be the most
sensitive reflection of acute eNOS activity. In the human
forearm circulation, stimulation of eNOSwith acetylcho-
line or inhibition of NOS activity with NG-monomethyl-
L-arginine acetate rapidly altered venous plasma nitrite
levels up or down, respectively, but without changes in
plasma nitrate levels (Lauer et al., 2001).
Furthermore, basal plasma nitrite levels in several
species were found to be similar, suggesting similar
levels of constitutive NOS activity, and application of
several different NOS inhibitors demonstrated cross-
species increases in vascular resistance that correlated
to decreases in plasma nitrite levels but not plasma
nitrate levels (Kleinbongard et al., 2003). Transgenic
mice with genetic deficiency in eNOS have 70% lower
plasma nitrite levels than wild-type C57BL6 litter-
mate controls, which was similar to the levels measured
in wild-type mice treated with an NOS inhibitor
(Kleinbongard et al., 2003). These observations suggest
that 70% of plasma nitrite is likely derived from eNOS.
Similarly, in humans with CVD risk factors, it has been
shown that plasma nitrite concentration inversely cor-
relates to increasing number of CV risk factors and
correlates directly to brachial artery flow-mediated di-
lation (FMD), suggesting that plasma nitrite levels could
be used as a surrogate for endothelial function in those
with CVD risk factors (Kleinbongard et al., 2006).
C. Exogenous Sources of Nitrite
Plasma nitrite levels are also determined by dietary
nitrite and nitrate consumption. Dietary nitrite intake
levels in humans are not as substantial as dietary
nitrate, with minimal intake occurring from drinking
water. Nitrite levels in drinkingwater are usually below
0.1 mg/l (World Health Organization, 2011). Daily
nitrite intake is similar across Europe and North
America, with estimates suggesting ingestion of 0.3–
0.9 mg/day, which equates to 6–20 mmol nitrite ingested
per day (Schuddeboom, 1993). The primary sources of
dietary nitrite consumption are cured, processed meats.
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Nitrite is added to meat as a preservative, as it prevents
oxidation of fatty acids, preventing rancidity and con-
trolling Clostridium botulinum (Hustad et al., 1973;
Honikel, 2008). Meat products contain up to 6.4 mg of
nitrite per kilogram (European Centre for Ecotoxicology
and Toxicology of Chemicals, 1988), whereas vegetables
contain very little nitrite (Hord et al., 2009).
In many studies exploring nitrite bioactivity, nitrite
salts have been used, with the most commonly used
being the sodium salt. The ;30-minute half-life men-
tioned above comes from work using NaNO2 in healthy
volunteers. In patients with diabetes, similar findings
have been observed. Kevil and colleagues demonstrated
that peak levels of circulating nitrite were achieved
within 30 minutes after ingestion of an 80-mg dose of
NaNO2, returning back to baseline within the 6-hour
measurement period (Greenway et al., 2012). This
group also assessed the impact of enteric coating upon
circulating levels of nitrite in the same patient group.
They showed that a statistically significant rise in
circulating levels was not achieved with the enteric-
coated NaNO2 over the 6 hours; however, there was a
trend for a rise that began to appear at around 1.5 hours
after ingestion, peaking at 2.5 hours and maintained
until 4.5 hours postingestion. Although, as noted, this rise
was not statistically different from baseline (Greenway
et al., 2012), the authors suggested that with doses higher
than 80 mg, it may be possible to provide longer-lasting
elevations of circulating nitrite that might prove useful in
therapeutics.
However, mean salivary volume swallowed is esti-
mated to be ;1.5 l/day (Dawes, 1972; Lagerlöf and
Dawes, 1984), andmean basal salivary nitrite levels are
;100–300 mmol/l (Lundberg and Govoni, 2004; Govoni
et al., 2008; Bahra et al., 2012). Thus, swallowing of
saliva could be responsible for total amounts of intra-
gastric nitrite in the order of 150–300 mmol daily. Mean
plasma nitrite levels are 0.2–0.5 mmol/l, suggesting
total circulatory nitrite levels at any one point of 1–
2.5 mmol. Thus, the same total amount of nitrite would
enter the stomach every 30 minutes. Although not all of
swallowed nitrite survives to appear in the circulation,
even if a fraction entered the circulation, it would make
an important contribution to plasma nitrite levels un-
der basal conditions. Some evidence suggests that
salivary nitrite might account for the 30% of plasma
nitrite concentration that cannot be accounted for by
eNOS activity. Under basal conditions, chronic use of
antibacterial mouthwash, which totally attenuated oral
nitrate reduction, reduced salivary nitrite concentra-
tion by 90% and plasma nitrite levels by 25% (Kapil
et al., 2013).
D. Systemic Nitrite Absorption
The nitrite that is formed in the oral cavity after
bacterial conversion from nitrate is swallowed and may
be directly acidified to increase levels of ·NO in the
stomach (Benjamin et al., 1994; Lundberg et al., 1994).
However, a significant proportion of swallowed nitrite
appears to survive passage into the stomach and, after
transfer across the gut wall, enters the systemic
circulation. The disappearance of nitrite from the
stomach is a rapid process, with decline of nitrite levels
by half within 10 minutes, as a consequence of absorp-
tion rather than chemical reactions of nitrite or gastric
emptying (Licht et al., 1986).
Similar to the lack of knowledge relating to nitrate
absorption in the GI tract, exactly how nitrite enters the
circulation is uncertain. As a charged anion, an active
uptake mechanism is likely to be involved, but this is
yet to be proven. Although little work has been
published describing active uptake mechanisms in
gastric environs specifically, there have been some
studies attempting to discern uptake mechanisms.
In erythrocyte ghosts, nitrite exchange with bicar-
bonate (HCO32) is inhibited by the nonspecific
anion-exchange inhibitor diisothiocyanatostilbene
disulfonate, suggesting that at least for erythro-
cytes, there may be a role for the anion-exchange
transporter-1 for the movement of nitrite across the
membrane (Shingles et al., 1997; Vitturi et al., 2009;
Jensen and Rohde, 2010). A similar anion-exchange
transporter-1 dependence for nitrite transport has
been demonstrated in pancreatic acini (Zhao et al.,
1994). However, other researchers have failed to
demonstrate the same effect of diisothiocyanatostil-
bene disulfonate (Zavodnik et al., 1999; May et al.,
2000; Jensen, 2005). Additionally, May et al. (2000)
demonstrated that nitrite uptake was dependent
upon sodium and phosphate levels and therefore
suggested that the sodium-dependent phosphate
transporter was important.
However, in the gastric lumen, pH is between 1.0 and
2.5. The pKa of nitrous acid (HNO2) in aqueous solutions
is 3.3–3.4 (Butler and Ridd, 2004), and therefore, most
of the nitrite will be in the neutral, lipophilic HNO2
form. It has been hypothesized that the passive move-
ment of HNO2 from the acidic gastric environment into
the neutral circulation may underlie the apparent
transport of nitrite across the gastric wall (eq. 1.4), a
possibility demonstrated to occur across the erythrocyte
membrane (Samouilov et al., 2007; Webb and Ahluwa-
lia, 2010). Arguing against the above proposal are
studies in rats assessing the importance of gastric pH
in circulating nitrite concentrations (Pinheiro et al.,
2012). Treatment of rats with large doses (30 mg/kg,
equivalent to 150 times the usual clinical dose) of the
proton pump inhibitor omeprazole (clinical daily doses
are usually 10–20 mg/day) followed by 15 or 45 mg/kg
NaNO2 orally, although increasing gastric pH from 4 to
6, did not impact upon circulating nitrite levels. Similar
observations have been seen in healthy volunteers
(Montenegro et al., 2017) in which treatment with
40 mg of esomeprazole did not lower circulating nitrite
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levels after an oral dose of 0.3 mg/kg (;0.3 mmol) of
nitrite. The exact contribution of passive diffusion of
HNO2 and/or active uptake of nitrite is still to be fully
determined and quantified. However, what is apparent
is that ingestion of inorganic nitrate, via the enter-
osalivary circulation and bacterial nitrate reduction,
eventually leads to increases in plasma and tissue
nitrite levels. Interestingly, it is now apparent that
tissue levels of nitrite can be widely different and that
plasma nitrite levels are, in general, the lowest in vivo,
with potentially most of the “blood” nitrite carried
inside the erythrocyte and much higher nitrite levels
in certain tissues of the body, particularly the blood
vessel wall (Bryan et al., 2005; Dejam et al., 2005).
V. Mechanisms of Nitrite Bioactivation
It is recognized that there are two distinct pathways
for nitrite bioactivation: either nitrite can be reduced to
·NO through acidification, as in the gut, or it can be
reduced via a host of mammalian enzymes, which we
describe below.
A. Nonenzymatic Nitrite Reduction
The acidic environment of the stomach lends itself to
the bioactivation of nitrite via the chemical reactions
outlined above and shown in eqs. 1.4–1.6 (Benjamin
et al., 1994). Firstly, nitrite is protonated, leading to the
formation of nitrous acid, and at low pH, HNO2
decomposes to form N2O3, which in turn can dissociate
to ·NO and NO2. It was proposed that this acidifica-
tion of nitrite to generate ·NO acts as a defense
mechanism against swallowed pathogenic microorgan-
isms (Benjamin et al., 1994) and that this effect was
responsible for the increases in ·NO measured in re-
sponse to dietary nitrate supplementation (Benjamin
et al., 1994; Lundberg et al., 1994). Whereas Benjamin
and colleagues used potassium nitrate to elevate stom-
ach nitrite levels, Lundberg and colleagues demon-
strated that ingestion of 50 g of iceberg lettuce
(1.3 mg/kg nitrate content) led to a 4-fold elevation in
exhaled ·NO 5 minutes after ingestion. This response
was abolished by pretreatment with 240 mg of omepra-
zole over a 24-hour period before lettuce ingestion
(Lundberg et al., 1994). A year later, it was demon-
strated using EPR spectroscopy and ·NO spin traps that
in rat hearts, negligible 15·NO is observed despite being
treated with 1 mmol/l 15N-nitrite; however, in the
ischemic rat heart, a 10-fold increase in the EPR signal
was observed (Zweier et al., 1995). The authors sug-
gested that the ischemia-induced acidosis provides the
protons required for the acidic disproportionation of
nitrite to ·NO without the need of a catalyst/enzyme.
However, although the chemistry is correct, it is now
clear that the reaction is facilitated by mammalian
enzymatic activity within tissues and that this catalytic
activity enables nitrite reduction under physiologic as
well as pathologic conditions, but the lower the O2
tension and pH, the greater the nitrite reduction.
Below, we summarize the evidence supporting the key
mammalian nitrite reductases that have been
identified.
B. Mammalian Nitrite Reductases
1. Molybdenum-Containing Oxidase Enzymes.
In mammals, there are four known molybdenum-
containing enzymes: XOR, sulfite oxidase (SO), alde-
hyde oxidase (AO), and mitochondrial amidoxime
reductase (mARC) (Fig. 6). Although all have been
shown to function as a nitrite reductase to various
degrees, XOR has been identified as perhaps the
major mammalian nitrite reductase and certainly is
the most prominent molybdenum-containing enzyme
responsible for nitrite bioactivation.
a. Xanthine oxidoreductase. XOR is widely distrib-
uted throughout the body, with the highest levels of
expression in the liver (Linder et al., 1999). XOR is
synthesized primarily in the liver and the lung, reflect-
ing the high expression found within these tissues, with
much lower levels of XOR expressed in most organs,
including the brain, gut, heart, and in blood vessels
(Abadeh et al., 1992, 1993). XOR has been localized
within the cytoplasm of numerous cell types (Jarasch
et al., 1981, 1986; Moriwaki et al., 1993; Radi et al.,
1997; Houston et al., 1999) but has also been localized
bound to the outer surface of cells through binding to
heparin sulfate glycosaminoglycans (GAGs). This ex-
pression on the cell surface via GAGs has been
suggested to account for substantial XOR expression
identified on the endothelial surface in patients with
coronary artery disease (Spiekermann et al., 2003) and
that observed in erythrocytes from individuals under-
going coronary artery bypass grafting (CABG) (Webb
Fig. 6. The primary sequence structure of the four known mammalian
molybdenum-containing enzymes. Numbers denote the first and last residues
of the domains highlighted (data obtained from NCBI/Protein). aa, amino
acid; Cyt, cytochrome b5; FE-S, iron-sulfur; Moco, molybdenum cofactor;
NCBI, National Center for Biotechnology Information; XO, xanthine oxidase.
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et al., 2008a), hypertensive rats, and patients with
hypertension (Ghosh et al., 2013). More recently, we also
identified XOR activity in erythrocyte preparations of
apolipoprotein E (ApoE) knockout (KO) mice (Khambata
et al., 2017), an atherosclerotic-prone mouse model in
which an upregulation of XOR activity versus wild-type
(WT) C57BL6 littermates was observed.
XORhas a FADdomain, two iron-sulfur domains, and
amolybdenum-binding domain, the latter being the site
for purine catabolism. The classically accepted function
of XOR is the oxidation of hypoxanthine to xanthine and
xanthine to uric acid, which occurs at the molybdenum
site (eq. 1.7a), and the reduction of O2, occurring at the
FAD site. However, in addition to these, it has been
known for;20 years that nitrite is reduced to ·NOat the
molybdenum site (Millar et al., 1998; Zhang et al.,
1998). The mechanism by which this reaction was
proposed to occur was through NADH acting as a
reducing substrate, donating electrons to the FAD site
to form FADH2 (eq. 1.7b); these electrons were then
proposed to be shuttled from the FAD site to the
molybdenum site via the iron-sulfur clusters (eq. 1.7c).
The authors suggested that Mo (VI) is reduced to Mo
(IV), and the O2 that is donated from nitrite results in
Mo (V) and the release of ·NO (eq. 1.7d). At the end of the
reaction, for each reducing substrate oxidized, two
molecules of ·NO were proposed to be formed in a one-
electron–reducing process resulting in Mo (VI). Equa-
tion 1.7 shows reactions of XOR.
Reaction at the molybdenum-binding site is as
follows:
Reaction at the FAD site is as follows:
b: NADH1 2H1
FADð Þ
↔NAD1 1H1 1 2e-
FADH2ð Þ
ð1:7bÞ
Internal electron shuttling is as follows:
c: MoIV=MoVI↔
Fe2S  ðIÞ= Fe2SðIIÞ
FADH2=FAD
1 ð1:7cÞ
Nitrite reduction at the Mo-Co site is as follows:
d:  2NO22 1   4H1 1 2e-
MoIVð Þ
→ 2_NO1   2H2O
MoVIð Þ
ð1:7dÞ
Millar et al. (1998) demonstrated that in the presence of
O2, purified bovine XOR was unable to catalyze the
reduction of nitrite (1–30 mmol/l) to ·NO; however,
under anaerobic conditions, i.e., ,1% oxygen, XOR
catalyzed this reaction. In this study, the authors
confirmed that XOR drove nitrite reduction at the
molybdenum-binding site with NADH as the reducing
substrate, since both allopurinol and diphenyleneiodi-
nium, the molybdenum and FAD-directed inhibitors,
respectively, blocked this reaction. Further studies by
Zweier’s group demonstrated that XOR could also
catalyze nitrite reduction to ·NO in both aerobic and
anaerobic conditions (Li et al., 2004). Using substrates
of xanthine or aldehyde, which act at the molybdenum
site as electron donors, it was shown that O2 functions
as a competitive inhibitor of nitrite reduction, whereas
using NADH as the electron donor at the FAD site,
nitrite reduction still occurs even in the presence of
oxygen at ;70% of the level observed in anoxia.
These observations have led us to suggest that a
potentially useful approach for therapeutics may be to
take advantage of this balance of reactions. We have
suggested that under optimal nitrite-reducing condi-
tions, XOR may be “switched” from a detrimental
ROS-generating enzyme to a protective one through
preferential generation of ·NO. We propose that in
conditions of excess nitrite and in the presence of the
reducing substrate NADH, electrons will be shuttled
from the FAD site to the molybdenum site via iron-
sulfur domains, resulting in a decrease in the availabil-
ity of the electrons needed for O2 reduction. This would
result in generation of ·NO and a concomitant reduction
of superoxide and H2O2, which are thought to be major
contributors to the oxidative stress that character-
izes many chronic disease states, in particular CVD
(Sugamura and Keaney, 2011), and to which XOR
contributes (Berry and Hare, 2004).
This latter point is particularly important in disease,
since both XOR expression and activity are substan-
tially enhanced, and this possibly offers an opportunity
for enhanced nitrite reduction too. An important obser-
vation, particularly relevant when discussing the po-
tential utilization of XOR-mediated nitrite reduction in
therapeutics, is that XOR activity is enhanced in
scenarios of hypoxia and acidosis, conditions that are
both prevalent in the setting of ischemia/reperfusion
(I/R) injury. Using purified XOR under aerobic condi-
tions, nitrite reduction was enhanced with acidic pH,
with ·NO generation 3 times greater at pH 6 compared
with pH 7.4 and a further 3 times greater from pH 6.4
to pH 5.5 when incubated with 1 mmol/l sodium nitrite
a: Hypoxanthine
MoVIð Þ
H2O1O2
Xanthine1 1e-
ðMoVÞ
H2O1O2
Uric acid1 1e-
ðMoIVÞ
ð1:7aÞ→ →
Nitrate-Nitrite-Nitric Oxide Pathway 707
(Li et al., 2004). In isolated rat heart preparations,
pH plummeted from 7.4 to 5.5 within 20 minutes of
ischemia (Zweier et al., 1999), providing the ideal
environment for XOR-dependent nitrite reduction.
Our own observations have supported these findings.
Using homogenates of rat and human heart, we dem-
onstrated an elevation of nitrite-derived ·NOproduction
not only with increasing concentrations of NaNO2 but,
importantly, also with decreasing pH (6.0–5.0) (Webb
et al., 2004). Additionally, Zweier and colleagues dem-
onstrated that rat heart homogenates incubated with
10 mmol/l NaNO2 gassed with 2% O2 demonstrated 50%
greater nitrite reduction than when under 5% O2, an
effect that was substantially inhibited by the XOR
inhibitor oxypurinol (Li et al., 2004). These observations
suggest that XOR-mediated nitrite reduction is perhaps
a phenomenon particularly relevant under ischemia, as
opposed to normal physiologic conditions of pH 7.4 and
normoxia. Although it is worth noting that under
physiologic conditions, O2 tension within organs can
vary enormously, with partial pressure of oxygen (PaO2)
of 90–100 mm Hg in arterial blood, 40 mm Hg in the
venous return, and 35 mm Hg in the heart and brain,
thus raising the possibility that, although within the
arterial side of the circulation in normoxia, XOR may
play little role as a nitrite reductase, this may not be the
case in regions that normally exist at lower O2 tensions.
Accordingly, evidence for a role for XOR in mediating
nitrite reduction under physiologic conditions (i.e., nor-
moxia and pH 7.4) has grown in the last few years. We
reported that bolus doses of NaNO2 (1–10,000 nmol/kg)
reduce mean arterial pressure (MAP) in the spontane-
ously hypertensive rat (SHR) model, effects abolished
by allopurinol (50 mg/kg) (Ghosh et al., 2013). We also
demonstrated enhanced XOR levels of erythrocytes
(measured using Western blotting) in the SHR model
compared with the normotensive Wistar Kyoto strain
control associated with elevated allopurinol-sensitive
nitrite reductase activity, measured by gas-phase chem-
iluminescence. There was a very similar profile of
activity in purified erythrocytes collected from normo-
tensive and hypertensive humans. However, a recent
study assessing erythrocytic nitrite reduction of blood
collected from both normotensive and hypertensive
volunteers demonstrated no effect of allopurinol upon
nitrite reductase activity, measured using EPR detec-
tion of nitrosyl Hb (Liu et al., 2015). The authors
highlighted a number of possible reasons for the differ-
ences between the two studies, including: concentra-
tions of nitrite used (Ghosh et al., 10–100 mmol/l; Liu
et al., 10mmol/l); differences in the buffer thatmay have
led to differing levels of XOR; potentially xanthine
dehydrogenase expression versus xanthine oxidase
expression; and that erythrocytes were collected from
drug-naïve hypertensives in the previous study (Ghosh
et al., 2013) as opposed to treated hypertensives.
However, another likely explanation is that in the study
by Kim-Shapiro and colleagues, blood was collected
with heparin as the anticoagulant, and heparin will
cleave any XOR bound via GAGs on the erythrocytes
(Adachi et al., 1993; Spiekermann et al., 2003). This fact
underlies why in all studies in our laboratory, when
assessing the nitrite reductase activity of blood ele-
ments, sodium citrate is used as the anticoagulant. In
contrast to the above, Rosenbaek et al. (2018) pre-
treated healthy individuals with placebo or allopurinol,
infused NaNO2 at 3.5 mmol/kg per hour, and found no
differences in brachial BP. However, the dose of NaNO2
used did not cause substantial BP lowering itself.
Furthermore, allopurinol may cause opposing effects
in reducing ·NO production but also potentially re-
ducing superoxide production, thereby mitigating mea-
surable vascular effects.
There is some evidence that nitrate and nitrite
interfere with each other with respect to XOR activity.
Damacena-Angelis et al. (2017), using high concentra-
tions of purified XOR (concentrations unlikely to occur
in vivo even in the most extreme of conditions), demon-
strated that 30 mmol/l NaNO3 attenuated NaNO2
(1 mmol/l) reduction to ·NO by ;60%. Although these
findings initially suggest that there is competition be-
tween the two anions, the use of suchhigh concentrations
to evidence these effects creates uncertainty regarding
potential physiologic relevance.
b. Aldehyde oxidase. Similar to XOR, AO consists
of an FAD binding site, iron-sulfur domains, and a
molybdenum-binding center and is highly expressed in
the liver, but it is also found in other tissues, such as
blood vessels, heart, lung, and kidney (Moriwaki et al.,
1998, 2001). AO has multiple functions, including
catalyzing the oxidation of aldehydes and heterocyclic
compounds to produce carboxylic acid. The first demon-
stration of the nitrite reductase capacity of AO came
from studies led by Jay Zweier. Using NaNO2
(100 mmol/l) and raloxifene (50 nmol/l), an AO inhibitor,
·NO production was reduced by ;40% in 1 g of rat liver
or heart homogenate (Li et al., 2008). Subsequent
studies by Zweier’s group demonstrated that the mech-
anism by which AO reduces nitrite is similar to that of
XOR in that nitrite reduction is enhanced in hypoxic
conditions and occurs at the molybdenum site (Li et al.,
2009). Similar to XOR, NADH acts as a reducing
substrate, donating electrons to the FAD site, an effect
inhibited by diphenyleneiodinium. Aldehydes can also
act as the electron donor at the molybdenum site of AO
to facilitate nitrite reduction (Li et al., 2009). Again,
similar to XOR, there is enhanced nitrite reduction
under acidic pH, with the greatest activity occurring
at pH 6 and decreasing at lower pHs (Li et al., 2009).
In contrast, however, recent testing of raloxifene in
healthy volunteers demonstrated that, if anything, the
activity of NaNO2 was enhanced with treatment, in-
timating that pathways other than AO were involved in
the effects seen (Omar et al., 2015). Thus, at present, the
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physiologic significance of the nitrite reductase activity
of AO is uncertain.
c. Sulfite oxidase. SO is located within the intermem-
brane space of mitochondria and exists as a homodimer,
with each monomer containing a molybdenum-
binding, an N-terminal cytochrome b5-type heme,
and a C-terminal domain. The physiological function of
SO is to oxidize sulfite (SO3
22) to sulfate (SO4
22), which
concomitantly reduces molybdenum from 16 to 14. It
has recently been demonstrated that SO is also capable
of reducing nitrite to ·NO under anaerobic conditions
(Wang et al., 2010), a process enhanced under acidic
conditions (Wang et al., 2015). Similar to XOR and AO,
reduction of nitrite to ·NO occurs at the molybdenum
domain; however, SO does this by the one-electron
oxidation of Mo16 to Mo15, which was demonstrated
using sulfite, a two-electron donor, and phenosafranine,
a one- or two-electron donor in which nitrite reduction
did not occur in the presence of the former (Wang et al.,
2015). The authors also demonstrated that human
fibroblasts collected from molybdenum cofactor-
deficient and SO-deficient individuals have signifi-
cantly reduced cGMP levels with the addition of
50 mmol/l nitrite in 1% and 20% oxygen, in comparison
with WT controls, demonstrating the importance of
SO-dependent nitrite reduction in vivo (Wang et al.,
2015).
d. Mitochondrial amidoxime reducing component.
Although mARC, a molybdenum-containing enzyme,
was described over a decade ago, its physiologic role is
unknown (Havemayer et al., 2006). Humans possess
two genes that encode for mARC-1 and -2, both of
which have been shown to reduce nitrite to ·NO, albeit
with suprapharmacological levels (NaNO2 1 mmol/l)
(Sparacino-Watkins et al., 2014). The authors demon-
strated that for nitrite reduction to occur, cytochrome b5
and cytochrome b5 reductase need to be present to
facilitate electron transport from the FAD site to the
molybdenum site within mARC, so NADH is also
required (Sparacino-Watkins et al., 2014). Using site-
directedmutagenesis to switch the cysteine of the active
molybdenum site to alanine (C273A), nitrite reduction
to ·NO was completely abolished. Similar to other
molybdenum-containing enzymes, the rate of nitrite
reduction is enhanced under acidic (3-fold, from pH 7.5
to pH 6.5) and hypoxic conditions (Sparacino-Watkins
et al., 2014). The physiologic role of mARC facilitating
nitrite to ·NO reduction remains uncertain.
2. Mitochondrial Respiratory Chain Enzymes.
mARC is not the only mitochondrial component capable
of reducing nitrite to ·NO. Experiments with rat liver
homogenates demonstrate that inhibition of complex I
or II leads to an attenuation of nitrite-derived ·NO
(NaNO2 50 mmol/l) at pH 7.25 and under anoxic
conditions (Kozlov et al., 1999). It was suggested that
inhibition of complex I or II will prevent electron flow to
complex III, which has been implicated as the site of
mitochondrial nitrite reduction. As such, inhibition of
complex III (also known as cytochrome bc1 complex/
cytochrome c reductase) completely abolished nitrite
reduction (Kozlov et al., 1999; Nohl et al., 2000). There is
also evidence to suggest that complex IV (cytochrome c
oxidase) may reduce nitrite to ·NO. Treatment of rat
liver homogenate with either antimycin A or myxothia-
zol (both complex III inhibitors) in the presence of the
electron donor N,N,N9,N9-tetramethyl-p-phenylenedi-
amine dihydrochloride, which feeds electrons down-
stream of complex III of the respiratory chain, did not
block nitrite reduction (Castello et al., 2006). Further-
more, carbon monoxide, a complex IV inhibitor,
inhibited nitrite reduction (Castello et al., 2006). How-
ever, NaNO2 (1 mmol/l) reduction in this in vitro setting
was only evident when experiments were conducted at
O2 concentrations below 2% being maximal under
anoxic conditions (Castello et al., 2006). The physiologic
relevance of this phenomenon likely pertains only to the
ischemic setting, and further investigation assessing
the impact of this pathway upon biologic function is
needed to better understand significance.
3. Globins. The globins are a family of globular
heme-containing proteins that are involved in the
transport of O2; however, an abundance of literature
supports a role for these proteins in facilitating nitrite
reduction. In particular, we summarize below the
evidence for Hb, Mb, neuroglobin, and cytoglobin as
nitrite reductases.
a. Hemoglobin. It was first discovered in the 1930s
by Brooks and further elucidated by Doyle and col-
leagues in the 1980s that deoxyHb (HbFe21) in the
presence of nitrite has the ability to produce ·NO,
metHB (HbFe31), and hydroxide (Brooks, 1937; Doyle
et al., 1981) (see eq. 1.2). Despite these observations
frommany years ago, it was not until 2003 that Gladwin
and colleagues proposed the biologic significance of this
reaction in terms of vasodilation. Gladwin’s studies
indicated that in the presence of deoxyHb, nitrite
generates ·NO, a phenomenon much reduced in the
presence of oxyHb (Cosby et al., 2003), the latter being
as one would suspect due to the rapid ·NO scavenging
characteristics of oxyHb. This opposing activity of
different Hb states has led to inevitable uncertainty
regarding the functional significance of Hb as a nitrite
reductase.
Further studies by Gladwin and colleagues investi-
gating the kinetics of these reactions has led to the
proposal that the extent of nitrite reduction and the rate
of reaction is dependent upon the state of the Hb
tetramer. Hb can exist in two states, the tense state
(T-state), in which Hb lacks oxygen, termed deoxyHb,
and the relaxed state (R-state), in which Hb is oxygen-
ated, termed oxyHb. It has been demonstrated that the
R-state reacts with nitrite ;100-fold faster than the
T-state (Huang et al., 2005a,b). This results in the peak
rate of ·NO production occurring when Hb is 50%
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saturated (p50) with oxygen. The physiologic relevance
of these observations has been demonstrated using
organ bath pharmacology. Precontracted rat aortic
rings subject to increasing concentrations of NaNO2
(10 nmol/l to 300 mmol/l) under decreasing O2 tensions
(60, 25, 15 mm Hg) relaxed the greatest under low O2
tension, with significant relaxant activity evident at
concentrations of 200 nmol/l NaNO2 (Crawford et al.,
2006), i.e., concentrations well within the physiologic
range of plasma nitrite concentration.
However, the issue still remains, considering the
nitrite chemistry proposed above, how can the ·NO
produced from nitrite reduction by Hb escape scaveng-
ing by oxyHb, particularly since maximal nitrite re-
duction occurs at p50, so considerable and sufficient
oxyHb is present. There have been various hypotheses
explaining how this might happen, including those
mentioned earlier relating to the cell-free layer at the
blood vessel wall created by flowing blood. However,
there is also some chemistry that has been proposed to
explain how thismight occur. It has been suggested that
the reaction of nitrite and deoxyHb forms an interme-
diate, such as N2O3, which is less reactive than ·NO and
so is able to escape the erythrocyte and, once outside,
can dissociate to release ·NO (Robinson and Lancaster,
2005; Basu et al., 2007; Hopmann et al., 2011). Simi-
larly, a second hypothesis is that S-nitrosohemoglobin
is generated, which allows escape from the erythrocyte
and subsequent dissociation to release ·NO (Stamler
et al., 1997; Pawloski et al., 2001; Nagababu et al., 2006;
Salgado et al., 2009). Although it is clear that Hb does
express nitrite reductase capacity, the continued un-
certainty regarding the issues highlighted above make
it difficult to be certain of the exact role of Hb in
mediating the functional effects that have been attrib-
uted to nitrite in vivo.
b. Myoglobin. Deoxy Mb (deoxyMb) was first dem-
onstrated to act as a nitrite reductase by Gladwin and
colleagues, who discovered that nitrite bioactivation is
;36 times faster with deoxyMb compared with deox-
yHb: an effect that was attributed to its lower heme
redox potential (Shiva et al., 2007a). The physiologic
relevance of Mb-mediated nitrite reduction has been
demonstrated in hearts excised from Mb KO mice, in
which there was;50% reduction inNaNO2 (100 mmol/l)-
derived ·NO, compared with hearts of WT mice pro-
duction after 30minutes at pH 7.4 (Hendgen-Cotta et al.,
2008). These transgenics have also helped to confirm the
biologic importance of this chemistry: WT mice sub-
jected to left anterior coronary artery occlusion and
treated with 48 nmol/l NaNO2 had 61% smaller infarcts
compared with those with no treatment, whereas there
was no difference between NaNO2-treated and un-
treated Mb KO mice (Hendgen-Cotta et al., 2008). It
has also been suggested that this chemistry of Mb is not
simply restricted to the heart, since Mb is also present
in vascular smooth muscle. Studies with mice and
under systemic hypoxia, induced by ventilation with
10%O2/90%N2, facilitatedNaNO2 (10mmol/l) reduction
that was associated with an;3-fold and 2-fold elevation
in plasma and aortic cGMP, respectively (Totzeck et al.,
2012).
c. Neuroglobin. Neuroglobin is found in the brain of
humans and mice and shares 21% and 25% homology
with Mb and Hb, respectively (Burmester et al., 2000).
Neuroglobin has been shown to express cytoprotective
effects in vivo (Sun et al., 2003; Khan et al., 2006),
although whether this relates to its ability to reduce
nitrite to ·NO is unclear. The mechanism of nitrite
reduction proposed is similar to that of the other globins;
however, neuroglobin contains a hexa-coordinate heme
atom, whereas Mb and Hb contain penta-coordinate
heme atoms (Tiso et al., 2011). Recombinant murine
and human neuroglobin elicit nitrite reductase activity
when in the ferrous formunder hypoxic conditions at pH
7.4 (Petersen et al., 2008; Tiso et al., 2011); however, the
rate is ;2000 faster in the penta-coordinate state as
opposed to the hexa-coordinate state (Jayaraman et al.,
2011; Tiso et al., 2011). One of the key differences
between neuroglobin and the penta-coordinate globins,
such as Mb, is that a distal histidine residue is bound to
the heme, whether in the ferrous or ferric form, and for
the heme to react with nitrite, the histidine must
dissociate from the heme. This issue is particularly
relevant because mutations in the histidine of neuro-
globin profoundly influence rates of nitrite reduction,
i.e., removal of His64 (E7) in neuroglobin results in a
2500 increased rate of nitrite reduction comparedwith
theWT (Tiso et al., 2011). Further studies exploring the
nitrite reductase activity of neuroglobinmore closely, by
expressing the zebrafish protein (which has high ho-
mology with the human protein) in Escherichia coli,
indicate that subtle alterations in the distal heme
binding pocket can result in a profound change in nitrite
reductase capacity, hinting at possibilities of engineer-
ing proteins with improved nitrite reductase activity
(Tejero et al., 2015).
d. Cytoglobin. Cytoglobin, although originally
thought to be predominantly a liver protein, is now
known to be widely expressed (Burmester et al., 2000)
across species and has been found in human, mouse,
and zebrafish, sharing;30% homology withMb and Hb
(Burmester et al., 2000). Similar to neuroglobin, the
heme atom is in a hexa-coordinate state, and a penta-
coordinate state is required for nitrite reduction. Under
hypoxic conditions, which favor nitrite reduction, cyto-
globin expression is elevated (Fordel et al., 2004).
However, initially it was suggested that recombinant
mouse ferrous cytoglobin had no nitrite reductase
activity at pH 7.4, with 7.4 mmol/l nitrite (Petersen
et al., 2008). In contrast, a subsequent study has shown
that although oxygenated cytoglobin, similarly to Hb,
will react with ·NO to form nitrate and so act to
scavenge ·NO, under anaerobic conditions and at pH
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7.4 or 8, ferrous cytoglobin reduces NaNO2 (100 mmol/l)
to form ·NO as measured by EPR (Li et al., 2012a). In
addition to this reaction occurring under physiologic
pH, nitrite reduction by cytoglobin was found to in-
crease with decreasing pH (Li et al., 2012a). The
discrepancy between the two studies may be due to
the differing concentrations of nitrite used.
That the nitrite reductase activity is catalytic and
thus potentially important in vivo (because of the
widespread expression of cytoglobin in tissues) was
recently elegantly demonstrated in experiments with
both human and fish cytoglobin. Gladwin and colleagues
demonstrated that cytochrome b5 and cytochrome b5
reductase reduce cytoglobin at rates that are up to 250
faster than for eitherHb orMb. The authors suggest that
this enhanced rate of activity with physiologic levels of
the reactants intimates that cytoglobin is the primary
substrate for these reductants in vivo and that, because
of its relatively ubiquitous expression in tissues, cyto-
globin may be a critical mechanism for ·NO generation
from nitrite in physiology (Amdahl et al., 2017).
4. Indoleamine 2,3-Dioxygenase 1. Very recently, it
has been demonstrated that indoleamine 2,3-dioxyge-
nase 1 (IDO1), a cytosolic heme enzyme involved in the
initial and rate-limiting step of L-tryptophan metabolism
in the kynurenine pathway, is capable of reducing nitrite
to ·NO under anaerobic conditions (Lim et al., 2019).
Similar to Mb and Hb, the heme in IDO1 is in a penta-
coordinate state, which may account for the increased
rates, as discussed above. A contrasting feature, in
comparison with other heme-containing nitrite reduc-
tases, is that the nitrite reductase activity of IDO1 is
enhanced in alkaline conditions (pH 8), which Lim and
colleagues speculate may be due to the close proximity of
histidine residues potentially capable of donating a proton
(Lim et al., 2019). These initial observations have been
made in recombinant human IDO1, and further studies
are required to assess the in vivo relevance of these
findings.
5. Nitric Oxide Synthase. Under anoxic conditions,
it has been demonstrated that endothelial NOS can
function as a nitrite reductase (Gautier et al., 2006;
Vanin et al., 2007). Recombinant eNOS in the presence
of anoxia, with NADPH (100 mmol/l) and NaNO2
(500 mmol/l) at pH 7.6, resulted in ferrous-nitrosyl
eNOS formation and then, consequently, ·NO genera-
tion (Gautier et al., 2006). This proposal was supported
by studies using 15N-labeled NaNO2 with EPR mea-
surements of 15·NO (Gautier et al., 2006). Subsequently,
studies with recombinant iNOS and neuronal NOS
have suggested that this activity is unique to the eNOS
isoform, since neither isoform generated ·NO from
relatively high concentrations of NaNO2 (500 mmol/l)
under anoxic conditions generated with argon (Mikula
et al., 2009). In addition, we have shown that eryth-
rocytes, collected from healthy individuals, when
incubated with physiologic concentrations of NaNO2
(10–100 mmol/l) under hypoxic conditions, generate
·NO; a response that is attenuated by the eNOS inhib-
itors N(g)-nitro-L-arginine methyl ester (L-NAME) and
NG-monomethyl-L-arginine acetate (300 mmol/l) (Webb
et al., 2008a). The identification of eNOS as a nitrite
reductase under hypoxia and anoxia is an interesting
finding and suggests that this enzyme, utilizing distinct
substrates dependent upon the environmental condi-
tions, may be equipped to produce ·NO under the full
spectrum of oxygen tension that is experienced in vivo.
6. Carbonic Anhydrase. More recently it has been
suggested that carbonic anhydrase, a key component
involved in acid-base regulation in the body through the
hydration of CO2 to produce protons and thus H2O and
bicarbonate (HCO3
2) (eq. 1.8), also acts as a nitrite
reductase, particularly in metabolically active tissue.
Hydration of CO2 is as follows:
Carbon  dioxide
CO2                 1
        waterH2O         ⇔
        carbonic  acidH2CO3       ⇔
          bicarbonateHCO32       1
proton
H1
ð1:8Þ
In 2004 work from Innocenti et al. (2004) demonstrated
that anions, including nitrite, could bind to the active
site of carbonic anhydrase and, in this way, inhibit CO2
hydration (Innocenti et al., 2004). However, it was not
until 2009 that the possibility that this interaction of
nitrite with the enzyme might actually yield ·NO too
was considered. Addition of NaNO2 (100 mmol/l) to
purified carbonic anhydrase at pH 7.2 resulted in ·NO
generation, an effect that was potentiated at pH 5.9
(Aamandetal., 2009).Additionofdorzolamide (250mmol/l),
an inhibitor of the hydration of CO2, resulted in a
significant elevation of ·NO generation (Aamand et al.,
2009). The explanation for the inhibitory activity for
CO2 hydration but not nitrite reduction was suggested
by the authors to imply that distinct binding sites for
the two exist, with the inhibitors only binding to the
active Zn21 binding site for CO2. The reactions proposed
to underlie this are shown previously (eqs. 1.4–1.6) with
a theoretical N2O3 intermediate formed (the levels of
which are increased with reducing pH) that rapidly
dissociates to give ·NO (along with an equivalent
of NO2).
This nitrite-reducing activity of carbonic anhydrase
was tested for functional importance using rat aorta
segments treated with NaNO2 (10 mmol/l) with and
without dorzolamide. The studies showed, as with the
purified enzyme, an increase (;50%) in the functional
relaxation response to NaNO2 (Aamand et al., 2009).
However, using EPR and measurement of nitrosyl Hb
as a readout, inhibition of carbonic anhydrase using
dorzolamide did not affect erythrocyte nitrite reduction
(Liu et al., 2015). Recently, it has also been shown that
human platelets treated with NaNO2 (100 mmol/l)
showed no change in cGMP or phospho-vasodilator–
stimulated phosphoprotein (phospho-VASP)S239, amarker
Nitrate-Nitrite-Nitric Oxide Pathway 711
of protein kinase G activity; however, with the addition
of recombinant bovine carbonic anhydrase, there was a
significant elevation in both markers (Hanff et al.,
2016). In healthy volunteers, treatment with dorzo-
lamide enhanced NaNO2-induced vasodilation of
the radial artery (Omar et al., 2015) and a similar
BP-lowering effect was seen in healthy volunteers
treated with acetazolamide and NaNO2 (Rosenbaek
et al., 2018). In contrast, more recently, a re-evaluation
of the nitrite reductase activity of carbonic anhydrase
has suggested little activity. Incubation of purified
bovine carbonic anhydrase at pH 5.9 with 100 mmol/l
NaNO2 demonstrated neither N2O3 nor ·NO generation
(Andring et al., 2018).
Although it is clear that there are numerous mam-
malian nitrite reductases that have been identified in
cell-free and cellular preparations, inWTand transgenic
animals, and in humans, the importance of these discov-
eries lies within the translational potential for enhanced
·NO delivery into real benefits in health and disease.
Below we discuss the major therapeutic areas in which
targeting and translation of the noncanonical pathway for
·NO in humans and patients has been investigated.
VI. Functional Effects of the Noncanonical ·NO
Pathway and Clinical Translation
Nitrite has been used as a cyanide antidote for more
than 75 years (Butler and Feelisch, 2008) and is used in
food preservation to prevent oxidation of fatty acids and
to prevent rancidity and malodor formation, as well as
critically controlling C. botulinum growth and toxin
production (Hustad et al., 1973; Honikel, 2008). In
addition, inorganic nitrite and nitrate have been used
as therapeutics in the CV system for over 85 years
(Reichert and Mitchell, 1880; Stieglitz, 1927), but it is
only through the relatively recent renewed interest in
these anions that potential translational opportunities
more broadly have been assessed.
The overwhelming evidence supporting the existence
and functional efficacy of this noncanonical pathway for
·NO generation has raised interest, particularly to
“rescue” levels of ·NO in diseases in which reduced
bioavailability plays a prominent role in pathogenesis.
This is of interest particularly in CVD, in which a
deficiency of bioavailable ·NO driven by decreased
L-arginine–derived ·NO generation is thought to con-
tribute to pathology.
Although there is limited data on the beneficial
effects of nitrite elevation directly or via oral conver-
sion of inorganic nitrate in a miscellany of unrelated
conditions, such as periodontitis (Jockel-Schneider
et al., 2016) and urea cycle disorders (Erez et al.,
2011; Nagamani et al., 2012), there is a wealth of
published preclinical and clinical studies demonstrat-
ing efficacy in disease areas in which known ·NO
deficiency contributes to, or ·NO supplementation
slows, disease progression.
A. Nitrite, Nitrate, and the CV System
Because of the classic role of eNOS-derived ·NO, and
lack thereof, in CV health and disease (Moncada and
Higgs, 2006), nitrite and nitrate as therapeutics are
most advanced in the realm of CVD.
1. Vasodilation. Although it had been long since
demonstrated that once-acidified supraphysiologic con-
centrations of inorganic nitrite exerted significant
vasodilator responses (Furchgott and Bhadrakom,
1953), it was only more recently in 2001 that the view
that nitrite was inert at physiologic levels within the CV
system was finally eroded. In rat aortic rings, applica-
tion of low micromoles per liter NaNO2 (2.5 mmol/l),
although inactive under physiologic pH, was shown to
cause significant relaxation of precontracted rat aorta
under acidic (pH 6.6) conditions (Modin et al., 2001).
The importance of this observation was finally appreci-
ated with demonstration by Gladwin and colleagues
that infusion of NaNO2 into the forearm of healthy
volunteers causes vasodilatation with concomitant in-
creased forearm blood flow, a phenomenon augmented
when the volunteers were asked to exercise by conduct-
ing handgrips (Cosby et al., 2003). The authors proposed
that this effect of exercise to increase nitrite-induced
vasodilation related to the fact that conversion of nitrite
to ·NO is enhanced under reduced O2 conditions. This
observation simply and elegantly indicated that nitrite
exerts significant biologic effects in the relative hypoxia
created by conditions relevant to the normal and typical
ranges in O2 tension that occur in day-to-day activity.
These findings intimated a potentially important role of
this anion in sustaining/regulating normal vasodilator
tone in the healthy individual, particularly since, in the
normal passage of blood through the circulation, O2
tension will drop from 100mmHg as it exits the heart to
40 mm Hg when it returns via the venous circulation.
The thesis that O2 tension determines the contribu-
tion that nitrite plays in regulating vascular tone was
further developed by studies conducted by Frenneaux
and colleagues, who used radiolabeled, autologous blood
together with standard forearm plethysmographic tech-
niques, thus enabling the separate determination of
arterial and venous vasodilation. Vascular reactivity
was measured over a 20-minute infusion period. Under
normoxic conditions, intra-arterial delivery of increas-
ing doses of NaNO2 (314 nmol/min to 7.84 mmol/min)
decreased venous tone in a dose-dependent manner by
up to 20%–35% (Maher et al., 2008). However, in contrast
to Gladwin and colleagues’ earlier works (Cosby et al.,
2003), low-dose NaNO2 infusions (314 nmol/min), asso-
ciatedwith;30% increases in forearmblood flow, did not
dilate the arterial side of the circulation (Maher et al.,
2008). Indeed, arterial dilation was only apparent (in-
creasing forearmblood flow by 60%–80%) atmuch higher
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doses (3.14–7.84 mmol/min) (Maher et al., 2008). These
findings replicate much earlier work that used detailed
tilt-table testing to elucidate the role of dilation of the
venous circulation (and not arterial circulation) as the
cause of nitrite-induced CV collapse (Weiss et al., 1937;
Wilkins et al., 1937). However, to make the arterial side
of the circulation “hypoxic,” subjects were put through
the protocol again, but only after arterial oxygen satura-
tions were maintained at 83%–88% by breathing 12%
O2. In this situation, although there was no change in
the magnitude or duration of the effects on the venous
side of the circulation, infusion of 314 nmol/min NaNO2
(which had no effect in normoxic conditions) increased
forearm blood flow by;40% (Maher et al., 2008). Such a
finding is consistent with the concept that the vasodi-
lator potential of nitrite is not solely limited to anoxia or
extreme ischemia but is proportional to the extent of
“hypoxia” in the tissues and blood as it deoxygenates
from arterial to venous sides.
More recently, the effect of nitrite on muscular,
conduit blood vessels has been shown. Infusion of a
single dose of NaNO2 (8.7 mmol/min) for 60minutes into
the brachial artery caused an ;30% increase in radial
artery diameter (Omar et al., 2015). Comparison of the
dose-response relationship of NaNO2 to GTN demon-
strated comparable effects. For example, with an in-
fusion of NaNO2 of 26 mmol/min (1.8 mg/min) for
20 minutes, a statistically significant ;30% increase
in diameter was evident, a magnitude of response
similar to that produced in the same healthy volunteers
by GTN 1.3 nmol/min, which is equivalent to 0.3 mg/min
(Omar et al., 2015). Furthermore, similar effects have
been seen in the coronary circulation (O’Gallagher et al.,
2018). Paradoxically the effect in the peripheral circu-
lation was most pronounced in normoxia and inhibited
by hypoxia or hyperoxia (Omar et al., 2015), an obser-
vation that conflicts with the findings previously dis-
cussed. Exactly why this is the case is uncertain.
Physiologically, the role of nitrite as an endocrine
storage form of ·NO that is released after a decrease in
O2 tension and is thus responsible for hypoxic vasodi-
latation has been investigated. Hypoxic vasodilation is
responsible for matching O2 demand from respiring
tissues to O2 delivery; thus, when metabolic demand
rises, O2 consumption increases, and with this, a mild
hypoxia develops that then triggers vasodilation to
increase O2 availability to the organ. Erythrocytes have
been identified as a key hypoxic sensor acting as a
source of ·NO delivery that underlies the biologic effect
(Segal and Duling, 1986; Stamler et al., 1997). However,
two competing theories for the form of ·NO that is
transported and stored ready to deliver ·NO on demand
have been proposed: nitrite and S-nitrosothiols.
Arterial-venous gradients of nitrite (Gladwin et al.,
2000) and nitrosothiols (Stamler et al., 1992), and the
formation of iron-nitrosylHb or S-nitroso-Hb asmarkers
of consumption and ·NO delivery have been measured
in the peripheral and cerebral circulation, with exercise
and under hypoxia. These studies demonstrate clear
evidence of arterial-venous gradients for nitrite and
formation of iron-nitrosylHb only, suggesting a role for
nitrite as an endocrine reservoir of ·NO activity
(Gladwin et al., 2000; Bailey et al., 2017).
It is likely that nitrite-induced vasodilatation is de-
pendent upon activation of the canonical ·NO-dependent
GC-1 pathway, since the GC-1 inhibitor 1H-[1,2,4]-
oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) attenuates
responses to nitrite in blood vessels of rodents and
pigs (Botden et al., 2012; Ghosh et al., 2013). It is
noteworthy that these observations recapitulate
much earlier studies using drugs such as methylene
blue to block GC-1 activity (Mittal et al., 1978;
Ignarro and Gruetter, 1980; Gruetter et al., 1981);
however, such observations have not been observed in
all vascular beds tested. Recent studies in the renal
microvasculature of the mouse demonstrate nitrite is
two orders of magnitude more potent than in other
vascular beds (Gao et al., 2015). Interestingly, ·NO
scavenging abolished nitrite-induced vasodilatation,
but treatment with ODQ did not, indicating a GC-1-
independent effect. In the same study, inorganic nitrate
supplementation reduced NADPH oxidase activity, a
prime source of oxidative stress, and the actions of
NADPH oxidase inhibition were synonymous and not
additive. These results suggest that NADPH oxidase, at
least in the renal microvasculature, could be a mecha-
nistic target for nitrite-derived ·NO and associated BP
lowering through reduction in oxidative stress (Gao
et al., 2015).
Furthermore, there may be additional effects on
vascular tone that are affected by nitrite-derived ·NO
that are centrally driven. Elevation of systemic nitrite
levels reduces renal sympathetic nerve signaling in rats
under L-NAME or angiotensin II–driven hypertension.
This treatment also reduces muscle sympathetic nerve
activity in humans, a gold-standard measure of efferent
sympathetic signaling (Notay et al., 2017; Guimarães
et al., 2019). The precise mechanism of nitrite-derived
·NO sympatholysis is not known but may relate to
alterations in expression of angiotensin II receptors in
the rostral ventral lateral medulla, the brainstem
sympathetic control center (Guimarães et al., 2019), or
to changes in peripheral chemoreflex activity. The
peripheral chemoreflex is primarily responsible for
augmenting ventilation in response to hypoxia but is
known to be augmented in human hypertension in
the absence of hypoxia and responsible for elevated
BP through efferent central sympathetic signaling
(Marshall, 1994), and this mechanism is attenuated
after inorganic nitrate supplementation in older
adult humans (Bock et al., 2018b).
Irrespective of the precise mechanism, these reported
effects of nitrite on vascular tone raise the possibility
that systemic nitrite administration or dietary nitrate
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supplementation, as a means to elevate circulating
levels of nitrite, may be useful in the treatment of
hypertension.
2. Blood Pressure. These demonstrations of the
vasodilator potential of nitrite are also concordant
with the effects of nitrite supplementation in normo-
tensive animals, as well as in animal models of hyper-
tension. In anesthetized rats, administration of NaNO2
(10–1000 mmol/kg, i.v.) was associated with dose-
dependent reductions in MAP for up to 30 minutes
(Vleeming et al., 1997), observations we ourselves have
reproduced in conscious tethered rats (Ghosh et al.,
2013). In free-moving rats, supplementation of drinking
water with extremely high concentrations of NaNO2
(36 mmol/l equivalent to 2.48 g/l) reduced BP measured
by telemetry (Vleeming et al., 1997). If we consider that
a typical Sprague-Dawley or Wistar averaged-sized
adult rat (;250 g) will drink 30–50 ml of water daily,
this would give a maximum daily dose of NaNO2 of
124mg, which in turn, would approximate to 500mg/kg,
a level exceeding the ADI by 135 times. Nevertheless,
these early studies clearly demonstrate BP-lowering
potential.
Similarly, in spontaneously hypertensive rats, acute
bolus doses of KNO2 (1–30,000 nmol/kg, equivalent to
;10 nmol to 0.3 mmol/l circulating concentrations)
(Ghosh et al., 2013), as well as prolonged oral adminis-
tration (up to 1 year) of extremely high concentrations of
NaNO2 (50–100 mmol/l equating to 3.5–6.9 g/l in
drinking water), were associated with dose-dependent
reductions in BP (Beier et al., 1995; Haas et al., 1999).
These observations indicate two important issues:
firstly, that the efficacy of nitrite was still evident in
the setting of raised BP [indeed, our studies indicated
a substantially enhanced potency of nitrite in this
setting (Ghosh et al., 2013)], and secondly, that signif-
icant BP lowering was evident even after 1 year of
ingestion. This latter observation hints at a key char-
acteristic of nitrite, and potentially nitrate, that might
endow these anions with a superior potential for
therapeutics over the organic nitrates, i.e., no devel-
opment of tolerance, which is the key limiting factor in
the use of organic nitrates clinically (Münzel et al.,
2005). This was tested more formally by Dejam et al.
(2007), in which NaNO2 (12.5 mg/kg per minute) was
infused in primates continuously over a 2-week period
and was also followed by a daily bolus of NaNO2 at a
dose of 12,000 mg/kg per minute. This bolus dose
lowered MAP by 18 mm Hg, with no diminution of
effect over time, indicating lack of tolerance. The utility
of nitrite as an antihypertensive either by acute or
chronic daily oral gavage or supplementation in water
has been confirmed in other models of hypertension,
such as the deoxycorticosterone acetate (DOCA)-salt,
two-kidney/one-clip, and L-NAME–induced hyperten-
sion (Tsuchiya et al., 2005; Montenegro et al., 2011,
2012; Amaral et al., 2015).
There is also evidence that nitrite lowers BP in
humans. Infusion of NaNO2 into the brachial artery
was associated with local nitrite concentrations of
;200 mmol/l and systemic elevation of nitrite to
16 mmol/l and was associated with a reduction in MAP
of 7 mm Hg (Cosby et al., 2003). Further studies from
the same group using stepped brachial infusions of
NaNO2 achieving local venous plasma nitrite concen-
trations of 30 mmol/l were associated with a drop in
MAP of 10 mm Hg, an effect that persisted for up to
3 hours (Dejam et al., 2007). Studies assessing the
feasibility of long-term infusion of NaNO2 in humans
has been assessed in healthy volunteers. Pluta et al.
(2011) examined the duration of action of increasing
doses of NaNO2 (4.2–445.7 mg/kg per hour) in healthy
volunteers, measuring circulating levels of nitrite,
together with assessment of metHB levels and BP. This
approach was taken because nitrite has a short half-life
(;30 minutes), and the authors wished to identify
whether continuous infusion might provide a mecha-
nism to exert persistent effects upon blood flow, partic-
ularly focusing upon the potential in conditions such as
cerebral vasospasm. In this study, they showed that the
BP-lowering effects of NaNO2 were maintained over
48 hours and were dose-dependent but that ceasing of
infusion resulted in a prompt restoration of BP to
baseline levels in association with circulating levels of
nitrite (Pluta et al., 2011).
The authors of some of the earlier animal studies
assessing responses to NaNO2 hypothesized that eleva-
tion of systemic nitrite levels from nitrate via bacterial
reduction would reduce BP, although they did not
explicitly test this (Classen et al., 1990; Vleeming
et al., 1997). However, there is now a substantial body
of evidence in both animal models and humans to
support this proposal.
In rats supplemented with 10 mmol/l NaNO3 in
drinking water over a week, BP was reduced when
measured by cannulation under anesthesia or in free-
moving animals using telemetric methods compared
with matched control. This effect of NaNO3 was abol-
ished by use of antibacterial mouthwash twice daily.
Notably, this oral treatment did not affect BP lowering
in response to NaNO2 supplementation (Petersson et al.,
2009). In uninephrectomized rats fed a high-salt diet as a
model of hypertension, supplementation with NaNO3
(0.1–1 mmol/kg per day) lowered BP and ameliorated
cardiac and renal fibrosis, suggesting beneficial effects
beyond BP lowering (Carlström et al., 2011).
A key feature in human hypertension and CVD is that
eNOS is dysfunctional, resulting in a generalized ·NO
deficiency. Several research groups have sought to
explore the potential utility of nitrite and/or nitrate2
to restore ·NO homeostasis and lower BP in hyperten-
sive animal models driven by reduced eNOS activity.
Using the eNOS inhibitor L-NAME to induce hyper-
tension, administration of NaNO2 in drinking water
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(20–200 mmol/l) or by oral gavage (0.2 mmol/kg per day)
for 3 to 4 weeks prevented the development of hyper-
tension (Tsuchiya et al., 2005; Montenegro et al.,
2014). Similarly, oral gavage with 0.1 mmol/kg per
day NaNO3 reduced BP in both eNOS KO mice and
L-NAME–treated rats (Carlström et al., 2010, 2015).
These results suggest that elevating systemic nitrite
levels, whether directly or via dietary nitrate supple-
mentation, can compensate for diminished eNOS-
derived ·NO, whether it is provided as a pretreatment
or used to reverse pre-existing hypertension driven by
reduced ·NO levels.
The above studies and concepts have been translated
into a range of clinical studies. Although much of the
preclinical data suggests that inorganic nitrite and
nitrate are efficacious approaches to lower BP, what-
ever the cause of the hypertension, in the clinical
setting, the majority of the studies to date have tested
dietary nitrate rather than nitrite, and this relates to a
number of reasons that include issues related to half-life
and potential toxicity (discussed later).
Given the pharmacokinetic disadvantages of nitrite
as a long-term therapy, only onemajor human study has
explored inorganic nitrite therapy and BP control
specifically. In this study, individual adults aged 50–
79, who were free of all cardiometabolic disease and
were normotensive at the start of the study (but with
diminished endothelial function at baseline), were
randomized in three parallel groups to receive either
40 mg (0.6 mmol) or 80 mg (1.2 mmol) NaNO2 or
placebo, all twice daily for 10 weeks (n5 10–11). Trough
plasma nitrite levels were significantly elevated (;2-
fold) in both intervention groups after 10weeks, but this
was not associated with any change in BP (DeVan et al.,
2016). The lack of any BP lowering in subjects with
optimal/normal BP is not surprising and may be consid-
ered ideal, identifying an approach that does not lead to
symptomatic hypotension and/or hypotension-related
syncope. The lack of any BP effect likely reflects the
accepted dogma that the magnitude of BP reduction
expected from any single dose of antihypertensive agent
is proportional to basal BP level (Law et al., 2003).
However, this result is at odds with the majority of
studies that demonstrate BP lowering in normotensive
persons after systemic nitrite elevation after inorganic
nitrate supplementation (Table 1) (Larsen et al., 2006;
Webb et al., 2008b; Bailey et al., 2009, 2010; Kapil et al.,
2010; Sobko et al., 2010; Vanhatalo et al., 2010; Lansley
et al., 2011a,b; Bahra et al., 2012; Bondonno et al., 2012,
2014b; Cermak et al., 2012a; Coles and Clifton, 2012;
Bond et al., 2013, 2014; Joris and Mensink, 2013; Kelly
et al., 2013; Liu et al., 2013;Wylie et al., 2013; Jajja et al.,
2014; Rammos et al., 2014; Ashor et al., 2015; Ashworth
et al., 2015; Bourdillon et al., 2015; Jovanovski et al.,
2015; Lee et al., 2015; Choi et al., 2016; Flueck et al.,
2016; Jonvik et al., 2016; Raubenheimer et al., 2017;
Jones et al., 2019). The first contemporary demonstration
of BP-lowering effect of inorganic nitrate via conversion to
nitrite used NaNO3 [0.1 mmol/kg (6.2 mg/kg)] daily for
3 days comparedwithmatchedNaCl control in 17healthy
subjects. Plasma nitrite levels increased ;1.5-fold after
nitrate supplementation only, together with a significant
reduction in diastolic BP (DBP; D3.7 mm Hg) (Larsen
et al., 2006).
Nitrate is also available in dietary form from vegeta-
bles, so the equivalency of providing nitrate in salt form
(as KNO3) and dietary form (as beetroot juice) was
established by us in 2008. Acute, single administration
of 22.5 mmol (1395 mg) dietary nitrate as beetroot juice
(compared with water control) and an approximate
equivalent of KNO3 (24 mmol; 1488 mg nitrate) com-
pared with matched KCl control in separate cohorts of
healthy subjects demonstrated similar time courses of
systemic nitrite elevation and BP reduction over
24 hours. Peak nitrite levels were contemporaneous to
peak BP reduction at 2.5–3 hours post–inorganic ni-
trate supplementation. Additionally, peak BP reduction
from baseline was similar for both forms of inorganic
nitrate supplementation (;10/7 mm Hg), with no
changes in either placebo group (Webb et al., 2008b;
Kapil et al., 2010) (Fig. 7A). Furthermore, change in
SBPwas significantly inversely correlated to changes in
plasma nitrite and the determining effect on BP (Webb
et al., 2008b; Kapil et al., 2010). These studies addi-
tionally demonstrated a dose-dependent effect of in-
organic nitrate supplementation on BP reduction and
provided the first evidence of bioactive ·NO production
after nitrate supplementation by determining signifi-
cant elevation of circulating cGMP concentrations
(Kapil et al., 2010); cGMP is a sensitive marker that
confirms bioactive ·NO generation (Batchelor et al.,
2010). An unintended but positive outcome of our work
has been the introduction of beetroot juice, with known
and measurable amounts of nitrate, as a mechanism to
explore the biologic efficacy of the enterosalivary circuit
of nitrate. The impact of this is shown in a PubMed
search demonstrating the uptake of this approach after
the 2008 publication (Fig. 8).
The importance of enterosalivary generation of ni-
trite was confirmed in our studies by asking subjects to
refrain from swallowing saliva post–nitrate ingestion,
thereby interrupting oral nitrate reduction but not
interfering with nitrate absorption itself (Webb et al.,
2008b). Elevation of circulating nitrate levels were
unaffected by this intervention, but it did prevent the
rise in circulating plasma nitrite level as had been
demonstrated by others previously (Lundberg and
Govoni, 2004). However, in addition to this, we demon-
strated that this effect was associated with an absence
of the BP reduction effect, thus confirming nitrite as the
bioactive moiety after nitrate supplementation (Webb
et al., 2008b).
Although the acute (i.e., ,24 hour) effects of inor-
ganic and dietary nitrate supplementation on BP are
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TABLE 1
Randomized, controlled studies evaluating nitrate supplementation on blood pressure in healthy volunteers
Reference Cohort Design Intervention TreatmentDuration Baseline BP (mm Hg) Max DBP (mm Hg)
Larsen et al., 2006 HV Crossover NaNO3, 0.1 mmol/kg per day 3 days Clinic BP not stated N.S./23.7
Age 5 24 n 5 17 NaCl, 0.1 mmol/kg per day placebo
Webb et al., 2008b HV Crossover Beetroot juice (500 ml), 22.5 mmol nitrate 1 day Clinic 108/70 210.4/28.0
Age 5 26 n 5 14 Matched-volume water control
Bailey et al., 2009 HV Crossover Beetroot juice, 11.2 mmol nitrate 6 days Clinic BP not stated 26/ N.S.
Age 5 26 n 5 8 Matched-volume black currant juice control
Kapil et al., 2010 HV Crossover KNO3, 24 mmol 1 day Clinic 110/70 29.4/26.0
Age 5 23 n 5 20 KCl, 24 mmol placebo
Kapil et al., 2010 HV Crossover Beetroot juice (250 ml), 5.6 mmol nitrate 3 h Clinic 121/71 25.4/ N.S.
Age 5 25 n 5 9 Matched-volume water control
Bailey et al., 2010 HV Crossover Beetroot juice, 5.1 mmol nitrate 6 days Clinic 125/73 25/22
Age 5 28 n 5 7 Matched-volume black currant juice control
Vanhatalo et al.,
2010
HV Crossover Beetroot juice, 5.2 mmol nitrate 15 days Clinic 127/72 27/ N.S.
Age 5 29 n 5 8 Matched-volume black currant juice control
Sobko et al., 2010 HV Crossover Japanese diet, 0.3 mmol/kg per day nitrate 10 days Clinic BP not stated N.S./24.5
Age 5 36 n 5 25 Low-nitrate diet (nitrate content not stated)
Lansley et al., 2011b HV Crossover Beetroot juice, 6.2 mmol nitrate 6 days Clinic 129/66 25/ N.S.
Age 5 22 n 5 9 Nitrate-deplete beetroot juice placebo
Lansley et al., 2011a HV Crossover Beetroot juice, 6.2 mmol nitrate 2.5 h Clinic 131/72 26/ N.S.
Age 5 21 n 5 9 Nitrate-deplete beetroot juice placebo
Cermak et al., 2012a HV Crossover Beetroot juice, 8 mmol nitrate 6 days Clinic 119/74 N.S.
Age 5 31 n 5 12 Nitrate-deplete beetroot juice placebo
Coles and Clifton
2012
HV Crossover Beetroot juice, 7.5 mmol nitrate 1 day Clinic 132/81 N.S.
Age 5 43 n 5 30 Matched-volume apple juice (colored) 24 h ABP not stated N.S.
Bahra et al., 2012 HV Crossover 8 mmol KNO3 3 h 116/67 24.9/ N.S.
Age 5 28 n 5 14 8 mmol KCl placebo
Bondonno et al.,
2012
HV Crossover High-nitrate meal (spinach), 2.9 mmol
nitrate
3.3 h Clinic 112/68 22.7/ N.S.
Age 5 47 n 5 30
Low-nitrate meal (apple) or drink (rice
milk), each , 0.1 mmol
Kelly et al., 2013 HV Crossover Beetroot juice, 9.6 mmol nitrate 3 days Clinic 125/74 25/23
Age 5 64 n 5 12 Nitrate-deplete beetroot juice placebo
Liu et al., 2013 HV Crossover High-nitrate meal (spinach), 3.5 mmol
nitrate
3.5 h Clinic 119/71 27.5/ N.S.
Age 5 59 n 5 26
Low-nitrate meal 1 rice milk (nitrate
content not stated)
(peak 2 h)
Joris and Mensink,
2013
HV Crossover Beetroot juice, 8.0 mmol nitrate 4 h Clinic 135/93 N.S./24
Age 5 61 n 5 20 Control drink (not specified)
Wylie et al., 2013 HV Crossover
(four limbs)
Beetroot juice, 4.2, 8.4, and 16.8 mmol
nitrate
1 day Clinic 119/68 16.8 mmol: 29/24;
8.4 mmol: 210/23;
4.2 mmol: 25/ N.S.
Age 5 23
n 5 10 140 ml water control
Bond et al., 2013 HV Crossover Beetroot juice, 12.1 mmol nitrate 2 h Clinic BP not stated 25/ N.S.
Bond et al., 2014 Age 5 21 n 5 12 Matched-volume orange juice
Bondonno et al.,
2014b
HV Crossover High-nitrate diet, estimated .4.8 mmol
nitrate daily
7 days Clinic 130/76 N.S.
Age 5 47 n 5 38
Low-nitrate diet, estimated ,1.6 mmol
nitrate daily
Rammos et al., 2014 HV,
moderate
CV risk
Parallel
(two-arm)
NaNO3, 0.15 mmol/kg per day 28 days Clinic 137/80 28/ N.S.
Age 5 63 n 5 10
to 11
Matched–molar weight NaCl placebo
Jajja et al., 2014 HV,
overweight
Parallel
(two-arm)
Beetroot juice, 2.6–6.5 mmol nitrate daily 21 days Home 130/77 Home: 27.2/ N.S.;
clinic: N.S.; 24 h
ABP: N.S.Ashor et al., 2015 Age 5 62 n 5 10
to 11
Matched-volume black currant juice control Clinic 135/77 24 h
ABP 126/81
Jovanovski et al.,
2015
HV Crossover High-nitrate soup (spinach), 13.6 mmol
nitrate daily
7 days Clinic 116/69 24.1/24.4
Age 5 25 n 5 27
Low-nitrate soup, 0.01 mmol daily control
Ashworth et al.,
2015
HV crossover High-nitrate food, estimated 5.5 mmol
nitrate daily
7 days Clinic 107/63 24.0/ N.S.
Age 5 20 n 5 19
Low-nitrate food, estimated 0.13 mmol
nitrate daily
Bourdillon et al.,
2015
HV Crossover NaNO3, 0.1 mmol/kg per day 3 days Plethysmographic
finger BP 125/75
N.S.
Age 5 31 n 5 12 NaCl, 0.1 mmol/kg per day placebo
Lee et al., 2015 HV Crossover Beetroot juice, 6.4 mmol nitrate 15 days Clinic 116/77 24/24
Age 5 22 n 5 14 Nitrate-deplete beetroot juice placebo
Jonvik et al., 2016 HV Crossover
(four-limb)
NaNO3, 12.9 mmol 5 h Clinic BP not stated NaNO3: N.S./24;
rocket: 26/26Age 5 28
n 5 18 Rocket, beetroot, and spinach juice, all
12.9 mmol nitrate
Beet: 25/27.5;
spinach: 27/25
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important, for translation to patients with hyperten-
sion, interventions need to provide sustained BP re-
duction in the long term. Therefore, studies over
prolonged time periods (.7 days) in healthy subjects
were required. This was first tested in humans in-
directly by making a comparison of the effects of a
traditional, nitrate-rich Japanese diet [0.3 mmol/kg
(18.6 mg/kg) nitrate daily], with a low-nitrate–
containing control diet in a crossover study (n 5 25,
10 days per dietary intervention). In this study, the
high-nitrate diet was associated with significantly
lower BP (DBP24.5 mm Hg) (Sobko et al., 2010). Since
this observation, several studies have tested dietary
nitrate supplementation over longer periods. Using
beetroot juice to deliver dietary nitrate [5.2 (322 mg)
or 6.4 (397 mg) mmol/day nitrate] compared with low-
nitrate control juice (n 5 8–14 for 15 days per in-
tervention), sustained lowering of DBP (;5–6.5mmHg)
was evident in healthy volunteers (Vanhatalo et al.,
2010; Lee et al., 2015). In healthy older persons with
prehypertension (baseline BP 137/80 mm Hg, n 5 10 to
11), 4 weeks of daily 150 mmol/kg (9.3 mg nitrate/kg)
NaNO3 (;10 mmol nitrate for a 70-kg subject) lowered
SBP by 8 mm Hg compared with a matched NaCl
control (Rammos et al., 2014).
The first study in patients with hypertension followed
a single dose over 24 hours and used water as a control
in a crossover design. In all, 15 drug-naïve patients with
hypertension (baseline daytime ambulatory BP; ABP
142/85 mm Hg) were given a single dose of dietary
nitrate [3.3 mmol (205 mg) as beetroot juice]. Plasma
nitrate and nitrite profiles were similar to responses
seen in normotensive persons, confirming that the
enterosalivary circulation was intact in hypertension.
Additionally, a peak BP reduction of ;11/10 mm Hg
(Ghosh et al., 2013) was observed, similar to the peak
reduction in healthy volunteers given 22.5mmol despite
having a fraction of the nitrate dose (Webb et al., 2008b;
Kapil et al., 2010). Importantly, in healthy persons
given a comparable 4 mmol (248 mg) nitrate dose, BP
reduction was not significant (Kapil et al., 2010). The
enhanced BP response in subjects with hypertension
after nitrate supplementation could simply reflect
higher baseline BP evident in the hypertensive cohort,
as BP lowering is proportional to pretreatment BP (Law
et al., 2003). However, it could also reflect increased
potency of nitrate/nitrite. In Wistar Kyoto rats treated
with phenylephrine to titrate BP to match the levels
evident in the strain-matched SHR, there is a dimin-
ished BP response to acute bolus doses of KNO2,
suggesting pretreatment BP is not solely responsible
for the augmented response seen in hypertension
(Ghosh et al., 2013). There is some evidence to suggest
that, in the scenario of reduced ·NO levels, the
downstream signaling target GC-1 or the components
of the pathway further downstream from GC-1 become
sensitized to ·NO. This has been demonstrated best
with respect to vasoactivity, in which an enhanced
vasorelaxant response to ·NO donors was shown in
mice treated with NOS inhibitors (Moncada et al.,
1991) and in eNOS KO mice (Brandes et al., 2000).
However, whether this is similar in human hyperten-
sion, a situation in which eNOS activity is similarly
reduced (Linder et al., 1990; Panza et al., 1993), is
not known.
In our single dietary dosing study in patients with
hypertension (Ghosh et al., 2013), SBP was reduced
24 hours postsupplementation by ;8 mm Hg, which is
at a level comparable to the expected BP-lowering effect
of antihypertensive medicines when used at standard
dose in mild hypertension (;9.1 mm Hg) (Law et al.,
2009). This dose also represented a peak-to-trough ratio
of 60% for dietary nitrate in this study and is a profile of
activity consistent with an effect size suitable (.50%) to
consider as a once-daily dosage for an antihypertensive
medication (Lipicky, 1994; Meredith, 1994). This initial
study was been taken forward into a prolonged study
assessing whether the acute effects are sustained in the
longer term (Kapil et al., 2015). In this double blind,
randomized, placebo-controlled, parallel study (n5 32 in
each limb) of drug-naïve and treated patients with
hypertension and uncontrolled BP, 4 weeks of daily
dietary nitrate [6.4 mmol (397 mg) as beetroot juice]
was compared with a nitrate-free beetroot juice [orig-
inally developed to provide a suitable placebo
(Gilchrist et al., 2014)] as a control intervention to
maintain patient and investigator blindness to achieve
optimal study design. BP, measured by three separate
TABLE 1—Continued
Reference Cohort Design Intervention TreatmentDuration Baseline BP (mm Hg) Max DBP (mm Hg)
Choi et al., 2016 HV Crossover
(two-limb)
Beetroot juice, 5.6 mmol nitrate 15 days 132/86 Both SBP and
DBP reducedAge 5 23
n 5 12 Colored water control
Raubenheimer et al.,
2017
HV Crossover
(two-limb)
Beetroot juice, 12.9 mmol nitrate 3 h 133/89 27.9/25.7
Age 5 64
n 5 12 Nitrate-deplete beetroot juice placebo
Jones et al., 2019 HV Parallel
(two-arm)
Beetroot juice, 6.5 mmol nitrate 4 wk 129/75 N.S.
Age 5 63
n 5 7–11 Prune juice control
HV, healthy volunteers.
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methods, was significantly reduced over 4 weeks in the
active intervention limb only: clinic (28/2 mm Hg),
home (28/4 mm Hg), and 24-hour ABP (28/5 mm Hg),
with no pharmacodynamic tolerance demonstrated by
weekly home BP (Fig. 7D) (Kapil et al., 2015).
There are now several studies that have assessed the
effects of dietary nitrate in patients with hypertension.
The individuals in these studies in general have
baseline BPs above 130/70 mm Hg (as some have
controlled BP on medication) and on balance indicate
a lowering of BP with dietary nitrate in patients with
uncontrolled BP at baseline (see Table 2) (Ghosh et al.,
2013; Kapil et al., 2015; Kerley et al., 2018; Broxterman
et al., 2019; Zafeiridis et al., 2019). Conversely, there are
studies that show BP-lowering benefits in treated,
controlled patients on medication. As an example, in a
smaller, shorter duration (n 5 27, 1 week) in treated,
controlled patients with hypertensions (baseline BP
133/76 mm Hg), 7 mmol (434 mg) dietary nitrate daily
as beetroot juice compared with control demonstrated
no effect on home or ambulatory BP, with means in
low- versus high-nitrate groups being 127–128/73–74
(Bondonno et al., 2015b). In a similar study to the
Kapil et al. (2015) study, in a mixed population of
both patients with prehypertension and untreated
hypertension, 2.5 mmol/day nitrate compared with
,0.5 mmol/day nitrate, both as blended vegetable juice
(4weeks,n530), ina crossover study showednodifference
in ABP (Blekkenhorst et al., 2018). The reasons for these
differing data are uncertain; however, it is possible that
these studies were underpowered (n 5 27–30) and, also,
that at least some of the volunteers had BP in the
normotensive range and certainly substantially lower
than the screening BPs; this fact may underlie the
neutral effects. In addition, biochemical analyses sug-
gest that at baseline, this group of participants had
unusual and very high circulating levels of nitrite of
2 mmol/l (Bondonno et al., 2015b; Blekkenhorst et al.,
2018). Although the authors suggested that this was
Fig. 7. Effects of changing nitrite concentration on BP in humans. (A) Changes in plasma nitrite (red) and nitrate (blue) and BP (green) after acute
nitrate supplementation. (B) Effect of antiseptic mouthwash on plasma nitrite levels. (C) Correlation of changes in BP with changes in plasma nitrite
levels after antiseptic mouthwash. (D) Changes in home BP after 4 weeks of dietary nitrate (black circles) or placebo (open circles) ingestion in patients
with hypertension. ##P , 0.01 and ###P , 0.001 for Bonferroni post hoc test, following 2-way ANOVA.
Fig. 8. Number of publications using beetroot juice.
718 Kapil et al.
likely due to contamination of samples through the
analytical procedures (although no measure of this
was made), it is also possible that these levels relate
to dietary intake. Dietary habits were recorded in this
study; however, they were not reported, and thus it is
not possible to assess this. Finally, 63% of the
recruited patients in the first study were women
(Bondonno et al., 2015b). Recent evidence from our
laboratory has shown that although women appear to
have greater baseline oral nitrate reductase activity
and thus greater circulating nitrite levels, this seems
to result in a reduced response to additional dietary
nitrate loading, possibly due to the fact that the
pathway is already being maximally activated
(Kapil et al., 2018). It is possible that the high number
of women in this cohort have therefore skewed the
effect.
Although all these studies measured peripheral BP,
recent evidence suggests that elevation of systemic
nitrite levels may have a greater effect on central
hemodynamics. Systemic intravenous NaNO2 nitrite
(8.7 mmol/min) in healthy volunteers selectively re-
duced central BP rather than peripheral BP (Omar
et al., 2015), and 6 months of dietary nitrate in patients
with or at risk of diabetes had no effect on peripheral BP
compared with placebo but did have a small, yet
significant, effect on central BP (Mills et al., 2017).
The explanation for the lack of peripheral BP reductions
in these studies in contrast to the large body of evidence
above is not clear, but it is worthy of further exploration.
Certainly, previous studies have failed to demonstrate
BP lowering in type 2 diabetes after increases in
systemic nitrite levels (Gilchrist et al., 2013; Mohler
et al., 2014; Shepherd et al., 2015a).
Overall, two recent independent meta-analyses of
BP-lowering studies suggest a meaningful pooled effect
size of ;5/2 mm Hg reduction on resting clinic BP
(Ashor et al., 2017; Jackson et al., 2018), although the
studies included ranges in duration from a few hours to
a few weeks, as indicated in Tables 1 and 2. For a
BP-lowering intervention to be adopted clinically,
support for sustained efficacy over several months is
clearly needed. Further studies are underway, includ-
ing a randomized, double blind, placebo-controlled
evaluation of 4 months of dietary nitrate in patients
with hypertensive target organ damage to assess
possible reversal (clinicaltrials.gov: NCT03088514).
3. Enterosalivary Generation of Nitrite Regulates
Basal BP. Nitrite is bioactive in the circulation,
leading to vasodilatation and BP lowering (Cosby
et al., 2003; Dejam et al., 2007), and further, the inverse
correlation between baseline plasma nitrite levels and
BP in healthy subjects (Kapil et al., 2010) intimates that
basal plasma nitrite levels (arising from endogenous
sources, i.e., eNOS) regulate BP of healthy subjects. It
was thus hypothesized that interruption of the enter-
osalivary circulation of nitrate to nitrite under basal
conditions would lower basal plasma nitrite levels and
increase BP. To test this hypothesis, oral microbiome–
related nitrate reduction (i.e., nitrite synthesis) was
disrupted using a validated antiseptic mouthwash pro-
tocol (Govoni et al., 2008). In a 2-week crossover study
(n 5 19), twice daily use of antiseptic mouthwash for
7 days nearly abolished oral nitrate reduction to nitrite.
More importantly, this effect was accompanied by a
decrease in plasma nitrite levels by ;25% (Fig. 7B),
similar to that predicted by studies using eNOS in-
hibition in humans (Lauer et al., 2001; Kleinbongard
et al., 2003). These studies indicate that, when one
excludes the influence of diet, 25% of circulating nitrite
levels arise from the enterosalivary circuit of nitrate
derived from the oxidative metabolism of endogenously
generated ·NO. In addition, this effect was associated
with a concomitant increase in BP (2–3.5 mm Hg) that
was measured by three distinct methods: clinic, home,
and ambulatory BP (Kapil et al., 2013). Evaluation of
home BP in this study revealed that the BP effect was
apparent within 1 day of mouthwash use, with no
evidence of tachyphylaxis over the week-long period of
intervention (Kapil et al., 2013). This effect of increasing
TABLE 2
Randomized, controlled studies evaluating nitrate supplementation on blood pressure in hypertensive patients
Reference Cohort Design Intervention TreatmentDuration
Baseline BP
(mm Hg)
Max DBP
(mm Hg)
Ghosh et al., 2013 Uncontrolled HTN Crossover Beetroot juice, 3.3 mmol nitrate 1 day 140/86 28.5/N.S.
Age 5 53 n 5 15 Matched-volume water control
Kapil et al., 2015 Uncontrolled HTN Parallel Beetroot juice, 6.4 mmol nitrate 4 wk Clinic 138/84 Clinic 28/22
Age 5 57 n 5 64 Nitrate-deplete beetroot juice placebo Home 139/82 Home 28/24
ABP 139/82 Abp 28/25
Bondonno et al., 2015b Controlled HTN Crossover Beetroot juice, 7 mmol nitrate 1 wk 133/76 N.S.
Age 5 63 n 5 30 Nitrate-deplete beetroot juice placebo
Kerley et al., 2018 Uncontrolled HTN Crossover Beetroot juice, 12.9 mmol nitrate 1 wk ABP 137/80 28/24
Age 5 63 n 5 20 Nitrate-deplete beetroot juice placebo
Broxterman et al., 2019 Controlled HTN Crossover Beetroot juice, 6.2 mmol nitrate 3 days 132/78 N.S.
Age 5 53 n 5 13 Nitrate-deplete beetroot juice placebo
Broxterman et al., 2019 Uncontrolled HTN Crossover Beetroot juice, 6.2 mmol nitrate 3 days 141/88 25/24
Age 5 49 n 5 14 Nitrate-deplete beetroot juice placebo
Zafeiridis et al., 2019 Uncontrolled HTN Crossover Beetroot juice, 8.1 mmol nitrate 2.5 h 144/95 26/22
Age 5 44 n 5 18 Nitrate-deplete beetroot juice placebo
HTN, hypertensive patients.
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BPwith disruption of the enterosalivary circulation has
been confirmed in further studies, including in healthy
volunteers (n 5 27) with confirmed disease-free oral
health status at baseline using chlorhexidine twice
daily for 7 days (Tribble et al., 2019). Importantly, this
effect is also seen in patients with CVD. In treated,
controlled patients with hypertension (n 5 15, baseline
home BP ;134/79 mm Hg) randomized to receive
antisepticmouthwash as above orwater control, mouth-
wash use led to significant increase in home SBP
(2.3 mm Hg) compared with control (Bondonno et al.,
2015a). More recently, however, in 17 healthy females
randomized to 3 days of antiseptic mouthwash or non-
antibacterial placebo mouthwash, despite abrogation
during the intervention period of both oral nitrate
reduction and salivary nitrite levels, there was no
change in plasma nitrite levels, and thus, ambulatory
BP was not different (Sundqvist et al., 2016).
Further studies have shown that other oral hygiene
treatments, in addition to chlorhexidine mouthwashes,
impact nitrate reduction and that this effect is de-
pendent upon the severity of the impact on oral micro-
biome function (McDonagh et al., 2015; Woessner et al.,
2016). Support for the hypothesis that the changes in
BP were related to lesser nitrite generated from the
oral microbiome comes from robust correlation of
changes in plasma nitrite concentration and changes
in BP after 7 days of antiseptic mouthwash interven-
tion (Fig. 7C) (Kapil et al., 2013). It is unlikely that
these effects relate to other mechanisms, such as
increased stress due to instillation of mouthwash,
since the effects on SBP were evident in the averaged
nighttime BP mean as well (Kapil et al., 2013).
Although these increases in BP were small (;DSBP
2–3.5 mm Hg), such effects at a population level are
known to lead to a significantly increased risk of
stroke and ischemic heart disease over a life course
(Lewington et al., 2002). Importantly, it appears that
recovery from acute use of antibacterial mouthwash
(twice daily for 1 week) is apparent both in microbi-
ological ecology and in vascular responses within
3–7 days (Tribble et al., 2019).
4. Endothelial Dysfunction. Endothelial dysfunc-
tion is synonymous with reduced bioavailable ·NO, is
an early marker common to all CVD risk factors, and is
predictive of future CVD events (Brunner et al., 2005).
Long-term dietary nitrite and nitrate deficiency wor-
sens ex vivo–assessed endothelial function in C57BL6
mice and was associated with CV death (Kina-Tanada
et al., 2017). Additionally, nitrite supplementation
improves ex vivo endothelial function in several differ-
ent models associated with cardiometabolic disease
(Sindler et al., 2015; Ling et al., 2016), whereas dietary
nitrate has been shown to improve endothelial function
in models of atherosclerosis (Bakker et al., 2016) as well
as to prevent the endothelial dysfunction that occurs in
mice subjected to long-term low dietary nitrate and
nitrite (Kina-Tanada et al., 2017) or aging (Rammos
et al., 2015).
There are several studies that have explored whether
such findings in mice translate to humans. With twice
daily NaNO2 (80 or 160 mg total daily for 10 weeks) in
older adults, there was a trend toward improved FMD
(DeVan et al., 2016). However, conflicting results have
been published for supplementation with inorganic
nitrate in healthy persons with normal baseline endo-
thelial function. Some studies have shown a positive
effect of dietary nitrate (Bondonno et al., 2012; Heiss
et al., 2012; Rammos et al., 2014), whereas others did
not (Bahra et al., 2012). In addition, in healthy volun-
teers in which a transient endothelial dysfunction is
induced by a brief exposure to an ischemic insult in the
forearm, prior (3 hour) acute nitrate supplementation in
the form of beetroot juice or KNO3 capsules prevented
this dysfunction (Webb et al., 2008b; Kapil et al., 2010).
In patients with pre-existing endothelial dysfunction, a
somewhat mixed picture has developed. In scenarios in
which endothelial function is impaired, and this impair-
ment is associated with risk factors for CVD, chronic oral
nitrate supplementation improves FMD, i.e., in patients
with hypertension and hypercholesterolemia (Kapil
et al., 2015; Velmurugan et al., 2016). However, FMD
was not improved after chronic supplementation in
patients with diabetes and after acute supplementation
in patients with peripheral arterial disease (PAD)
(Kenjale et al., 2011; Gilchrist et al., 2013).
5. Arterial Stiffness. Central, large-artery stiffen-
ing caused by aging-related arteriosclerosis is an im-
portant independent predictive marker of CV risk
(Vlachopoulos et al., 2010b), with the gold-standard
measurement of this phenomenon being aortic pulse
wave velocity (PWV) (Laurent et al., 2006). The evi-
dence indicates that in those with stiffened central
arteries, a rapid reflection of incident pressure waves
leads to greater augmentation of central SBP (Safar,
2010), which is more predictive of CV events than
brachial SBP (Vlachopoulos et al., 2010a). It has been
demonstrated that increased arterial stiffness precedes
incident hypertension in large, prospective cohorts
(Kaess et al., 2012; Zheng et al., 2015). Moreover, the
importance of stiffening in driving hypertension comes
from observations that large-artery stiffening alone
explains age-related increases in BP and failure of
normal renal and baroreflex-mediated regulatorymech-
anisms to prevent this (Pettersen et al., 2014).
Studies in healthy volunteers have shown that acute
inhibition of eNOS activity increases measures of
elastic artery stiffness in vivo (Wilkinson et al., 2002;
Schmitt et al., 2005; Bellien et al., 2010). Hence,
increasing bioavailable ·NO, via increment of systemic
nitrite, should decrease PWV. In this respect, nitrite
supplementation in aged rodents (0.8 mmol/l NaNO2 in
drinking water for 3 weeks) and adults (1.2 or 2.4 mmol
NaNO2 orally for 10weeks) reduced PWV (Sindler et al.,
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2011; Fleenor et al., 2012; DeVan et al., 2016). Infusion
of NaNO2 (8.7 mmol/min i.v.) for 60 minutes into the
brachial artery resulted in significant, large reductions
in central SBP (Omar et al., 2015), with no change in
brachial SBP, similar to the effects of oral nitrite dosing
(DeVan et al., 2016). In healthy subjects, acute (8 mmol
KNO3) or chronic [4 weeks of daily 150 mmol/kg NaNO3
(;10mmol nitrate for a 70-kg subject)] inorganic nitrate
supplementation reduced PWV (Bahra et al., 2012;
Rammos et al., 2014), with elevation of plasma nitrite
and cGMP levels, confirming the production of bioactive
·NO (Bahra et al., 2012).
In patients with hypertension, acute (3.3 mmol ni-
trate as beetroot juice) or chronic (daily 6.4mmol nitrate
as beetroot juice for 4 weeks) inorganic nitrate supple-
mentation also resulted in significant reductions in
PWV (Ghosh et al., 2013; Kapil et al., 2015). This result
intimate, therefore, that benefits accrued from nitrate
supplementation observed in hypertensive cohorts are
not only due to reductions of elevated arterial tone but
likely also reflect modulation of elastic distensibility of
the arterial tree by nitrite2-derived ·NO.More recently,
despite reduction of central BP after 6months of dietary
nitrate supplementation in patients with or at risk of
diabetes, there was no effect on PWV (Mills et al., 2017).
Hutchinson-Gilford progeria syndrome is a rare genetic
disease associated with multiple hallmarks of accelera-
ted aging, including arterial stiffness and premature
CVD despite a relative lack of traditional CV risk
factors, leading to an average age of death ,15 years
old (Hennekam, 2006). Mutant LMNA (the gene encod-
ing lamin A that is defective in the syndrome) mice
supplemented with NaNO2 (500mg/l in drinking water)
had improved aortic stiffness parameters and remodel-
ing, suggesting a potential therapeutic approach in this
orphan disease (Del Campo et al., 2019).
Further studies are now needed to determine the
relative contributions of the reduction of distending BP
in the aorta and other elastic arteries, and specific direct
effects on arterial destiffening in mediating the effects
of nitrite-derived ·NO.
6. Cerebral Blood Flow. The cerebral vasculature is
a vascular bed in which the potential effects of the
noncanonical pathway have been particularly assessed.
In part, this is due to the fact that ·NO is known to
regulate cerebral blood flow (Buchanan and Phillis,
1993) and critically regulates neurovascular coupling of
neural activity to blood flow (Attwell et al., 2010). Since
elevation of systemic nitrite concentration delivers ·NO
and improves blood flow in the peripheral circulation,
whether similar effects can be seen within the cerebral
circulation, which is normally tightly autoregulated for
flow in health, is particularly intriguing.
Nitrite infusion (1 mmol/kg per minute) in rats has
been shown to reverse L-NAME–induced cerebral va-
soconstriction and the consequent reduction in cerebral
blood flow (Rifkind et al., 2007). Raising systemic levels
of nitrite via acute dietary inorganic nitrate supple-
mentation in older adults is also associated with
improved blood flow to the frontal cortex, which is
implicated in cognitive function andmay be particularly
vulnerable during aging (Presley et al., 2011), and
reduces cerebral vascular resistance in the middle
cerebral artery (Bond et al., 2013). The effect of in-
organic nitrate supplementation on cognitive function
has also been studied, although results are equivocal,
with some smaller studies showing neutral results
(Kelly et al., 2013; Bondonno et al., 2014; Thompson
et al., 2014), and one study demonstrating improvement
on some tasks that activate the frontal cortex in young
adults (Wightman et al., 2015).
Recently, there has been some controversial work
suggesting that migraneurs express an oral microbiome
that is likely to lead to increased generation of ·NO,
which might contribute to the cerebral vasodilatation
that is thought to underlie headaches in this setting
(Gonzalez et al., 2016). The authors used analyses of the
16S rRNA Illumina sequencing of a cohort of migra-
neurs and nonmigraneurs from The American Gut
Microbiome Project, matching to known genomes for
their analyses. The authors made predictions regarding
the expression of nitrate, nitrite, and ·NO-reducing
genes and suggested that there were higher levels of
bacteria expressing these genes in the migraneurs
(Gonzalez et al., 2016). However, the authors did not
actually measure these genes, and unfortunately, detail
regarding the individuals from whom the samples were
collected was not made available. Further studies are
needed to determine the importance, or not, of such a
pathway in migraine.
Subarachnoid hemorrhage (SAH) is associated with
significant morbidity and mortality related to delayed
cerebral vasospasm that has been linked to diminished
·NO levels (Pluta et al., 2001; Sadamitsu et al., 2001).
Infusion of NaNO2, whether at the time of experimental
SAH formation or delayed by 7 days, was associated
with reduced arteriographic vasospasm in primates
(Pluta et al., 2005; Fathi et al., 2011), suggesting nitrite
could be a useful adjunct to existing therapies, and a
small pilot study has recruited six patients for a 7-day
nitrite infusion after a diagnosis of SAH with vaso-
spasm, although results have not been published to
date (clinicaltrials.gov NCT02176837). Interestingly,
electroencephalographic responses to intravenous ni-
trite infusion (NaNO2 10 mg/kg per minute for 1 hour)
predicted the occurrence of delayed cerebral ischemia,
suggesting such a test could be used to prognosticate
and stratify treatment (Garry et al., 2016).
B. Nitrite and Nitrate in Exercise and Muscle Biology
The intramyocyte and muscle pH and microvascular
O2 tension decline in the contracting skeletal muscles
(Richardson et al., 1995; Ferguson et al., 2015; Tanaka
et al., 2016). Since it is well established that nitrite
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reduction is potentiated in an acidic and hypoxic
environment (Modin et al., 2001; Castello et al., 2006),
there has been considerable interest in the possibility
that this anion might offer a novel approach to deliver
·NO to enhance skeletal muscle function. ·NO has been
demonstrated to influence a number of physiologic
processes that are relevant to skeletal muscle function,
including metabolism, perfusion, and contractility
(Stamler and Meissner, 2001; Suhr et al., 2013). In
support of the view that nitrite reduction is likely to
occur within the exercised muscle are the findings
published now some time ago demonstrating the nega-
tive difference in the arterial-venous plasma nitrite
concentration across the contracting skeletal muscle
bed (Abadeh et al., 1992). The potential benefits of the
noncanonical pathway in improving muscle function
have now been extensively investigated in different
cohorts of individuals, in terms of exercise capacity,
from the severely exercise tolerance impaired to the
highly trained elite endurance athlete.
1. Nitrate and Exercise Performance on Moderately
Trained Athletes. The first study to observe benefits of
dietary nitrate ingestion on exercise was a randomized,
double blind, placebo-controlled crossover study involv-
ing nine well trained healthy men of ;28 years (Larsen
et al., 2007). In this study, the subjects consumed
0.1 mmol/kg per day of NaNO3 or a NaCl placebo for
3 days before completing a continuous incremental cycle
ergometer test. Nitrate supplementation caused a
significant decrease in maximal oxygen consumption
(VO2max) at submaximal work rates, with a mean
reduction in VO2max of 5%. This reduction was surpris-
ingly associated with significant improvements in mus-
cle efficiency, from 19.7% 6 1.6% to 21.1% 6 1.3%
(calculated as the work output per unit energy
expended), and occurred without changes in blood
(lactate), intimating that there was no increase in
energy production. In addition, there were no differences
in heart rate, ventilation, or respiratory exchange ratio
between nitrate and placebo for any of the submaximal
work rates (corresponding to 45%–80% VO2max). These
resultswere particularly surprising since a basic principle
of human exercise physiology is that the O2 cost of
submaximal exercise at a given work rate is fixed,
irrespective of other factors such as health, fitness status,
and age and indifferent to known nutritional, physical, or
pharmacological interventions (Suhr et al., 2013). From
these observations, the authors suggested that endurance
exercise performance is a function of VO2max, the
fractional utilization of VO2max, and exercise efficiency
and that if all other factors are constant, an improve-
ment in muscle efficiency would be expected to enable a
greater work output for the same energy cost. This, in
turn, translates into improved exercise performance
(Larsen et al., 2007). These seminal findings caught the
imagination of the sports and exercise world and led to a
surge of interest to assess whether inorganic nitrate
may be useful in terms of placing the body in an optimal
condition to use O2 most efficiently to gain advantage in
numerous forms of exercise, particularly for the elite
endurance athlete.
The first independent study to corroborate thework of
the Karolinska group came from Jones and coworkers in
the UK (Bailey et al., 2009). This group took advantage
of the recent discovery at that time that beetroot juice
could be used as a simple and effective nitrate delivery
method (Webb et al., 2008b). As per the study of Webb
and colleagues, they gave 500 ml of beetroot juice
(containing 11.2 6 0.6 mmol/l nitrate) in a placebo-
controlled crossover study of eight men (aged 19–38
years) in which black currant cordial (containing negli-
gible nitrate) was used as the placebo for six consecutive
days. The study was described as double blind; however,
it is likely that the differences in the two liquids was
evident to all. In this study the volunteers, as in the
2007 study of Larsen et al., completed a series of “step”
moderate-intensity and severe-intensity exercise tests
on the last 3 days (Bailey et al., 2009). As expected,
plasma nitrate concentration was significantly elevated
compared with placebo (beetroot juice: 273 6 44 nmol/l
vs. placebo: 140 6 50 nmol/l), and this was associated
with statistically significant decreases in SBP, demon-
strating efficacy of the intervention. However, the key
observation documented was that, in agreement with
the Karolinska group, dietary nitrate reduced the “O2
cost” of cycling at a fixed submaximal work rate. The
authors show that muscle fractional O2 extraction
during modest exercise and gain in pulmonary O2
uptake after onset of moderate exercise were reduced
by 19%.However, in addition to this benefit, the authors
found that during severe exercise, the O2 uptake “slow
component” was reduced. This slow component is
thought to represent a progressive loss of muscle
efficiency as high-intensity exercise continues (Jones
et al., 2011). The peak oxygen uptake (VO2) attained
during high-intensity exercise was not different be-
tween treatments, but attainment of the peak VO2
was delayed with nitrate treatment, resulting in a
longer time to exhaustion. These observations were
repeated by the group in another study, which used a
different form of exercise (i.e., knee extensors) (Bailey
et al., 2010) and was again reproduced by Larsen et al.
(2010) using combined arm and leg cranking as the form
of exercise. Interestingly, in this study, the group found
that the peak VO2 was reduced with dietary nitrate
(Larsen et al., 2010) during maximal exercise using a
large active muscle mass and that it was associated
with a trend toward increased time to exhaustion. The
authors suggested that this implied involvement of two
separate mechanisms in the benefits of inorganic
nitrate: one that reduces VO2max and another that
improves the energetic function of the working muscles.
Although these early observations have fueled in-
terest in assessing the mechanisms and whether the
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effects can be sustained in the long term, there has
been some controversy regarding effective dose. Using
a similar exercise test of submaximal cycle ergometry,
VO2max was shown to be reduced (by ;3%–5%) after
the acute ingestion of 0.033 mol/kg nitrate, equating
to ;2.5 mmol nitrate in a 70-kg individual (Larsen
et al., 2010), 5.2 (Vanhatalo et al., 2010), 6 (Wylie et al.,
2016), and 16.8 mmol nitrate (Wylie et al., 2013), but
conversely not after the acute ingestion of 3 (Wylie
et al., 2016), 4.2 (Wylie et al., 2013) and;8mmol nitrate
(Betteridge et al., 2016) with no effect upon exercise
tolerance (Vanhatalo et al., 2010; Wylie et al., 2013).
However, in the study of Wylie and colleagues, in-
creasing the dose substantially (8.4 and 16.8 mmol)
did result in significant improvements (Wylie et al.,
2013). These results seem to suggest that the acute
ingestion of nitrate from 2.5 to 6 mmol of nitrate may be
sufficient to enhance exercise economy during submax-
imal cycling but that higher doses are required to
demonstrate any improvement in exercise tolerance.
Importantly, these effects on cycling economy after
short-term nitrate supplementation have been shown to
be maintained when dosing is extended over 15 days
(although not at 5 days in this study) (Vanhatalo et al.,
2010) or 6 mmol/day for 28 days (Wylie et al., 2016).
These findings indicate that, as with the effects upon
BP, there is no development of tolerance as occurs
with organic nitrates (Münzel et al., 2005). It is also
worth noting that there are dissenting studies in which,
despite elevation in plasma nitrite concentration after
supplementation with nitrate in both recreationally
active and moderately trained endurance athletes, no
improvement in cycling exercise economy or performance
was evidenced (Breese et al., 2013; Kelly et al., 2014).
Similar improvements in exercise economy and tol-
erance after nitrate supplementation have been shown
during running (Lansley et al., 2011b; Murphy et al.,
2012; Porcelli et al., 2015), knee extension (Bailey et al.,
2009), walking (Lansley et al., 2011b), desert marching
(Kuennen et al., 2015), kayaking (Muggeridge et al.,
2013; Peeling et al., 2015), and rowing (Bond et al.,
2012; Hoon et al., 2014). However, whether improved
exercise tolerance (i.e., time to exhaustion in a constant
work rate task) in turn then translates into an associ-
ated improvement in exercise performance (i.e., a set
distance or amount of work is completed in a shorter
time frame) is controversial. In one study, no such
benefit is seen with acute administration of nitrate
(Cermak et al., 2012b), but chronic (up to 6 days) nitrate
supplementation did enhance cycling performance
(Cermak et al., 2012a) in moderately trained endur-
ance, suggesting that chronic nitrate supplementation
may have more possibilities as an ergogenic aid than
acute nitrate ingestion.
a. Mechanisms for enhanced exercise performance
after nitrate supplementation. A number of possible
mechanisms have been proposed to underlie the
lower O2 cost of exercise. Bailey et al. (2010), using
31P-magnetic resonance spectroscopy, demonstrated
a blunting of increases of ADP and inorganic phos-
phate (Pi) concentration and sparing of intramuscu-
lar phosphocreatine concentration (PCr) with nitrate
treatment. These effects were apparent without in-
creased contribution of anaerobic glycolysis to energy
turnover, excluding the possibility that nitrate or
nitrite had resulted in an inhibition of respiration
(Brown and Cooper, 1994; Cleeter et al., 1994). The
authors suggested that by reducing the ATP cost of
force production, this facilitated a sparing of the
finite PCr stores and a reduction in the O2 cost of
exercise, resulting in an improved tolerance of intense
exercise. The authors suggested that this effect likely
relates to the activity of ·NO on the sarcoplasmic
reticulum calcium ATPase or the actin-myosin ATPase
(Ishii et al., 1998; Viner et al., 2000; Evangelista et al.,
2010) and reason that a reduced ATP cost would blunt
the changes in intramuscular substrates and metabo-
lites that stimulatemitochondrial respiration (e.g., PCr,
ADP, Pi) (Mahler, 1985; Meyer, 1989). Intriguingly,
the depletion of muscle PCr and the buildup of Pi and
ADP have been associated with the development of
muscle fatigue during high-intensity exercise (Allen
et al., 2008).
Other suggestions have been that nitrate supplemen-
tation improves muscle oxygenation and, therefore,
mitochondrial efficiency (therefore lowering VO2) and
muscle oxygenation (therefore sparing muscle PCr)
(Wilson, 1994). Indeed, assessment of muscle biopsies
postexercise and nitrate treatment shows a reduction in
the expression of adenine nucleotide translocase (which
is a protein involved in mitochondrial proton conduc-
tion) associated with a 19% improvement in the mito-
chondrial phosphate/oxygen ratio (which is a ratio of the
amount of O2 consumed per ATP produced). This
observation suggests that nitrate impacts upon leakage
of protons across the inner mitochondrial membrane.
The authors speculate that since ·NO has been shown to
inhibit cytochrome C oxidase (Brown and Cooper, 1994;
Cleeter et al., 1994) in the setting of hypoxia, nitrite
reduction is facilitated, delivering increased ·NO, which
results in the effects seen. Interestingly, acute supple-
mentation of nitrite to isolatedmitochondria in vitro did
not affect phosphate/oxygen ratio, suggesting that
several days of persistently elevated nitrite levels are
needed for the induction of changes in the expression of
mitochondrial proteins (i.e., adenine nucleotide trans-
locase) and accords with observations suggesting im-
proved benefits with dietary nitrate and prolonged daily
ingestion.
There is also some suggestion that the mitochondria-
independent effects of nitrate/nitrite relate to changes
in muscle Ca21 handling and, hence, contractile func-
tion. Inmice fedNaNO3 (1mmol/l in the drinkingwater)
for 7 days, intracellular Ca21 levels were increased and
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were associated with enhanced contractions in fast-
twitch muscle fibers, but not slow twitch, at stimulation
frequencies from 20 to 150 Hz (Hernandez et al., 2012).
Expression analyses demonstrated that within the fast-
twitch muscle cells, there was an increase in both
calsequestin 1 and dihydropyridine receptor expression
that resulted in enhanced Ca21 store and, thus, avail-
ability of Ca21 upon store release, thus causing a faster
rate of force development and increased contractile
force, particularly at low-frequency stimulation; al-
though the exact molecular pathway responsible for
this change in expression was not determined. The
authors suggested, therefore, that improved perfor-
mance with inorganic nitrate/nitrite, at least in part,
related to increased muscle function during normal
movement independent of changes in mitochondrial
function (Hernandez et al., 2012).
Another potential contributory mechanism for im-
proved muscle performance is the possibility that di-
etary nitrate increases blood flow, particularly
considering the prominent vasodilator properties of
nitrite, as discussed earlier. Indeed, in rats, dietary
nitrate (in the form of beetroot juice fed to rats for
5 days) (Ferguson et al., 2013a) lowered exercising
(treadmill) BP in tandem with lower blood lactate
concentrations and substantial increases in hindlimb
muscle blood flow. Using microspheres injected into the
rats during the exercise, the authors were able to
discriminate exactly which muscles were experiencing
elevated blood flow and demonstrated that this oc-
curred only in the exercising muscles and particularly
in the type II muscle fibers [invoked in moderate to
severe exercise intensity (Henneman et al., 1965)], thus
providing improved O2 delivery where and when it was
most needed. In a subsequent study, this view was
supported by observations reporting much slower falls
in microvascular O2 pressure after the onset of electri-
cally evoked contractions of the spinotrapezius muscle
of rats fed beetroot juice compared with those fed water
(Ferguson et al., 2013b), implying increased muscle O2
delivery and, thus, a resistance to muscle fatigue,
particularly of type II muscle fibers. These findings
have been tested in humans. Breese et al. (2013)
measured the effects of 4–6 days of nitrate supplemen-
tation on VO2 and muscle deoxyHb [which would reflect
the balance between muscle O2 utilization and muscle
O2 delivery kinetics (Koga et al., 2012)]. Nine healthy,
physically active subjects were assigned in a randomized,
double blind, crossover design to receive nitrate-containing
beetroot juice (140 ml/day, containing;8 mmol nitrate)
or nitrate-deplete juice (140 ml/day) for 6 days. On days
4, 5, and 6 of the supplementation periods, subjects
completed a double-step exercise protocol that included
transitions from unloaded to moderate-intensity ex-
ercise (in which predominately type I muscle fibers
are recruited), followed immediately by moderate- to
severe-intensity exercise (in which the additional force
production would be predominately gained through the
recruitment of type II muscle fibers). The study found
that nitrate supplementation accelerated the VO2
and muscle deoxyHb kinetics in the moderate- to
severe-intensity work rate increment but not the
low- to moderate-intensity work rate increment (Breese
et al., 2013).
2. Nitrate and Exercise Performance in Patient
Populations. The above evidence supports the view
that during the hypoxemia created by exercise in which
type II muscle fibers are recruited to drive muscle
contraction, inorganic nitrate/nitrite acts to improve
function. Thus, in individuals with a greater proportion
of type IImuscle (Hernandez et al., 2012; Ferguson et al.,
2013a; Kelly et al., 2014), such as that found in patients
with metabolic, respiratory, and CVD (Schaufelberger
et al., 1995; Gosker et al., 2000; Mador and Bozkanat,
2001; Raguso et al., 2004; Askew et al., 2005; Oberbach
et al., 2006), inorganic nitrate/nitrite may be therapeu-
tically useful. Indeed, several studies have now shown
improved exercise capacity in patients with chronic
obstructive pulmonary disease (COPD) (Berry et al.,
2015; Kerley et al., 2015; Leong et al., 2015; Shepherd
et al., 2015b), PAD (Kenjale et al., 2011) and heart failure
(HF) (Coggan et al., 2015; Zamani et al., 2015; Eggebeen
et al., 2016). However, healthy older adults (Kelly et al.,
2013) or patients with type II diabetes did not benefit
from dietary nitrate intervention (Shepherd et al.,
2015a). These studies are discussed more fully below.
Finally, in addition to improving exercise performance,
there is also preliminary evidence to suggest that nitrate
supplementation can aid recovery postexercise (Clifford
et al., 2016).
There are now numerous studies that have explored
the potential advantage that inorganic nitrate might
provide to endurance athletes. The evidence to date is
mixed, with some reports identifying small but compet-
itively important benefits, and others showing no effect
(see Table 3). This discord has in part been attributed to
the fact that in well trained endurance athletes, phys-
iologic remodeling of the skeletal muscle occurs during
chronic endurance training. Moreover, this remodeling
is associated with an increase in NOS expression in
both skeletal muscle [neuronal NOS (McConell et al.,
2007)] and the vasculature supplying the muscles
[eNOS (Green et al., 2004)], and also to an increase in
the content of Ca21-handling proteins in type II muscle
(Kinnunen and Manttari, 2012) to promote both a
lower percentage of type II skeletal muscle (Wilson
et al., 2012) and lower mitochondrial UCP3 content
(Fernstrom et al., 2004), which is an important determi-
nant of exercise efficiency (Mogensen et al., 2006). Hence,
the differing vascular physiology and skeletal muscle of
well trained endurance athletes compared with lesser
trained athletes may explain a diminished advantage
of nitrate supplementation in well trained endurance
athletes.
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Since there is a greater proportion of type II muscle
used during high-intensity exercise (Krustrup et al.,
2004), several research groups have focused on the
possibility that this form of exercise may preferentially
benefit from nitrate supplementation. Again, there are
studies demonstrating benefit, whereas others show no
advantage (see Table 4). This apparent discord may be
due to the enormous heterogeneity in the studies with
respect to the exercise modality, training status of the
athletes/participants, the nitrate supplementation pro-
tocol, and/or the intermittent nature of the exercise
regimes. On balance, however, it does seem that nitrate
supplementation has ergogenic potential for athletes
participating in sports in which speed, power, and
repeated sprint ability are important determinants of
success.
3. Cardiac Muscle Function and Heart Failure.
Dysfunction of the classic pathways that underlie ·NO
production are thought to play a major role in the
pathogenesis of both HF with reduced ejection fraction
(HFrEF, commonly referred to as systolic HF) and
preserved ejection fraction (HFpEF, commonly referred
to as diastolic HF) (Drexler, 1999; Cai and Harrison,
2000; van Heerebeek et al., 2012). Left ventricular
ejection fraction (LVEF) for humans with HFrEF is
typically ,40%, HFpEF LVEF .50%, with an interme-
diate group of HF with mildly reduced ejection fraction
for those with LVEF 40%–49% (Ponikowski et al., 2016).
Patients are high risk for HF as the cause of their
symptoms with elevated NT-pro-brain natriuretic
peptide (NT-proBNP) (sinus rhythm .1000 pg/ml and
atrial fibrillation .1600 pg/ml) and brain natriuretic
peptide (BNP) (sinus rhythm .300 pg/ml and atrial
fibrillation .500 pg/ml) levels, although lower levels
remain compatible with the diagnosis depending on the
acuity of the clinical setting (Ponikowski et al., 2016).
Standard prognostic therapy in HF with angiotensin-
converting enzyme inhibitors, angiotensin receptor
blockers, statins, and the novel b-adrenoceptor antag-
onists all increase ·NO bioavailability through reduced
oxidative stress and increased NOS activity (Omar
et al., 2016). Although the organic nitrates provide an
efficacious treatment option in the setting of acute HF
and have shown some benefit in chronic HF (Cohn et al.,
1986; Taylor et al., 2004), they have proven difficult to
use as a long-term option because of the rapid develop-
ment of tolerance, reflex tachycardia, and the induction
of endothelial dysfunction (Münzel et al., 2011, 2013). As
the global prevalence ofHF increases, with the associated
high levels of morbidity and mortality (Meta-analysis
Global Group in Chronic Heart Failure (MAGGIC), 2012;
Ponikowski et al., 2016), it has become increasingly
important to identify and exploit novel methods by which
to treat the HF syndrome. The role of inorganic nitrite
and nitrate to restore diminished ·NO is one such
possibility (Paulus and Tschöpe, 2013).
a. ·NO as an inotrope. ·NO has both positive
(Sarkar et al., 2000; Paolocci et al., 2003) and negative
(Sandirasegarane and Diamond, 1999) inotropic effects
in the failing heart, with many observations suggesting
that these effects are cGMP-dependent (e.g., Balligand
et al., 1993; Kojda et al., 1996), but there is also clear
evidence of independence of GC-1 and cGMP signaling
(Sarkar et al., 2000) and stimulation of b-adrenoceptors
(Paolocci et al., 2003). These GC-1–independent effects
have largely been attributed to the formation of nitroxyl
anion and recruitment of ATP-sensitive K1 (KATP)
channels and/or possibly the neuropeptide calcitonin
gene-related peptide (Paolocci et al., 2001a,b; Zhu et al.,
2015). There is also a growing body of evidence impli-
cating S-nitrosation as the pathway for ·NO-mediated
cardiac effects. In particular, with respect to cardiac
hypertrophy, studies with mice show a dependence of
b-adrenoceptor signaling upon ·NO generation that is
thought to trigger consequent S-nitrosation of key
cardiac proteins, including phospholamban and tro-
ponin C, to regulate cardiac function accordingly (Irie
et al., 2015). Interestingly, there is growing support
for the view that S-nitrosation, rather than being the
protein modification responsible for the effects of ·NO,
represents a transient chemical step on the path to
protein oxidation and disulfide bond formation and that
the oxidation of proteins underlies changes in protein
function in the setting of nitrosative stress (Wolhuter
et al., 2018).
However, many studies have shown the importance of
·NO-mediated GC-1 signaling using phosphodiesterase
(PDE)-V inhibition to enhance cGMP availability.
In a pressure-overload–induced model of HF using
thoracic aortic constriction (TAC), C57BL6J mice
received 6 weeks of treatment with 100 mg/kg per
day of sildenafil in soft diet (vs. placebo). Sildenafil
prevented further cardiac chamber dilatation, dys-
function, fibrosis, and molecular remodeling, all with
beneficial increased myocardial PKG activity (Nagayama
et al., 2009). This was coupled with in vitro evidence of
improved cardiac muscle contractility, relaxation, and
enhanced calcium handling. A further study demon-
strated the beneficial effects of PDE-V inhibition
using vardenafil in a rabbit model of I/R injury via
·NO-dependent opening of the mitochondrial KATP
channel (Salloum et al., 2006), as well as with sildenafil,
albeit over a shorter time frame (Salloum et al.,
2003). Finally, there is also evidence of the ·NO-mediated
protective effect of sildenafil in doxorubicin-induced
cardiotoxicity secondary to generation of ROS formation
in cardiac mitochondria and ROS-induced cardiomyocyte
apoptosis (Fisher et al., 2005). Cardiotoxicity as a result
of anticancer treatment is an increasingly recognized
clinical area of major unmet need (Bloom et al., 2016;
Zamorano et al., 2016). In their study, Fisher et al.
(2005) demonstrated this protective effect in the male
ICR strain of mice, in which sildenafil attenuated the
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TABLE 3
Clinical studies assessing the effect of nitrate supplementation upon exercise economy and/or endurance performance
Reference Cohort Intervention Design Outcome
Wilkerson
et al., 2012
Eight well trained male
cyclists
Nitrate-replete (;6 mmol
nitrate) or -deplete
beetroot juice as placebo
Randomized, single blind, crossover
study
Nitrate supplementation did
not improve 50-mile time
trial performance in well
trained cyclists.
Measurements performed on two
laboratory-based 50-mile time trial
2.5 h after consuming juice
intervention
MacLeod
et al., 2015
11 trained male cyclists Nitrate-replete or -deplete
beetroot juice as placebo
Randomized, double blind study Nitrate supplementation did
not lower the O2 cost of
steady-state exercise or
improve exercise
performance in normoxia
or hypoxia in a small
sample of well trained male
cyclists.
Measurements 2 h after consuming
70 ml of intervention and prior to a
15-min self-selected cycling warm-
up, then a fixed 15 min of steady-
state exercise at 50% maximum
power output, and a 10-km time
trial in either normoxic or hypoxic
(altitude) conditions
Peacock
et al., 2012
10 male junior cross-country
skiers
Nitrate-replete or -deplete
beetroot juice as placebo
Two trials both randomized, double
blind
Measurements 2.5 h prior to two
5-min submaximal tests on a
treadmill at 10 km/h (55% of
VO2max) and 14 km/h (75% of
VO2max), followed by a 5-km
running time trial
Nitrate supplementation did
not reduce O2 cost of
submaximal exercise or
enhance endurance
exercise performance in
highly trained cross-
country skiers.
Boorsma
et al., 2014
Eight male 1500 m elite
distance runners
210 ml of nitrate-replete
(19.5 mmol) or -deplete
beetroot juice as placebo
Randomized, double blind, crossover
study
Acute and chronic nitrate
supplementation did not
reduce running VO2 or
improve time trial
performance.
Volunteers supplemented for 8 days
with.1 wk between interventions.
On days 1 (acute) and 8 (chronic),
subjects completed a submaximal
treadmill run and 1500-m time
trial.
Bescos
et al., 2012
13 well trained athletes Sodium nitrate (10 mg/kg) or
sodium chloride (10 mg/kg)
placebo
Randomized, double blind, crossover
study.
Sodium nitrate
supplementation did not
improve trial performance
in endurance athletes.
Measurements after a 40-min cycle
ergometer distance-trial test after
two 3-day periods of dietary
intervention
Christensen
et al., 2013
10 highly trained cyclists 0.5 l nitrate-replete beetroot
juice or 0.5 l black currant
juice as a placebo
Randomized, double blind, crossover
study
Nitrate supplementation did
not affect VO2 kinetics and
performance in elite
cyclists.
Measurements of VO2 kinetics (3 
6 min at 298 6 28 W), endurance
(120-min preload followed by a
400-kcal time trial), and repeated
sprint capacity (6  20-s sprints,
recovery 100 s) during two 6-day
dietary intervention intervals
Porcelli
et al., 2015
21 subjects (mean age, 22.7 6
1.8 yr) with different
aerobic fitness level
Supplementation with either
0.5 l/day of nitrate
(5.5 mmol)-containing
water or nitrate-free water
as placebo
Crossover, double blind, placebo-
controlled study 6-day treatment.
Participants performed an
incremental running test until
exhaustion and four repetitions of
6-min submaximal (approximately
80% of gas-exchange threshold)
constant load exercise on a
motorized treadmill. Moreover,
subjects performed a 3-km running
time trial on the field.
Individual aerobic fitness
level influenced ergogenic
benefits induced by nitrate.
Muggeridge
et al., 2013
Eight male kayakers 70 ml of nitrate-replete
(5 mmol) concentrated
beetroot juice or tomato
juice as placebo
Participants completed four
performance trials of 15 min of
paddling at 60% of maximum work
rate, five 10-s all-out sprints, and a
1-km time trial. The second and third
trials were preceded by
supplementation 3 h prior to
measurements
Nitrate supplementation had
no effect on repeated
supramaximal sprint or
1-km time trial kayaking
performance.
Peeling
et al., 2015
Male (n 5 6) athletes (Study
A) and international-level
female (n 5 5) athletes
(Study B)
Study A: a 70-ml beetroot
juice shot containing
;4.8 mmol of nitrate or
placebo
Study B: two 70-ml beetroot
juice shots containing
;9.6 mmol of nitrate or
placebo
Nitrate-replete or -deplete
beetroot juice as placebo
Study A: participants completed three
laboratory-based sessions on a kayak
ergometer of 7 4-min step test, two
4-min maximal effort performance
trials. At 2.5 h prior to thewarm-up of
each test, the athletes received
intervention.
Study B: participants completed two
field-based 500-m time trials,
separated by 4 days. At 2 h prior to
each test, athletes received
intervention.
In national-level male and
international-level female
kayak athletes, nitrate
supplementation improved
exercise economy in tasks
predominantly reliant on the
aerobic energy system and
time trial performance,
respectively.
(continued )
726 Kapil et al.
toxic effects of doxorubicin, with loss of that protection
after treatment with the NOS inhibitors L-NAME and
5-hydroxydecanoate.
b. Cardiac hypertrophy and ·NO. Cardiac hypertro-
phy in response to increased afterload (e.g., systemic
hypertension) is initially an adaptive response to in-
crease wall stress. Subsequently, this develops into a
maladaptive response with progressive left ventricular
(LV) dilatation and reduction of ejection fraction. Left
ventricular hypertrophy is an important risk factor for
developing HFrEF, HFpEF, and atrial fibrillation, as
well as for sudden cardiac death in patients (Katholi
and Couri, 2011). The importance of ·NO in LV remod-
eling has been demonstrated in several experimental
works—for instance, in transgenicmicewith cardiomyocyte-
restricted overexpression of eNOS (NOS3-TG) versus
WT littermates after myocardial infarction (MI) by left
anterior descending artery ligation (Janssens et al.,
2004). Pre-MI, a 30-fold increase in cardiac eNOS
expression led to attenuation of the inotropic response
to b-adrenoceptor agonist isoproterenol. Although in-
farct size was similar in both groups, NOS3-TG mice
had significantly less cardiac dilatation and dysfunction
(by LV end systolic diameter and fractional shortening),
and enhanced contractile performance and ventricular
relaxation (by rate of change of pressure (dP/dt)max and
dP/dtmin). There was no protective effect of enhanced
eNOS expression on either remote cardiac fibrosis or
survival.
ZSF1-HFpEF (leptin-resistant, obese, hypertensive
Zucker diabetic fatty/spontaneously hypertensive HF
F1hybrid) rats develop aHFpEFphenotype after 20weeks,
with elevated LV filling pressures, preserved LVEF, in-
creased lung weight with pulmonary congestion, and in-
creased myocardial stiffness (Hamdani et al., 2013).
Importantly, there was evidence to suggest reduced ·NO
bioavailability (by3-nitrotyrosine expression) in theHFpEF
mice, with a significant reduction in PKG activity and
cGMP concentration, confirming abnormalities in canonical
·NO/GC-1/cGMP/PKG signaling (Hamdani et al., 2013).
This lack of bioavailable ·NO and subsequent GC-1
signaling (Paulus and Tschöpe, 2013) has important
effects and not only correlates with the level of diastolic
dysfunction (Tschöpe et al., 2005) but also plays a key
role in the reduced systemic vasodilator response un-
derlying impaired exercise capacity in patients with
HFpEF (Borlaug et al., 2010; Edelmann et al., 2011;
Haykowsky et al., 2012).
c. Positive inotropic and antihypertrophic effects of
nitrite and nitrate. Subsequently, studies have shown
that nitrite and nitrate treatment also produces a pro-
file of activity reminiscent of ·NO. Pellegrino et al.
(2009) used the Langendorff rat heart model to demon-
strate that even at low concentrations, NaNO2 (1 nmol/l)
significantly improves contractility, with reductions
in LV pressure and improved relaxation. These effects
were shown to be ·NO-mediated and to act via the
·NO/cGMP/PKG pathway, but independent of NOS
activity. The positive inotropic activity of inorganic
nitrite is broadly expressed across a range of species,
as demonstrated by the same group in fish, amphibian,
and mammalian hearts, in which exogenously applied
nitrite improved the Frank-Starling response, with
increases in stroke volume, stroke work, LV pressure,
and LV relaxation (LV dP/dtmax) (Angelone et al., 2012).
Using male Wistar rats, Ashmore et al. (2014) demon-
strated similar benefits with dietary nitrate (0.7 mmol/l
vs. equimolar NaCl) treatment, which prevented hypoxia-
induced mitochondrial dysfunction and reduced oxida-
tive stress, while increasing available circulating ·NO
through increased tissue L-arginine and reduced sup-
pression of cardiac arginase expression. Similarly, in a
mouse model of doxorubicin-induced cardiac dysfunc-
tion, provision of NaNO3 (1 g/l, equivalent to 12 mmol/l)
for 7 days prior to administration of doxorubicin
improved both LV systolic, end-diastolic pressures,
and ejection fraction (Zhu et al., 2011). These positive
effects of ·NO and the evidence indicating deficiencies
of ·NO in the HF setting have spurred researchers
on to determine whether the noncanonical pathway for
·NO delivery may be useful for improving outcome in
this setting.
d. Preclinical studies: cardiac dysfunction, nitrite,
and nitrate. In WT rats given L-NAME to induce
TABLE 3—Continued
Reference Cohort Intervention Design Outcome
Hoon et al.,
2014
10 highly trained male rowers Nitrate-replete or -deplete
beetroot juice as placebo
Placebo-controlled, double blind,
crossover study
Compared with placebo, a
high (8.4 mmol nitrate) but
not moderate (4.2 mmol
nitrate) dose improved
rowing performance.
Nitrate-replete juice
administered as a single
shot containing 4.2 mmol or
a double shot containing
8.4 mmol nitrate
Intervention was consumed 2 h prior
to undertaking a 2000-m rowing-
ergometer test.
Bond et al.,
2012
14 well trained junior male
rowers
Beetroot juice made from raw
vegetables delivering 5.5.
mmol/day of nitrate for
6 days
A commercially available
black currant juice with
negligible nitrate content
was used as placebo
Randomized, double blind, crossover
study
After supplementation, rowers
completed six maximal 500-m
ergometer. A 7-day washout period
followed repeat of the trial. Blood
pressure, oxygen saturation,
maximum heart rate, urine, and
lactates were measured.
Nitrate supplementation
improved maximal rowing-
ergometer repetitions.
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TABLE 4
Clinical studies assessing nitrate supplementation on exercise performance during high-intensity exercise
Reference Cohort Intervention Design Results Outcome
Wylie et al.,
2013
14 male
recreational
team-sport
players
Nitrate-replete or
-deplete beetroot
juice as placebo
(490 ml)
Double blind, randomized,
crossover study with juice
delivered over ;30 h
preceding the completion of
a Yo-Yo intermittent
recovery level 1 test
Performance in the Yo-Yo IR1 was
4.2% greater with nitrate
compared with the placebo.
Acute nitrate supplementation
improved performance during
intense intermittent exercise
in team sports players.
Thompson
et al., 2014
16 male team-
sport
players
Intervention of
nitrate-replete
(140 ml/day;
12.8 mmol of
nitrate2) -or
deplete beetroot
juice as placebo
(140 ml/day;
0.08 mmol nitrate)
Double blind, randomized,
crossover study. On day
7 of supplementation,
subjects completed tests
on a cycle ergometer
during which cognitive
tasks were
simultaneously
performed.
Total work done during the sprints was
greater with nitrate treatment (123 6
19 kJ) compared with the placebo
(119617 kJ; P, 0.05). Reaction time
of response to the cognitive tasks was
also improved. There was no
difference in response accuracy.
Nitrate supplementation
enhanced repeated sprint
performance and
attenuated the decline in
cognitive function (and
specifically reaction time)
that may occur during
prolonged intermittent
exercise.
Aucouturier
et al., 2015
12 male
subjects
Intervention of
beetroot juice,
500 ml with
680 mg/l of nitrate
Randomized crossover
design single blinded to
the subjects with a 3-day
supplementation
The number of repetitions completed
before reaching volitional
exhaustion was significantly
higher in the nitrate group than in
the placebo (26.1 6 10.7 vs. 21.8 6
8.0 respectively, P , 0.05). In
contrast during exercise performed
at intensity below the peak oxygen
uptake (VO2 peak), oxygen uptake
(VO2) was unaffected.
Nitrate supplementation
enhanced tolerance to
exercise at supramaximal
intensity, with increased
microvascular total RBC
concentration in the
working muscle, in the
absence of effect on
contractile function and
resting hemodynamic
parameters.Placebo of apple-black
currant juice with
nitrate
content ,5 mg/l
AUC for microvascular total
hemoglobin (AUC-THb) in the
vastus lateralis muscle assessed
by near infrared spectroscopy
during exercise was increased with
nitrate.
Muggeridge
et al., 2013
Eight male
kayakers
Intervention of 70 ml
nitrate-replete
(5 mmol)
concentrated
beetroot juice or
tomato juice as
placebo
Randomized crossover
study measuring work
rate during performance
trials composed of 15 min
of paddling at 60% of
maximum work rate, five
10-s all-out sprints, and a
1-km time trial. The
second and third trials
were preceded by
ingestion of intervention
3 h before exercise.
VO2 during steady-state exercise was
lower in the nitrate-treated than
in the PL treated with no
differences in either peak or time
trial performance.
Nitrate supplementation had
no effect on performance.
Martin
et al., 2014
Team-sport
athletes
(9 male, age
22.3 6
2.1 yr;
7 female,
age 20.7 6
1.3 yr)
Intervention of 70 ml
of nitrate-replete
(0.3 g nitrate)
concentrated
beetroot juice or
Double blind, randomized,
crossover study with
participants consuming
interventions 2 h prior to
tests
There was no difference in overall
mean power output or the mean
power output for each individual
sprint test.
Nitrate supplementation did
not improve performance.
nitrate-deplete
beetroot juice as
placebo
Wylie et al.,
2016
34 healthy
subjects
Intervention of
nitrate-replete (3 or
6 mmol nitrate/day)
concentrated
beetroot juice or
nitrate-deplete
(0.08 mmol
nitrate/day)
beetroot juice as
placebo
Randomized
counterbalanced design.
Two moderate-intensity
step exercise tests 2 h
after the first ingestion
and after 7, 28, and
30 days of
supplementation,
subjects completed.
Compared with pre-treatment
baseline, 6 mmol nitrate reduced
the steady-state V_O2 during
moderate-intensity exercise by 3% at
2 h (P 5 0.06), 7 days and at 28–
30 days (both P , 0.05) but was
unaffected by 3 mmol nitrate at all
measurement points.
Up to;4 wk supplementation
with nitrate at 6 but not
3 mmol reduced
submaximal exercise V_O2.
Bescos
et al., 2012
13 well trained
endurance
athletes
Intervention of
NaNO3, 10 mg/kg of
body mass
Randomized, double blind,
crossover study with a
40 min cycle ergometer
distance-trial test after
two 3 day periods of
dietary supplementation
There were no differences in either
the mean distance or mean power
output between treatments.
Nitrate supplementation did
not improve a 40-min
distance-trial performance.
Placebo: sodium
chloride, 10 mg/kg
of body mass
Coggan
et al., 2015
Healthy men
and women
(n 5 12;
age 5 22–
50 yr)
Nitrate-replete
(140 ml, 11.2 mmol)
or -deplete beetroot
juice as placebo
Double blind, placebo-
controlled, randomized
trial
Nitrate treatment increased breath
NO by 61%. This was accompanied
by a 4% (P , 0.01; effect size 5
0.74) increase in peak knee
extensor power at the highest
angular velocity tested (i.e., 6.28
rad/s).
Acute nitrate
supplementation increased
whole-body NO production
and muscle speed and
power in healthy men and
women.
Assessments at 2 h after
intervention
Calculated maximal knee extensor
power was greater after dietary
nitrate.
(continued )
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hypertension leading to cardiac enlargement and fibro-
sis, supplementation in drinking water with NaNO2
(100 mg/l) attenuated cardiac enlargement and fibrosis to
a similar degree as captopril (100 mg/l), an angiotensin-
converting enzyme inhibitor and first-line treatment of
hypertension and HF (Sonoda et al., 2017). In a murine
model of pressure overload byTAC, inducing hypertrophy
and subsequent HF, NaNO2 (50 mg/l, ;9–12 mg/kg per
day in drinking water) versus vehicle for 9 weeks
significantly reduced BNP levels, cardiac hypertrophy,
and pulmonary edema at 9 weeks (Bhushan et al.,
2014). Furthermore, nitrite pretreatment significantly
TABLE 4—Continued
Reference Cohort Intervention Design Results Outcome
Sandbakk
et al., 2015
Nine male
elite cross-
country
skiers [age
18 6 0 y,
VO2max
69.3 6
5.8 ml ×
min(21) ×
kg(21)]
Combined
supplementation
with 6 g L-arginine
and 614 mg nitrate
against 614 mg
nitrate alone and
placebo
Randomized, crossover,
double blind study with
48 h pretreatment
There were no differences in
physiologic responses during
submaximal running or in 5-km
performance between treatments.
There were no effects of
nitrate supplementation on
exercise economy or
endurance running
performance in endurance-
trained cross-country skiers.
Haider and
Folland,
2014
19 healthy
untrained
men (21 6
3 yr)
Nitrate-replete
(9.7 mmol/day) or
-deplete beetroot
juice as placebo
Double blind, randomized,
crossover study, with
intervention given for
seven consecutive days.
After the last
supplementation dose,
force was recorded while
participants completed a
series of voluntary
involuntary (electrically
evoked) unilateral
isometric contractions of
the knee extensors.
Nitrate enhanced peak force
response to low-frequency electrical
stimulation. Explosive force
production during the first 50 ms of
evoked maximal twitch and octet
contractions (eight electrical impulses
at 300 Hz) was 3%–15% greater after
nitrate compared with placebo.
Maximum voluntary force was
unchanged nitrate.
Nitrate supplementation
enhanced the contractile
properties of human
skeletal muscle.
Rimer et al.,
2016
13 trained
athletes
Nitrate-replete
(;11.2 mmol
nitrate) or -deplete
beetroot juice as
placebo
(0.004 mmol)
Double blind crossover
study, with maximal
inertial-load cycling
trials (3 to 4 s)
immediately before and
after consuming
intervention.
Participants also
performed maximal
isokinetic cycling (30 s) to
assess performance
differences after
supplementation.
PMAX was increased after nitrate
treatment. RP Mopt was increased
with nitrate treatment.
Acute nitrate
supplementation enhanced
maximal muscle power in
trained athletes.
Lane et al.,
2014
12 male and
12 female
competitive
cyclists
Trials were
undertaken with a
caffeinated gum
(3 mg/kg body
mass, 40 min prior
to the TT),
concentrated
beetroot juice
supplementation
(8.4 mmol of nitrate,
2 h prior to the TT),
caffeine plus beetroot
juice, or a control.
Cyclists each completed
four experimental trials
in a double blind random
Latin square design.
There was no effect of nitrate
supplementation when used or
when combined with caffeine.
Nitrate supplementation was
not ergogenic under the
conditions of this study.
Lansley
et al., 2011
Nine club-
level
competitive
male cyclists
Nitrate-replete (BR)
or -deplete beetroot
juice (PL)
Randomized, double blind,
crossover study with
intervention delivered 2.5 h
before the completion of a 4-
and a 16.1-km time trial
VO2 during time trial were not
different between groups but nitrate
treatment significantly increased
mean PO during the 4-and 16.1-km
time trials.
Acute nitrate
supplementation improved
cycling economy.
BR containing
;6.2 mmol of nitrate
PL containing
;0.0047 mmol of
nitrate
Flueck
et al., 2016
12 healthy,
well trained
men
Dosages were 3, 6,
and 12 mmol
nitrate as
concentrated
beetroot juice or
sodium nitrate
dissolved in water
vs. water placebo.
Placebo-controlled, single
blind, crossover,
randomized study
At severe-intensity exercise, end-
exercise oxygen consumption was
;4% lower in the 6 mmol nitrate
juice group compared with the
6 mmol salt ingestion or placebo.
Nitrate supplementation with
juice reduced O2
consumption to a greater
extent compared with
nitrate salt
supplementation.
Measurements 3 h after
ingestion. Participants
cycled for 5 min at
moderate intensity and a
further 8 min at severe
intensity. End-exercise O2
consumption at moderate
intensity.
BR, beetroot juice; IR1, intermittent recovery test level 1; PL, placebo; RBC, red blood cell; TT, time-trial.
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prevented LV dilatation in both systole and diastole, as
well as attenuating LV dysfunction (as measured by
LVEF) at 9 weeks. These findings were replicated in a
reversal model more representative of the clinical
scenario in which patients might present, in which
nitrite treatment was commenced 3 weeks after TAC.
More recently, the view that perhaps dietary nitrate
might improve outcome by improving mitochondrial
function has been tested in healthy rats. Interestingly,
NaNO3 in the drinking water (1 g/l) for 7 days resulted
in elevation of circulating nitrate concentrations with
reduction in both SBP and LV end diastolic volumes but
absolutely no change in mitochondrial bioenergetics,
suggesting that at least in healthy animals the effects
of nitrate were not due to improved mitochondrial
efficiency or oxidative capacity as has been suggested
in other studies. However, what the authors did show
was that nitrate treatment was associated with an
increase in mitochondrial H2O2 emissions in LV ho-
mogenates without any change in redox state (Monaco
et al., 2018).
The ability of nitrite and nitrate to enhance skeletal
muscle performance is discussed elsewhere in this
review. However, there is increasing evidence for a
specific role of this particular characteristic of the
anions in patients with HF (Coggan and Peterson,
2016). A recent study in rats that develop HF after
induction of MI by coronary artery ligation (Ferguson
et al., 2016) has demonstrated the benefits of dietary
nitrate treatment. At 21 days after coronary artery
occlusion, rats were randomized to 5 days of nitrate-rich
(1 mmol/kg per day nitrate) versus nitrate-deplete
beetroot juice and underwent investigations of skeletal
muscle blood flow and vascular conductance. Blood flow
and vascular conductance at rest were 22% and 20%
higher, respectively, and significantly greater during
exercise in the nitrate-fed rats.
Perhaps one of the key aspects of the nitrate-nitrite-
·NO pathway that has led to so much interest in its
therapeutic utility has been the fact that one can easily
and safely test its potential in the clinical setting
through dietary administration. HF is no exception,
with very rapid translation to the clinical setting after
these early preclinical observations.
e. Clinical translation. In the first-in-human study
by Ormerod et al. (2015), 25 patients with HFrEF
established on best-tolerated HF therapy, undergoing
elective right heart catheter during the workup for
cardiac transplantation, were subjected to an infusion of
NaNO2 for 5 minutes at 10 mg/kg per minute (group 1,
n5 8) and 50 mg/kg per minute (group 2, n5 17), and a
Swann-Ganz catheter used to measure cardiac and
pulmonary hemodynamic parameters. Only the latter
dose caused significant increases in plasma nitrite
levels, but this rise was associated with a drop in SBP
of 4 mm Hg over the course of the infusion, as well as
decreases in pulmonary and systemic vascular
resistance. With this higher dose of nitrite, a significant
decrease in right atrial pressure (40%) and increases in
trans-septal gradient (3 mm Hg), cardiac output (13%),
and stroke volume (14%) were evident. In addition, in a
subgroup analysis of patients with high pulmonary
capillary wedge pressure (.15 mm Hg), stroke volume
was increased by 20%, whereas in those with wedge
pressures below 15 mm Hg, no change was observed.
This study therefore demonstrated therapeutic po-
tential for stable patients with HFrEF with clinically
marked disease, suggesting that the worse the symp-
toms, the greater the potential benefit (Ormerod
et al., 2015).
A number of small studies have been undertaken
investigating the role of dietary nitrate in patients with
or at risk of HF. Type 2 diabetes mellitus is a strong risk
factor for both HFrEF and HFpEF (Cavender et al.,
2015). In patients with or at risk of developing type
2 diabetes mellitus, 6 months of dietary nitrate
supplementation (4.5 mmol/day) was associated with
a reduction of LV volumes assessed by standard
transthoracic echocardiography, but not in other
parameters of improved cardiac performance, or with
BP reduction in comparison with placebo (Faconti
et al., 2019). This disappointing result may reflect
issues with coexisting drug therapy (i.e., metformin)
or microbial bioactivation of nitrate (Cabreiro et al.,
2013; Forslund et al., 2015; Sun et al., 2018), as
similar neutral results have been seen in other
studies with dietary nitrate and diabetes (Gilchrist
et al., 2013).
Hirai et al. (2017) in a double blind, randomized,
placebo-controlled crossover study in 13 patients with
LVEF # 40%, supplemented with 12.9 mmol daily of
dietary nitrate for 9 days, investigated the impact of
treatment upon time to exercise intolerance. Ten pa-
tients completed low- and high-intensity cardiopulmo-
nary exercise testing with noninvasive measures of
central hemodynamics, arterial BP, pulmonary oxygen
uptake, quadriceps muscle oxygenation, and serum
lactate. Over the short period of intervention, they
demonstrate that the enterosalivary circuit is intact,
with significantly higher plasma nitrite concentrations
after intervention versus placebo (240 6 48 vs. 56 6
8 nmol/l, respectively). However, they were not able to
demonstrate significant benefit in their primary out-
come of time to exercise intolerance (4956 53 vs. 4896
58 s, P . 0.05) or in their other quoted measures over
the short period of intervention. In contrast, in a
separate randomized, placebo-controlled, double blind
crossover study of nine patients with HFrEF (LVEF
28% 6 11%, NYHA II/III) assessing the potential of
an 11.2 mmol dose of dietary nitrate as beetroot juice
(Coggan et al., 2015), significant improvements in muscle
power using isokinetic dynamometry compared with pla-
cebo in both peak knee extensor power and calculated
maximal velocity of knee extension were evidenced.
730 Kapil et al.
Interestingly, these effects were made 2 hours after
treatment, and although circulating nitrate levels were
increasedat this timepoint, nitrite concentrationswere not.
This apparent dissonance between the effects of a
single acute dose and daily dosing over several days was
assessed in a single study in patients with HFpEF.
Twenty older (69 6 7 years) hypertensive patients with
HFpEF received a once-daily dose of 6.1mmol nitrate as
beetroot juice (vs. nitrate-deplete placebo juice) in a
phase II randomized double blind crossover study over
7 days (Eggebeen et al., 2016). The first dose of juice had
no impact on submaximal exercise capacity ;1.5 hours
after ingestion; however, over 1 week of intervention,
there was a 24% increase in the time to volitional
exhaustion compared with placebo. There was a further
benefit of a significant reduction in SBP, at rest and
during unloaded exercise, with a trend at volitional
exhaustion. This is in line with previous findings using
approximately double the dose, with 12.9 mmol dietary
nitrate, with improvements in exercise duration, work
done, and peak VO2 in addition to increased cardiac
output and a fall in systemic vascular resistance
(Zamani et al., 2015), and concurs with two recent pilot
studies in patients with hypertension and HFpEF in
which time to volitional exhaustion was again increased
after dietary nitrate supplementation (Shaltout et al.,
2017). Shaltout et al. (2017) report the results of their
pilot studies in older patients with hypertension and
older patients with HFpEF, in which no additional
benefit of dietary nitrate (8 and 6.1 mmol) above and
beyond exercise training compared with placebo was
evident. However, within-group comparisons in terms
of peak O2 consumption, reductions in SBP, and
improved arterial compliance were observed. In this
study, the authors suggest that escalating doses of
dietary nitrate might confer additional benefit, but
these studies also suggest enhanced benefits of pro-
longed over acute dosing in patients with HF similar to
observations in healthy volunteer studies (Vanhatalo
et al., 2010; Hoon et al., 2013). More recently, a multi-
center, placebo-controlled, cross-over, randomized trial
has investigated the effects of nebulised sodium nitrite
(1.2 mmol nitrite thrice daily for 4 weeks in 105
patients) in patients with HFpEF (Borlaug et al.
2018). Despite significant resting BP reduction with
inhaled nitrite (difference in MAP ;5 mmHg) suggest-
ing sufficient nitrite dosing/elevation to cause a hemo-
dynamic effect (there were no direct measures of plasma
nitrite concentrations), there was no effect on VO2MAX
(primary outcome there) or other important secondary
outcomes measures used in HF trials (daily activity
levels, symptom and functional class scores, NTproBNP
levels, echocardiographic indices of diastolic dysfunction)
(Borlaug et al., 2018). The reasons for the discrepancy
between this and previous studies is not immediately
clear butmay relate to the half-life of nitrite and the dose/
route used.
Despite the variable results noted to date, the general
excitement regarding such a simple intervention for
this patient cohort is reflected by the fact that there are
a number of further studies registered across the globe
that continue to investigate the potential therapeutic
role of inorganic nitrate/nitrite (summarized in
Table 5). The outcome of these studies is eagerly
awaited.
C. Nitrite and Nitrate in Inflammation
·NO is a potent anti-inflammatory mediator. Perhaps
the primary characteristic that underlies this particular
feature of ·NO bioactivity is that it potently inhibits
leukocyte recruitment (Kubes et al., 1991), a key feature
of inflammatory responses (Kolaczkowska and Kubes,
2013). The mechanism of this action of ·NO has been
attributed primarily to the canonical pathway, i.e.,
GC-1 activation, to elevate cGMP levels, which then
results in a suppression in expression of the adhesion
molecule CD62P (P-selectin), which plays a key role in
the first step, rolling, of the leukocyte recruitment
process (Ahluwalia et al., 2004). Despite this, relatively
few studies have investigated whether nitrate/nitrite-
derived ·NO has the potential to reduce inflammatory
responses in humans. In contrast, there are now several
studies in mouse models demonstrating important anti-
inflammatory effects of the anions.
Bryan and his coworkers were the first to explore
this particular phenomenon in a mouse model of
hypercholesterolemia-induced microvascular inflam-
mation. In this study, healthy C57BL6 mice were fed
a high-cholesterol diet for 3 weeks, increasing choles-
terol levels from ;70 mg/dl in controls to ;115 mg/dl,
elevating circulating leukocyte numbers from 4.8 to
6.8  106 cells/ml, and resulting in a 4-fold increase in
leukocytes adhering to the venular endothelium and an
;70-fold increase in emigrated cells measured by in-
travital microscopy in the cremaster tissue (Stokes
et al., 2009). In mice treated concomitantly with 50 or
150 mg/l NaNO2 in the drinking water, a similar
reduction in both leukocyte adhesion and emigration
was demonstrated. The authors suggested that this
effect upon leukocyte recruitment related to an im-
provement in endothelial function due to elevations in
tetrahydrobiopterin levels and, in this way, improves
endothelium-derived ·NO activity rather than acting as
a delivery method of ·NO per se.
Similar effects have been observed in another study,
in which leukocyte recruitment was induced by an acute
(90-minute) superfusion of the cremaster muscle with
the neutrophil-specific chemokine (C-X-C motif) ligand
2 (CXCL2) (Macrophage Inflammatory Protein 2). This
resulted in elevations of leukocyte adhesion and emi-
gration, which were attenuated by a bolus of NaNO2
(1.3 mg/kg) given intravenously 1 hour prior to CXCL2
superfusion (Jädert et al., 2012). This effect of nitrite
upon leukocyte adherence was shown to be dependent
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upon the activation of GC-1 and elevation of cGMP since
the guanylyl cyclase inhibitor, ODQ, administered
simultaneously with NaNO2, significantly attenuated
leukocyte adhesion but, curiously, had no effect on
leukocyte emigration. The authors suggested that this
differential effect was likely due to an important role for
cGMP in leukocyte adhesion but not margination,
although if adherence of leukocytes is attenuated, one
would expect some knockon effect upon emigration
since the former is a prerequisite for the latter. The
authors also demonstrated that after 1 week of treatment
with NaNO3 (10 mmol/l) added to the drinking water, a
similar reduction in baseline leukocyte rolling was evi-
dent, although adhesion or emigration were unaffected,
and that leukocyte adhesion and emigration were also
reduced in response to CXCL2 (Jädert et al., 2012).
It is now reasonably certain that systemic treatment
with nitrite (predominantly NaNO2) results in a re-
duction of the numbers of proinflammatory leukocyte at
sites of inflammation. This has been demonstrated in a
wide array of distinct animalmodels in several different
species, including in dextran sodium sulfate–induced
colonic inflammation as a model of colitis in rats
(Ohtake et al., 2010; Jädert et al., 2013); a mouse model
of postoperative ileus, a frequent outcome after abdom-
inal surgery (Cosyns et al., 2015); chlorine gas exposure
as a model of environmental toxicity and potential
chemical warfare in mice, rats, and rabbits (Samal
et al., 2012; Honavar et al., 2014, 2017); elastase-
induced pulmonary emphysema in a mouse model
(Sonoda et al., 2018); and lung transplantation in rats
(Sugimoto et al., 2012). In all of these models, reduced
inflammatory responses correlate with reduced numbers
of cells, and in many instances, this relates specifically
to reduced numbers of neutrophils (Ohtake et al.,
2010; Samal et al., 2012; Sugimoto et al., 2012; Cosyns
et al., 2015).
This activity of nitrite against neutrophil recruitment
has also been demonstrated with dietary nitrate. In a
mouse model of atherosclerosis, the ApoE KO mouse,
fed 15 mmol/l KNO3 in the drinking water for 12 weeks,
exhibited reduced leukocyte rolling and adhesion mea-
sured using intravital microscopy (Khambata et al.,
2017). In addition, after only 2 weeks of dietary nitrate,
neutrophil recruitment into the peritoneum in response
to zymosan or tumor necrosis factor alpha (TNFa) in the
C57BL6 or littermate ApoE KO mice were also atten-
uated. Jädert et al. (2012, 2013) demonstrated sim-
ilar effects of dietary nitrate (10 mmol/l NaNO3 for up
to 7 days in the drinking water) against both
Dextran sulfate sodium and nonsteroidal anti-
inflammatory drug (NSAID)-induced colitis.
The studies above demonstrate a clear impact of
nitrite or nitrate treatment on neutrophil recruit-
ment and activation; however, this effect has been
suggested to be responsible for the associated reduc-
tions in monocyte/macrophage recruitment. In ApoE
KO mice fed a high-fat Western diet with 15 mmol/l
KNO3 for 12 weeks, although plaque size was not
altered, macrophage accumulation within the ath-
erosclerotic plaque was significantly attenuated
(Khambata et al., 2017). A similar outcome was evident
with nitrite treatment and lung grafting (Sugimoto
et al., 2012).
A possible mechanism for these antileukocyte effects
of nitrate and nitrite is the selective inhibition of key
adhesion molecules involved in the leukocyte recruit-
ment process that enable the passage of the leukocyte
from the centerline of blood flow to the endothelium and
then across the blood vessel wall. As mentioned above,
there is good evidence that ·NO targets CD62P on
endothelial cells to attenuate leukocyte rolling. In a
rat model of NSAID-induced inflammation of the
small intestine, endothelial CD62P expression was
profoundly suppressed by treatment of rats prior
with NaNO3 (10 mmol/l) in the drinking water—
interestingly, an effect that was lost when the rats
were pretreated with chlorhexidine mouthwash to
suppress the oral nitrate reductase microbiome (Jädert
et al., 2012). Further support for such an effect comes
from the reported sensitivity of the anti-inflammatory
effects of nitrate or nitrite to agents that scavenge ·NO
[2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-
oxyl-3-oxide (C-PTIO)] or block rises in cGMP through
inhibition of GC-1 activity, namely by ODQ treatment
(Sugimoto et al., 2012; Cosyns et al., 2015), since it is
known that cGMPmediates ·NO-induced suppression of
CD62P expression (Ahluwalia et al., 2004).
However, there are a number of observations demon-
strating that other endothelial adhesion molecules and
key molecules expressed on the leukocytes themselves
may also be targets for nitrite-derived ·NO. In TNFa-
treated human dermal microvascular endothelial cells,
NaNO2 (1–100 mmol/l) caused a concentration-dependent
attenuation of intercellular adhesionmolecule-1 (ICAM-1)
expression, which is a ligand for several b2-integrins
(Jädert et al., 2012). Our own studies in ApoEmice have
shown that treatment with KNO3 in the water (15 and
45 mmol/l) causes a selective reduction in TNFa-
induced neutrophil CD11b expression (an a-integrin,
a component of CD11b/CD18, also known as macro-
phage-1 antigen), with no effects observed on either
CD62L (L-selectin) or CD162 (P-selectin glycoprotein
ligand-1) expression (Khambata et al., 2017). Un-
fortunately, in this study, the potential impact upon
endothelial CD62P expression was not assessed.
There is also some indication that treatment with
these anions likely impacts upon mediator genera-
tion at the site of inflammation. Several of the above
studies demonstrate reduced cytokine expression
after treatment with the anions, particularly with
respect to interleukin (IL)-1, IL-6, and TNFa (Ohtake
et al., 2010; Sugimoto et al., 2012; Cosyns et al., 2015;
Justice et al., 2015; Kautza et al., 2015). The exact
732 Kapil et al.
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mechanisms of this effect are uncertain but may
relate to ·NO-induced suppression of nuclear factor
kappa B expression and thus block of transcription of
these cytokines (Sugimoto et al., 2012; Jädert et al.,
2013). In addition, there has been some attention to
the possibility that attenuation of leukocyte recruit-
ment might relate to suppression of local chemokine
generation and, again, there is some evidence to
support this contention, including reduced circulat-
ing neutrophil chemokine levels (CXCL1 and CXCL2)
and reduced monocyte chemokine (C-C motif) ligand
2 (CCL2) in ApoE KO mice fed dietary nitrate
(Khambata et al., 2017). However, others have found
no change in the levels of these cytokines in other
inflammatory scenarios, including chlorine toxicity
in lungs (Honavar et al., 2014), or in the inflamma-
tory setting of aging. In the latter, the Karolinska
group demonstrated no impact upon CCL2 and a
number of key inflammatory cytokines after 17 months of
treatment with NaNO3 (1 mmol/l) in their drinking water
(Hezel et al., 2015).
Finally, there is some evidence to suggest that, in
addition to suppressing proinflammatory pathways, the
nitrate/nitrite anions may also induce anti-inflammatory
pathways. Interestingly, levels of mRNA for IL-10 levels,
an anti-inflammatory cytokine, were increased within
the plaque region in ApoE KO mice fed dietary KNO3
compared with KCl-treated controls (Khambata et al.,
2017). In addition, in TNFa-induced peritonitis, 2weeks
of pretreatment with 15 mmol/l KNO3 resulted in
elevated IL-10 peritoneal levels at 4 hours (Khambata
et al., 2017). However, again, there is data contradicting
these observations. In the extended studies of aging and
chronic treatment with dietary nitrate for 17 months,
circulating IL-10 levels were reduced (Hezel et al., 2015).
In sum, there is strong evidence that inorganic nitrate
and nitrite treatment reduces the inflammatory re-
sponse in a variety of preclinical inflammatory disease
models. Whether these effects translate to humans and
in the clinical setting has not yet been extensively tested
prospectively. In two studies, the effect of dietary nitrate
supplementation on proinflammatory monocyte-platelet
aggregates has been assessed. In both, an acute supple-
mentation study in healthy older volunteers (n 5 12,
13 mmol nitrate) and our own work in a medium-term
study in patients with hypercholesterolemia (n 5 67,
6 mmol nitrate/day for 6 weeks), a reduction in proin-
flammatory monocyte-platelet aggregates was observed
that was not apparent after placebo (Velmurugan et al.,
2016; Raubenheimer et al., 2017). Furthermore, acute
dietary nitrate supplementation was associated with a
modest reduction in the activation state of circulating
neutrophils (measured by CD11b expression) 3 hours
postsupplementation, a time when nitrite levels peak
post–dietary nitrate supplementation (see earlier)
(Raubenheimer et al., 2017). Two further studies in
healthy volunteers are underway specifically to look
at whether dietary nitrate is able to abrogate both the
inflammatory process and the resulting vascular dys-
function associated with this, utilizing two different
acute experimental models of inflammation, and the
results are eagerly awaited (clinical trials NCT:
NCT03183830, NCT02715635).
1. Thrombosis. Platelets are critically important in
the formation of clinically relevant thrombosis (Davì
and Patrono, 2007) and are exquisitely sensitive to local
generation of ·NO (Azuma et al., 1986), so much so that
in the early days of ·NO biology, this response was used
as a bioassay for ·NOproduction (Radomski et al., 1990).
·NO has numerous effects on platelet biology, including
reduction in adhesion, aggregation, recruitment, and
formation of platelet-leukocyte aggregates (Radomski
et al., 1987, 1990; Freedman et al., 1997; Chung et al.,
2004). Accordingly, a deficiency of ·NO is associated
with a state of platelet activation in relation to the
actions above (Cadwgan and Benjamin, 1993; Stagliano
et al., 1997; Freedman et al., 1998, 1999; Gkaliagkousi
et al., 2009), and organic nitrovasodilators are known to
have modest effects on platelet function (Hampton
et al., 1967; Schafer et al., 1980).
Platelet inhibitionby ·NOismediatedbyGC-1/cGMP/PKG
canonical signaling (Massberg et al., 1999), and this
PKG activation, in turn, through phosphorylation of
specific targets, leads to attenuation of platelet reactivity
by triggering downstream inhibition of P-selectin ex-
pression (Murohara et al., 1995), phosphorylation of the
thromboxane receptor (Wang et al., 1998), and VASP
(Massberg et al., 2004), which further inhibits glycopro-
tein IIb/IIIa. Whatever the specific molecular pathways
involved, it is clear that ·NO influences all of the major
components of platelet function, including Ca21 mobili-
zation, shape change, secretion, and both integrin acti-
vation and outside-in signaling and thus, in this way,
plays a key role in ensuring a coordinated regulation of
platelet activity (Naseem and Roberts, 2011; Makhoul
et al., 2018). However, the exact cellular source and
localization of ·NO generation that reduces platelet
activity is more controversial. There is evidence that
supports the endothelium (Moore et al., 2010); how-
ever, there are also several observations identifying
the platelet itself as the site for NOS-derived ·NO
(Radomski et al., 1990), particularly eNOS (Freedman
et al., 1999; Webb et al., 2008a; Radziwon-Balicka et al.,
2017), although others have failed to localize eNOS
within platelets (Gambaryan et al., 2008; Gambaryan
and Tsikas, 2015). Irrespective of localization, it is clear
that basal ·NO generation plays a critical role in
repressing platelet reactivity under normal conditions.
Thus, in scenarios in which there is a deficiency of
bioavailable ·NO, restoration of ·NO levels, through ·NO
delivery, should recover normal platelet function.
Several research groups have assessed whether pro-
vision of inorganic nitrate and nitrite might achieve
this outcome.
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Ex vivo incubation of platelet-rich plasma, collected
from healthy volunteers with supraphysiologic nitrite
concentrations (60 mmol/l NaNO2) was shown many
years ago to reduce aggregatory responses to a wide
range of platelet stimuli (ADP, arachidonic acid, and
collagen), whereas similar concentrations of NaNO3 had
no effects (Schafer et al., 1980). This finding has been
supported more recently, when physiologically relevant
nitrite concentrations (no more than 1 mmol/l) achieved
through in vivo treatment with dietary inorganic ni-
trate (Webb et al., 2008b) resulted in a suppression of
ex vivo–assessed platelet aggregation responses. How-
ever, further work has shown convincingly that ex vivo
treatment with nitrite salts does not directly alter
platelet reactivity at physiologic concentrations. Rather,
the evidence suggests that to reveal the antiplatelet
effects of nitrite, reactivity must be assessed in the
whole blood environment wherein platelets remain in
close contact with the circulating elements of the blood.
In platelet-rich plasma, 0.1 mmol/l NaNO2 inhibited
stimulus-induced platelet aggregation only when in the
presence of erythrocytes (Srihirun et al., 2012). Similar
findings were separately published by Velmurugan
et al. (2013), in which KNO2 (0.1–0.3 mmol/l) caused
concentration-dependent suppression of platelet aggre-
gation only when incubated with whole blood and not
when incubated with platelet-rich plasma alone. In-
terestingly, the antiplatelet effects of nitrite are en-
hanced by deoxygenation of erythrocytes and blocked by
·NO scavenging (Srihirun et al., 2012), as well as being
associated with elevations in cGMP (Velmurugan et al.,
2013). These findings fit well with the view that nitrite
reduction in blood is in part dependent upon the
reductase activity of erythrocytic Hb and requires
partial deoxygenation (Cosby et al., 2003).
As one would suspect, the elevation of cGMP in the
platelet with nitrite treatment results in the antiplate-
let effects typical of ·NO-induced GC-1 activation and is
associated with suppression not only of P-selectin
expression (Akrawinthawong et al., 2014) but also
gpIIb/IIIa expression, both key pathways regulating
platelet activity and known to be influenced by ·NO
(Murohara et al., 1995; Keh et al., 1996). Further
studies with inhaled NaNO2 (40 mg) have also demon-
strated increased platelet phospho-VASP, confirming
NO/GC-1/cGMP/PKG signaling and diminution of
stimulus-induced platelet aggregation (Parakaw et al.,
2017). These results together suggest that nitrite re-
duction does not occur at the level of the platelet itself
but rather occurs at the level of the erythrocyte and that
the ·NO generated acts on the neighboring platelet
to elevate cGMP, resulting in downstream inhibition of
key platelet activating pathways.
Platelets themselves contain nitrite (Apostoli et al.,
2014), the levels of which are substantially reduced by
treatment with ascorbic acid ex vivo [a nonspecific
reducing agent, as per previous evidence shown in
erythrocytes (Sibmooh et al., 2008)], which also simul-
taneously results in inhibition of platelet aggrega-
tion that is associated with elevations in cGMP and
phospho-VASP and effects that are enhanced by in-
hibition of PDE-V and inhibited if treated with ODQ or
C-PTIO. However, in this paper, the authors also show
nitrate in platelets, the levels of which likewise are
decreased with ascorbate. This observation is curious,
since ascorbate provides a one-electron reduction; how-
ever, for nitrate reduction, two electrons are needed.
The authors also show that treatment with NaNO2
causes inhibition of platelet aggregation that is also
enhanced by treatment with ascorbate or PDE-V inhib-
itors; and that is prevented by treatment with ODQ or
C-PTIO. The authors propose a number of controversial
explanations for their observations. Since coincubation
with NOS inhibitors had no impact upon any of the
responses and since the authors previously have failed
to show eNOS expression in platelets, they reason that
the source of the widely reported capacity of platelets to
generate ·NO is in fact due to nitrite reduction and not
NOS catalytic activity. Moreover, unlike several other
publications, since the authors conducted all of their
ex vivo experiments in the absence of erythrocytes, they
suggest that the platelet itself has the capacity to reduce
nitrite directly (Apostoli et al., 2014), although the exact
nitrite reductase was not identified.
As mentioned briefly, the beneficial effect of nitrite
upon platelet reactivity can be exposed after elevation of
circulating nitrite levels through oral administration
of inorganic nitrate. Oral supplementation of healthy
volunteers with either 2–8 mmol KNO2 (Richardson
et al., 2002; Velmurugan et al., 2013) or 3.1–22.5 mmol
dietary nitrate (192–1395 mg nitrate as beetroot juice)
(Webb et al., 2008b; Velmurugan et al., 2013) prior to
venepuncture, followed by examination of ex vivo plate-
let aggregation, results in a modest reduction in the
platelet aggregatory response to stimulatory agonists
such as ADP and collagen, with associated increases in
platelet cGMP and suppression of P-selectin expression
(Velmurugan et al., 2013). The modulating effects of
dietary nitrate supplementation are additionally seen
in healthy older adults after acute nitrate supplementa-
tion (13 mmol nitrate, n5 12) with reduction in platelet
P-selectin expression and clotting time in whole blood,
relating to both intrinsic and extrinsic pathways inwhole
blood but not plasma coagulation tests post–dietary
nitrate supplementation (Raubenheimer et al., 2017).
Interruption of the enterosalivary circulation by
spitting negated the anti-platelet effects of dietary
nitrate, reconfirming the requirement for bioactiva-
tion of nitrate to nitrite within the oral cavity (Webb
et al., 2008b). Similar effects are seen in mice—whilst
treating mice for 1 week with NaNO2 (0.1 g/l) or NaNO3
(1 g/l) reduced ex vivo platelet aggregation and pro-
longed bleeding time, when mice were fed with a low-
NOx diet, the opposite occurred, with enhanced
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platelet aggregation and shorter bleeding time (Park
et al., 2013). Finally, this beneficial profile of activity of
nitrite and nitrate upon platelets evidenced in these
acute healthy volunteer and preclinical studies does
translate into the patient setting. In patients with
endothelial dysfunction and modest hypercholesterol-
emia, 6 weeks of a once-per-day dietary nitrate supple-
mentation (;6 mmol) was associated with lower basal
and stimulus-induced platelet P-selectin expression
and leukocyte-platelet aggregates (Velmurugan et al.,
2016). Again, these studies show a modest but signifi-
cant effect. Such a profile of activity, we argue, lends
itself as an alternative approach in primary and
secondary prevention. Perhaps one of the key diffi-
culties associated with antiplatelet therapy in the
secondary prevention setting is the negative side
effect profile of bleeding complications. Similarly, it
is these very same bleeding complications that have
resulted in cessation of the use of aspirin as a primary
prevention strategy. We speculate that with such a
modest but important antiplatelet profile, dietary
nitrate offers a relatively safe and easy-to-administer
option.
2. Peripheral Arterial Disease. The positive effects
of inorganic nitrate/nitrite against inflammation and
platelet function, in addition to the benefits in terms
of skeletal muscle function, suggest that in diseases
with chronic tissue, ischemia such as PAD associated
with impaired blood flow, enhanced inflammation,
and platelet activation, inorganic nitrate may be of
value. In addition, since ·NO has a positive impact upon
angiogenesis (Papapetropoulos et al., 1997; Cooke and
Losordo, 2002), effective ·NOdelivery through inorganic
nitrate/nitrite might offer a mechanism for therapeutic
angiogenesis.
In a mouse hindlimb ischemia model, both chronic
nitrite and nitrate therapy increase ischemic tissue
blood flow with associated endothelial cell proliferation
and angiogenesis (Kumar et al., 2008; Hendgen-Cotta
et al., 2012). In addition, evidence in humans suggests
that dietary nitrate supplementation is associated with
mobilization of circulating angiogenic cells (Heiss et al.,
2012), strongly supporting the suggestion that nitrate
therapeutics may work in PAD. However, again there
is controversy. Major optimism was generated by
the first study in patients with PAD demonstrating
benefit. After a 3-month supervised exercise program
in patients with PAD, significant improvements in
exercise capacity were seen and correlated to increases
in plasma nitrite concentration (Allen et al., 2010). But
more importantly, acute dietary nitrate supplementa-
tion (18 mmol nitrate in beetroot) was associated with
;20% improvement in claudication onset time and peak
walk time (Kenjale et al., 2011). However, divergent
results have been apparent with chronic administra-
tion. After 10 weeks of twice-daily supplementation
with NaNO2 (40 or 80 mg) versus placebo in diabetic
patients with PAD, there was an improvement in
endothelial function in these patients with nitrite treat-
ment, but there was no effect on 6-minute walk time
(Mohler et al., 2014). Conversely, 8 weeks of NaNO3
(8.5 mmol/day nitrate) was associated with a ;40 m
improvement in the 6-minute walk test (Bock et al.,
2018a), although there was only a trend for similar effect
(;30 m) after 12 weeks of 4.2 mmol nitrate with a
structured exercise program compared with exercise
and placebo (Woessner et al., 2018). However, these
effectsmay have been explained, despite randomization
and blinding, by a slightly worse baseline in the nitrate-
treated group and thus greater apparent improvement.
Further definitive studies are awaited, but at present,
whether dietary nitrate might be useful for PAD is
uncertain.
3. Atherosclerosis. There is a wealth of evidence
demonstrating that vascular ·NO is critical in sustaining
vascular patency and that a deficiency in bioavailable
·NO is a pivotal phenomenon involved in triggering
atherogenesis (Böger et al., 1997; Antoniades et al.,
2007). As discussed above, we know that ·NO reduces
leukocyte adhesion and transmigration, reduces low
density lipoprotein cholesterol oxidation, and inhibits
vascular smooth muscle proliferation [for review, see
Moncada and Higgs (1993)]. Moreover, from studies
using NOS inhibitors and eNOSKOmice, we know that
eNOS is the primary source of the vascular ·NO that
underlies protection against atherogenesis in health
(Kauser et al., 2000; Kuhlencordt et al., 2001). Further-
more, the uncoupling of eNOS in the disease setting is
thought to be responsible for the reduced bioavailable
·NO and endothelial dysfunction, which is implicated in
the atherosclerotic process (Libby, 2002; Napoli et al.,
2006). As a result, numerous studies have sought to
restore ·NO levels utilizing ·NO donors, particularly the
organic nitrates, L-arginine (the substrate for conven-
tional ·NO synthesis), or the essential cofactor for NOS,
tetrahydrobiopterin. Many of these studies have shown
positive outcomes, including improvements in vascular
function, systemic inflammatory profile, and local in-
flammation at lesional sites and positive effects upon
platelet reactivity (Clarkson et al., 1996; Theilmeier et al.,
1997; Wolf et al., 1997). However, translation of these
findings to the clinical setting has not gone as well as
hoped (e.g., Nakamura et al., 1999; Blum et al., 2000;
Cunnington et al., 2012). The reasons for these discor-
dant findings are variously attributed to eNOS uncou-
pling for L-arginine (Förstermann and Sessa, 2012),
tolerance and induction per se of vascular dysfunction with
theorganicnitrates (Münzel et al., 2013), and/or oxidationof
tetrahydrobiopterin (Cunnington et al., 2012). Although all
of these approaches are distinct, they all aim to provide ·NO
delivery to the atherogenic blood vessel. The failure of
translation of all of these approaches supports the conten-
tion that alternative, but more effective, strategies to
improve bioavailable ·NO levels are warranted. It is this
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need that underlies the testing of inorganic nitrate and
nitrite in atherosclerosis.
As mentioned earlier in the review, there have been
some studies that have begun to assess the potential of
nitrate/nitrite as an ·NO delivery method in atheroscle-
rosis. Inorganic nitrite and nitrate supplementation has
been shown to reduce leukocyte-endothelial cell inter-
actions in hypercholesterolemia (Stokes et al., 2009),
and a 6-week, once-per-day dietary nitrate treatment in
patients with hypercholesterolemia improved endothe-
lial function together with some evidence (although the
study was not powered for some of these indices)
suggesting that this improved vascular function was
associated with a reduced systemic inflammation and
reduced platelet reactivity (Velmurugan et al., 2016).
These positive mechanistic findings have been fol-
lowed up by testing of the impact of inorganic nitrate
salt supplementation upon plaque formation and size
in mouse models of atherosclerosis. The first study
assessing this reported in 2016 and, disappointingly,
was negative. In this study, low density lipoprotein
cholesterol receptor KO mice were fed a Western diet
for 14 weeks and treated concomitantly with NaNO3
(1 g/l) or equimolar NaCl in drinking water. At the end
of this treatment period, there were no differences
between the two groups in plaque size, histologic
plaque scores, and macrophage, collagen, and smooth
muscle content. It is noteworthy, however, that al-
though there have been numerous studies demon-
strating efficacy of such a dosing schedule, in this
study, nitrate supplementation was not associated
with an increase in systemic nitrite levels, and there
was no change in BP. These results suggest that, at
least in these animals, this dosing regimen was in-
sufficient to evoke modulation of the nitrate-nitrite-
·NO pathway (Marsch et al., 2016). This failure may
underlie the absence of any effects seen.
Interestingly, in ApoE KO mice, supplementation
with 15 mmol/l KNO3 for 12 weeks was associated with
increases in systemic and organ nitrite levels in com-
parison withmice treated with equimolar KCl. This rise
was associated with reduced leukocyte rolling and
adherence, assessed using intravital microscopy of the
cremaster microcirculation, reduced circulating neutro-
phil numbers and monocyte activation, and upregula-
tion of IL-10–dependent anti-inflammatory pathways.
This multitude of anti-inflammatory effects resulted in
a reduction in the inflammatory load within the plaque,
while having no effect upon plaque size (Khambata
et al., 2017). Intriguingly, in this study, we showed that
tissues of the ApoE KO expressed greater nitrite re-
ductase activity assessed ex vivo and that this activity,
at least in part, was driven by elevated XOR activity,
observations fitting with studies in humans indicat-
ing that individuals with coronary artery disease
have increased vascular XOR expression and activity
(Spiekermann et al., 2003). In a separate study, low to
moderate dosing with KNO3 (0.1 and 1mmol/kg per day)
but not high-dose (10 mmol/kg per day) supplementation
for 10 weeks in ApoE KO mice was associated with
increased collagen expression and reduced lipid de-
position and also, similarly, no differences in plaque
size (Bakker et al., 2016). These two latter studies
support the contention that reduced inflammation
within the atherosclerotic plaques coupled with in-
creased smooth muscle and collagen content, al-
though not influencing plaque size, likely provides a
more stable plaque phenotype (Stefanadis et al.,
2017).
Interestingly, and perhaps contradicting the above
work, is evidence suggesting that nitrite has important
activity limiting intimal hyperplasia. Rats pretreated
with NaNO2 (administered intraperitoneally, orally,
or nebulized) inhibited pathologic intimal hyperplasia,
caused in response to vascular wall injury through
insertion of a balloon and inflation in the carotid
artery. Importantly, treatment of rats after injury
(15 days later) also resulted in a statistically significant
reduction in hyperplasia assessed at 28 days. In addition,
the authors demonstrated that this beneficial effect of
nitrite was attenuated if rats were pretreated allopuri-
nol, implicating XOR as the nitrite reductase in this
setting (Alef et al., 2011).
Although there does seem to be some contrast in
pathways, the evidence does support the view that
the nitrate-nitrite-·NO pathway may offer opportu-
nities for limiting atherosclerosis and that such an
approach may have utility not only in terms of
dietary lifestyle interventions that limit disease
from occurring in the first place but also as an
additional strategy that may prove useful in the
secondary prevention setting.
D. Nitrite and Nitrate in the Respiratory System
In the respiratory system, ·NO can be produced under
physiologic conditions by heterogenous cell types, in-
cluding pulmonary vascular endothelial cells, immune
cells, respiratory epithelial cells, and intrinsic respira-
tory nerves (Barnes andBelvisi, 1993). Exhaled ·NO can
be detected in the range of 20–60 ppb, although it may
be that the majority of this is derived from the upper
respiratory tract and that the distal airways in the lung
parenchyma are associated with much lower levels
(1–6 ppb) (Dillon et al., 1996). The physiologic role of
·NO in the respiratory system is complex to understand
in any specific area given the many different sources of
·NO. The activity of ·NO will naturally depend on other
local factors, including levels of oxidant stress (in a high-
oxygen environment).
In early studies, nitrovasodilators were shown in
isolated airway smooth muscle to activate the canonical
GC-1/cGMP pathway to produce muscular relaxation
(Gruetter et al., 1989). Furthermore, inhaled ·NO
was found to have small effects on bronchodilation in
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patients with asthma and to prevent methacholine-
induced bronchoconstriction in a concentration-dependent
manner in rodents. (Dupuy et al., 1992; Högman et al.,
1993). There is also a contribution to physiologic bronchial
tone by inhibitory nitrergic signaling that counteracts
the excitatory cholinergic pathway (Belvisi et al., 1992;
Ward et al., 1993). Perhaps therapeutically more im-
portant than effects on bronchial tone, ·NO is a key
signaling molecule regulating basal pulmonary vascu-
lar tone to counteract pulmonary hypoxic vasoconstric-
tion (Crawley et al., 1990; Persson et al., 1990; Liu et al.,
1991). In addition to its actions mediated via elevation
of cGMP, there are some ·NO effects in the respiratory
system that are largely independent of this pathway.
In particular, high levels of ·NO that can be gener-
ated by iNOS may be antimicrobial and tumoricidal
by DNA deamination and inhibiting DNA synthesis
(Kwon et al., 1991; Wink et al., 1991). Given the wide-
ranging actions of ·NO in the pulmonary system, it is not
surprising that strategies to harness ·NO activity have
been explored in various respiratory-related diseases.
1. Pulmonary Hypertension. Pulmonary arterial
hypertension (PAH) is a rare condition characterized
by increased pulmonary vascular resistance and asso-
ciated elevated pulmonary arterial pressure (PAP),
leading to right HF. Patients with PAH experience
significant dyspnea, fatigue, and accelerated mortality.
Pathophysiological alterations in PAH include abnormal
pulmonary vasoconstriction and endothelial dysfunction,
smooth muscle cell proliferation, and adverse remodel-
ing of the pulmonary circulation. It has been known for
some time that defects in ·NO-mediated vasodilatation
is one of the hallmarks of disease (Adnot et al., 1991),
and this has led to the exploration of drugs that target
the ·NO-GC-1-cGMP pathway for the reduction of PAP.
Inhaled NO (iNO), by virtue of its scavenging in the
circulation by Hb, results in selective delivery of ·NO to
the pulmonary circulation without the potential ad-
verse effects of systemic ·NO delivery, such as systemic
arterial hypotension. Inhaled ·NOwas demonstrated to
be a selective pulmonary vasodilatormore than 30 years
ago (Frostell et al., 1991; Pepke-Zaba et al., 1991), but
the need for continuous nebulization restricts its utility
in ambulant patients with PAH. This limitation has,
however, been overcome by taking the strategy of using
selective inhibitors of cGMP breakdown by blocking the
activity of PDE-V, thus augmenting the pulmonary
vasodilatory effects of endogenously produced ·NO. This
approach is associated with clear improvements in
patient-related and hemodynamic outcomes (Palmieri
et al., 2004; Galiè et al., 2005, 2009; Pepke-Zaba et al.,
2008) and is now commonly used clinically for this
indication. Since it is widely accepted that there is a
reduction in ·NO bioavailability in PAH (Hu et al.,
2010), there has been considerable focus on bypassing
this step of the pathway through generation of direct
activators/stimulators of GC-1. Riociguat is the first in
class of these drugs to have received widespread mar-
keting authorization for PAH after the positive results of
the PATENT studies, demonstrating improvements in
the 6-minute walking test (the most commonly used
intermediate endpoint) and dyspnea scores in patients
with PAH (Ghofrani et al., 2013).
Given the recent evidence of the ability of nitrate-
nitrite-·NO reduction to produce bioactive ·NO and the
fact that this pathway appears to be augmented in
hypoxia, this knowledge has spurred interest in whether
inorganic nitrite andnitrate could ameliorate pulmonary
hypertension. Recent preclinical studies have explored
the utility of this pathway in pulmonary hypertension. In
ovine models of PAH induced by hypoxia, thromboxane,
and hemolysis, both iNO and inhaled NaNO2 reduced
pulmonary vasoconstriction and ameliorated PAP.
An important distinction between the two treatment
forms was that nitrite therapy was associated with
less systemic hypotensive effects (Hunter et al., 2004;
Blood et al., 2011). The effects of inhaled nitrite were
kinetically slower than those for iNO and associated
with less rebound vasoconstriction on termination of
intervention (Hunter et al., 2004). Similarly, in both
monocrotaline and hypoxia-induced PAH in rats,
repeated inhaled nitrite application prevents but
also reverses established effects of PAH on PAP,
vascular smooth muscle proliferation, and right
ventricular function (Zuckerbraun et al., 2010). As-
sessment of nitrite reductase ex vivo suggested that
this effect was largely XOR-mediated, and in vivo, the
effects of nitrite were abrogated by both XOR in-
hibition and dietary tungsten replacement of molyb-
denum in XOR (Zuckerbraun et al., 2010).
The potential beneficial effects of elevation of sys-
temic levels of nitrite have been explored by both
injection of inorganic nitrite and through dietary
nitrate (via the enterosalivary circulation) and ni-
trite provision in drinking water. Acute intravenous
and chronic intraperitoneal inorganic nitrite appli-
cation are associated with improvements in PAP and
right ventricular hypertrophy in monocrotaline- and
hypoxia-induced PAH in rats (Casey et al., 2009;
Pankey et al., 2012). However, for effective translation
to human therapeutics, a more convenient form of
systemic nitrite elevation would be desirable. In mice
exposed to 3 weeks of hypoxia to induce typical patho-
logic changes of PAH, both dietary nitrite (0.6 mmol/l)
and nitrate (45 mmol/l) supplementation via drinking
water reversed elevation of right ventricular pressure
and hypertrophy. Dietary nitrate supplementation
was also effective in a pathologically distinct model
of PAH induced using bleomycin (Baliga et al., 2012)
and monocrotaline (Tawa et al., 2019). Further work
utilizing eNOS KO mice and XOR inhibitors sug-
gested that both enzyme systems were important for
the beneficial effects of elevated nitrite levels in
these models, with evidence also implicating ·NO-
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mediated activation of GC-1-cGMP pathways (Baliga
et al., 2012).
Whether local or systemic elevation of nitrite will
translate to effective treatments in human disease is
currently unknown. Earlier clinical studies in healthy
volunteers given i.v. NaNO2 (1 mmol/min) suggested
acute improvements in hypoxia (12%)-induced pul-
monary artery pressures (measured by transthoracic
echocardiography) (Ingram et al., 2010). Furthermore, a
series of dose-ranging phase I pharmacokinetic studies
of inhaled NaNO2 in healthy persons have suggested
suitable safety parameters supporting a thrice daily
maximal tolerated dose of 90 mg of NaNO2 (Rix et al.,
2015) to allow further exploration of inhaled nitrite in
patients with PAH. In patients with PAH due toHFpEF
and chronic lung disease, acute inhaled nitrite lowered
PAP, pulmonary capillary wedge pressures, and pulmo-
nary vascular resistance (Simon et al., 2016). Recently, a
report in five patients with echocardiographic evidence
of PAH associated with b-thalassemia has suggested
that acute inhaled nitrite rapidly decreases PAP,
and this reverts shortly after inhalation terminates
(Yingchoncharoen et al., 2018). In a pilot crossover
study in 15 patients with PAH, randomized to two
7-day treatment periods (16 mmol/day nitrate vs.
placebo), ingestion of a fixed dose of dietary nitrate
was associated with increases in exhaled ·NO and
plasma and salivary NOx and was not associated with
any adverse systemic hemodynamic changes. Therewere
no significant changes in pulmonary hemodynamic
parameters assessed by echocardiography or cardiopul-
monary exercise testing, or of function tests, such as the
6-minute walk test, although there were trends for
improvements in right ventricular function and peak
power per liter oxygen consumed, particularly in those
patients in whom plasma nitrite flux was .30% post–
nitrate ingestion (Henrohn et al., 2018). Although these
data are encouraging, it remains for larger, adequately
powered trials to determine whether inorganic nitrate
supplementation has benefit in PAH, with or without
other drugs that modulate the ·NO-GC-1-cGMP system.
2. Chronic Obstructive Pulmonary Disease. COPD
describes a progressive respiratory disease affecting
the airways and lung parenchyma, resulting in irre-
versible airway obstruction. Patients with COPD de-
scribe dyspnea and reduced exercise tolerance due to a
combination of ventilatory/gas-exchange impairment
leading to hypoxia and skeletal muscle deconditioning.
Exercise and pharmacological management improve
the exercise capacity and physical function of patients
with COPD (Barnes et al., 2015).
Given the effects of inorganic nitrate supplementa-
tion, via elevation of systemic nitrite levels, on various
measures of exercise capacity in healthy persons de-
scribed above and hypoxia-related augmentation of the
nitrite-derived ·NO production, the utility of inorganic
nitrate supplementation in COPD has been studied.
Two separate studies have shown that acute supple-
mentation of dietary nitrate (7.6–12.9 mmol nitrate)
improves 75% submaximal exercise time by 30 seconds
and incremental shuttle walk test by 40 m compared
with placebo (Berry et al., 2015; Kerley et al., 2015); in
contrast, however, further studies using 13.5 mmol
nitrate daily for 2.5 days (Shepherd et al., 2015b) or
20 mmol nitrate for 6 days (Friis et al., 2017) showed no
benefit on the O2 cost of exercise or 6-minute walk test
(Shepherd et al., 2015b; Friis et al., 2017). Importantly,
in these studies, plasma nitrite levels were increased,
and BP was robustly reduced, suggesting that both the
chemical and functional effects of the nitrate-nitrite-
·NO pathway are present in patients with COPD. The
difference between the responses in the two sets of
studies is uncertain but may relate to differences in
dosing schedules and warrants further investigation.
Further evaluation of dietary nitrate supplementation
(6.5 mmol/day nitrate for 8 days) in patients with COPD
showed no improvement in gas diffusion or peak exercise
capacity, despite robust increases in exhaled ·NO, but was
associated with statistically significant (but small in
magnitude) improvements in respiratory-focused quality
of life (St. George’s Respiratory Questionnaire) scores
(Behnia et al., 2018). Similar to the position with PAH,
large adequately powered studies are awaited to defini-
tively explore the therapeutic potential of inorganic nitrate
in COPD.
3. Sleep-Disordered Breathing. Obstructive sleep
apnea syndrome (OSA) is the most common form of
sleep-disordered breathing problem and results from
recurrent occlusion of the upper airway during sleep.
Numerous epidemiologic studies have implicated
OSA as a causative, independent factor for CVD
(Arzt et al., 2005; Yaggi et al., 2005; Somers et al.,
2008). The pathophysiological links between OSA and
CVD are not fully understood, but several mecha-
nisms, such as elevated sympathetic drive, increased
oxidative stress, andvascular inflammation resulting from
repeated nocturnal hypoxia/reoxygenation cycles, have
been suggested (Somers et al., 2008). Importantly, ·NO
levels are diminished in OSA and are partially restored
with the most common, effective form of therapy, contin-
uous positive airway pressure (Ip et al., 2000; Schulz et al.,
2000; Alonso-Fernández et al., 2009), suggesting that
·NO delivery in this setting may be of value.
The only study exploring the nitrate-nitrite-·NO
pathway in patients with OSA is restricted to a small
(n 5 3) 14-day, controlled crossover study. Nitrate
supplementation (12.9 mmol nightly) was associated
with increased plasma nitrate levels (nitrite was
not measured) and with improvement in fatigue and
visual attention scores, although no change in sleep
quality or Epworth sleepiness scores, and changes in
apnea/hypopnea index were not assessed. All patients
had controlled BP levels on ambulatory monitoring at
index, but there was a trend toward reduced nocturnal
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BP after nitrate supplementation (Kerley et al., 2016),
providing confidence in the dosing schedule efficacy in
this study.
Sleep-disordered breathing is also an occurrence in
the acclimatization to hypobaric hypoxia at altitude.
Given the reductions in O2 consumption associated with
nitrate supplementation seen at sea level (see ear-
lier), Patrician et al. (2018) investigated the acute
effects of acute nocturnal dietary nitrate supplementa-
tion (10 mmol/day nitrate) in lowlanders after ascent
to 3700–4900 m, in comparison with a peri–sea level
(300 m) on cardiorespiratory responses during sleep.
Acute dietary nitrate supplementation had no effect
on various measures of sleep-disordered breathing.
Similar longer-term studies in lowland volunteers
ascending to high altitude (4600 m) demonstrated
that 7 days of dietary nitrate supplementation (3.7 mmol
nitrate three times daily) had no effect on respiratory
parameters, such as O2 saturation, or acute mountain
sickness, despite robust increase in fractional exhaled
·NO (Cumpstey et al., 2017).
Further studies are required to delineate the potential
benefit of nitrite-derived ·NO in patients with sleep-
disordered breathing, not only on the respiratory ab-
normalities but also on the elevated CV risk profile that
such patients exhibit.
4. Toxic Lung Injury. Chlorine gas has been impli-
cated in mass casualties due to accidental or deliberate
exposure in civilian and military settings. The patho-
physiology of chlorine gas–related lung injury includes
pulmonary and systemic increased oxidative and nitro-
sative stress and hypoxemia, with persistence of airway
remodeling and airway hyperreactivity over time (White
and Martin, 2010). Since nitrite-derived ·NO has bene-
ficial effects in I/R lung injury (Sugimoto et al., 2012;
Okamoto et al., 2013), this has spurred interest as to
whether itmay be beneficial in other forms of lung injury.
Rats exposed to 400 ppm chlorine gas for 30 minutes
were given NaNO2 (1 mg/g, i.p.) repeatedly for up to
6 hours and then euthanized. Treatment with nitrite
was associated with reduced bronchoalveolar lavage
protein levels and reduced epithelial cell apoptosis
(Yadav et al., 2011), with some evidence that in-
tramuscular delivery was more effective than in-
traperitoneal delivery (Samal et al., 2012), which is
more translatable to the management of mass casu-
alty disaster scenarios by first responders. In an
adaptation of this methodology, in rats exposed to a
higher exposure of chlorine (600 ppm for 30 minutes)
that induces 80% fatality, a single intramuscular in-
jection of nitrite (10mg/kg) 30–60minutes postexposure
reduced mortality to 50%.
These findings have been repeated in a nonrodent
model using New Zealand white rabbits. Chlorine gas
(600 ppm, 45 minutes) is 35% lethal after 18 hours and
is associated with airway protein and neutrophil accu-
mulation. Nitrite (1 or 10 mg/kg, via i.m. injection)
administered 30 minutes post–chlorine gas exposure
prevented death in all rabbits, and this was associated
with attenuated indices of acute lung injury (Honavar
et al., 2017). Further mechanistic evaluation revealed
that neutrophil depletion reduced the lethality of chlo-
rine exposure but also abrogated any further improve-
ment by nitrite, suggesting a neutrophil-dependent
mechanism for nitrite-derived protection in this model
(Honavar et al., 2014).
Taken together, these data provide further rationale
for developing nitrite as a postexposure treatment to
ameliorate chlorine gas exposure–related lung injury,
although the pathway for further development of this
approach is awaited given the complexities of trying to
perform a clinical trial in this area.
E. Nitrite and Nitrate in the GI System
In normal GI tract physiology, ·NOmodulates smooth
muscle tone, thereby regulating intestinal peristalsis
and gastric emptying, andmaintains GImucosa through
regulation of acid and gastric mucus secretion and
maintenance of mucosal blood flow (Salzman, 1995).
Additionally, ·NO has roles in controlling pathogen
growth (Fang, 1997), and from the first demonstrations
of nitrite-derived ·NO production, the antimicrobial
effects of this pathway particularly relevant to the gut
were explored. Nitrite-derived ·NO controls both path-
ogenic fungal and bacterial growth in culture (Benjamin
et al., 1994; Dykhuizen et al., 1996, 1998) through
bactericidal activity (Björne et al., 2006).
In addition to antimicrobial activity, intragastric ·NO
production, through acidification of nitrite, has local
gastroprotective effects, increasing gastric mucosal
blood flow and mucus thickness (Björne et al., 2004;
Petersson et al., 2007). This pathway is thought to
underlie ·NO-mediated reductions of gut injury from
bothNSAIDand stress-induced ulcer formation (Miyoshi
et al., 2003; Jansson et al., 2007). In inflammatory bowel
disease, a common finding is disruption of the protective
mucosal barrier and diminished mucus layer. In an
experimental dextran sodium sulfate model of colitis,
both peritreatment and post-treatment with inorganic
nitrite (1 mmol/l in drinking water for 7 days) improved
mucus thickness, disease activity score, and histologic
scores and restored goblet cell abundance (Jädert
et al., 2013). Further studies in cultured human colonic
epithelial cells demonstrate that nitrite application
(100 mM) improved wound closure after an incision
into the cultured monolayer (Jädert et al., 2013),
demonstrating that in addition to improvements in
blood flow, nitrite treatment accelerates healing of
wounds.
More recently, pretreatment with intravenous nitrite
(48 nmol) before intestinal manipulation that induces a
model of postoperative ileus showed an improvement in
intestinal transit and restored intestinal contractility
within 24 hour (Cosyns et al., 2015). This effect was
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attributed to reductions in inflammatory cytokines and
ROS and was dependent also upon elevations of cGMP
(Cosyns et al., 2015). This approach is being assessed in
a randomized clinical trial of pretreatment of 1 week
with dietary nitrate prior to planned colorectal surgery
(n 5 30, NCT03772444). In contrast, a recent report
using an acute supraphysiological dose of NaNO2
(20, 40, 60, and 75 mg/kg b.wt.) in rats demonstrated
dose-dependent increase in abnormal structure and
significant morphologic damage in the intestine in
animals examined 24 hours postdose (Ansari et al., 2017),
although the relevance of these acute doses to human
gut physiology is unclear, and previous reports in rats
using similar doses have not shown the same effect
(Roediger et al., 1986).
Whether nitrite- or nitrate-based therapeutic inter-
ventions are pursued in additional clinical studies
for GI disorders is not clear at the present time,
and manual search of publicly available clinical trial
databases did not discover additional planned studies
at this time.
F. Nitrite and Nitrate in Metabolic Diseases
With increasing prevalence worldwide of obesity
(Hruby and Hu, 2015), there has been a dramatic
increase in the numbers of patients suffering from
insulin resistance syndromes such as type II diabetes
mellitus (Kharroubi and Darwish, 2015) and the
related metabolic syndrome (Sorrentino, 2005), a
clustering of cardiometabolic risk factors that are
associated with increased risk of diabetes and CVD
(Eckel et al., 2005). eNOS deficiency in animal models
(Duplain et al., 2001; Cook et al., 2003) or long-term
treatment with eNOS inhibitors leads to features
of metabolic syndrome and diabetes, such as weight
gain, insulin resistance, and dyslipidemia (Balon et al.,
1999), a profile that is replicated in humans with eNOS
polymorphisms (Monti et al., 2003; Fernandez et al.,
2004). These data suggest that manipulating ·NO levels
may have therapeutic utility in diabetes and metabolic
disorders. Importantly, in C57BL6 mice on long-term
(up to 18 months) dietary restriction of nitrite and
nitrate, these abnormalities (increased visceral adi-
posity, dyslipidemia, glucose intolerance, insulin re-
sistance) are replicated (Kina-Tanada et al., 2017).
These results suggest not only that reduction in NO
signaling is important irrespective of the source
but also that augmenting bioactive NO through the
nitrate-nitrite-NO pathway may be a useful thera-
peutic strategy.
Furthermore, intriguing epidemiologic data could
also support this view: green leafy vegetable consump-
tion (rich in dietary nitrate) is associated with reduced
risk of developing type 2 diabetes (Carter et al., 2010),
and habitual use of mouthwash [potentially interfering
with enterosalivary conversion of nitrate to nitrite
(c.f. effects on BP (Kapil et al., 2013)] is associated
with progression of dysglycemia in overweight adults
(Joshipura et al., 2017).
Several preclinical studies have explored elevating
systemic nitrite levels inmodels of diabetes ormetabolic
syndrome, using both nitrite and nitrate. In adenosine
A2B–deficient mice (a model of metabolic syndrome on
chow diet), acute nitrate loading (0.1 mmol/kg i.p.) was
associated with improvement in insulin resistance
(homeostatic model assessment of insulin resistance)
and glucose clearance (Peleli et al., 2015). These acute
effects are also established in longer-term experiments.
In another model of metabolic syndrome (eNOS de-
ficiency), mice supplemented for 8–10 weeks with
NaNO3 at a dose expected to recapitulate normal
endogenous nitrate production from oxidative ·NO me-
tabolism (1 mmol/l in drinking water) had reductions in
visceral fat and weight and improvements in glucose
homeostasis (Carlström et al., 2010). Similar results
have been seen with nitrite supplementation in genetic
models of diabetes. Nitrite supplementation of drinking
water (50 mg/l nitrite) to db/db mice, KKA(y) mice, and
obese ZSF mice (Jiang et al., 2014; Ohtake et al., 2015;
Lai et al., 2016) or 100 mg/kg nitrite via miniosmotic
pump in oblep mice (Singamsetty et al., 2015) was associ-
ated with improvements in glucose tolerance and insulin
sensitivity across all models.
Similar results have been seen for drug-induced
models of diabetes using streptozotocin using nitrate
supplementation (100 mg/l) for up to 2 months, result-
ing in improved glucose tolerance and insulin sensitiv-
ity (Khalifi et al., 2015; Gheibi et al., 2017). Lastly, in
dietary models of metabolic syndrome using high-
fructose diets (with or without high-fat diets), both
dietary nitrate (by gavage, 60 mg/kg) (Li et al., 2016b)
or nitrate salts (by gavage, 150 mg/kg) (Essawy et al.,
2014) were similarly associated with improvements in
glucose tolerance and insulin sensitivity.
The mechanisms of such benefits via elevation of
nitrite may be linked to: increased glucose transporter
type 4 translocation in skeletal muscle (Jiang et al.,
2014; Ohtake et al., 2015); by nitrite-related sirtuin
3-AMP-activated protein kinase (AMPK) activation,which
shares a common effect with metformin (Lai et al., 2016);
from improvedpancreatic blood flowandb-cell stimulation
for insulin release (Nyström et al., 2012; Gheibi et al.,
2017); or from browning of white adipose tissue (Roberts
et al., 2015) that may have antimetabolic effects.
Taken together, these results are similar across genetic,
dietary, and drug-induced models of dysglycemia—nitrite
or nitrate supplementation is associated with improve-
ments in glucose tolerance and insulin sensitivity and
suggest an exciting possibility that nitrite- or nitrate-
based therapeutics could be added to the armamentar-
ium for type 2 diabetes and/or metabolic syndrome.
Unfortunately, there has been scant translation of these
effects in human studies to date. In patients with type
2 diabetes given 7.5 mmol of dietary nitrate daily for
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2 weeks, despite significant elevations in systemic
nitrite levels, there was no change in insulin sensitivity
using the hyperinsulinemic euglycemic clamp method
or improvements in BP or FMD (Gilchrist et al., 2013)
that have been seen in numerous other patient groups
(Rammos et al., 2014; Kapil et al., 2015; Velmurugan
et al., 2016). Furthermore, in healthy persons, acute
dietary nitrate supplementation with 11.9mmol nitrate
did not change plasma glucose, C-peptide levels, or
incretin levels and did not change hepatic blood flow,
measured using magnetic resonance imaging (MRI)
(Shepherd et al., 2016). The explanations for the lack
of effect in type II diabetes is puzzling, but it might be
that sirtuin 3-AMPK activation by metformin renders
further nitrite stimulation of this pathway (Lai et al.,
2016) redundant or that glycated Hb has altered nitrite
reductase activity (James et al., 2004), meaning that
despite elevated nitrite levels, bioactive ·NO is not
produced. There is also growing evidence that the
biologic activity of metformin is dependent upon the
metabolism of the microbiome. Although the focus of
studies has revolved around the gut, it is possible that
the bioactivation of nitrate is impaired by the impact of
metformin on the oralmicrobiome community (Cabreiro
et al., 2013; Forslund et al., 2015; Sun et al., 2018).
An additional avenue of therapeutic utility in this
area may be in the context of the complications of
hyperglycemia, namely painful diabetic peripheral neu-
ropathy. The first study to suggest possible benefit was
conducted in patients with PAD (n5 55 total,;2/3 type
2 diabetes) randomized to 40 or 80 mg twice daily of
sodium nitrite (or matching placebo) for 10 weeks
followed by a further week of double-dosing—at the
end of the study, there was a significant improvement in
the pain domain of the physical component of the RAND
36 quality of life questionnaire despite no overall
improvement in quality of life, although this was only
apparent for the lower dose studied (40mg twice daily of
nitrite) (Mohler et al., 2014). This paper was recently
followed by a pilot study using a novel sustained-release
formulation of sodiumnitrite in patientswith a diagnosis
of diabetic peripheral neuropathy of.3month’s duration
and significant pain using a numeric pain scale (n 5
24 total). Patients were similar, randomized to either
40 mg twice daily, 80 mg twice daily, or matched
placebo. In this study, there were three questionnaire-
based assessments of pain as an unpowered secondary
endpoint, with a suggestion of improvement with nitrite
dosing for one of three pain scores used, although the
study was underpowered to produce meaningful effect
sizes or statistical confidence (Soin et al., 2018). Further
studies are to be planned with larger n numbers.
G. Nitrite and Nitrate in I/R Injury
1. Cytoprotection. There is a significant body of
evidence demonstrating that nitrite operates as a major
storage form of ·NO in blood and tissues (Bryan et al.,
2005) that can be reduced readily to ·NO to initiate
cytoprotective signaling during pathologic states, partic-
ularly during I/R injury (vanFaassen et al., 2009;Calvert
and Lefer, 2010). The mechanisms by which this process
occurs have been extensively studied, with increasing
evidence suggestive of changes inmitochondrial function
and anti-inflammatory, antiplatelet, and vasodilatory
effects.
2. Potential Mechanisms for Nitrite-Induced Reduction
in I/R Injury. A number of distinct molecular path-
ways have been proposed to underlie the reduction of
nitrite in the setting of I/R injury. There is strong
evidence demonstrating that the benefits of nitrite in
I/R injury are due, at least in part, to its conversion to
·NO. Several studies have shown that nitrite-induced
protection is blocked by the ·NO scavenger C-PTIO
(Webb et al., 2004; Jung et al., 2006; Tripatara et al.,
2007). This effect is also independent of NOS activity, as
cytoprotection induced by nitrite is not prevented by
NOS inhibition (Webb et al., 2004; Lu et al., 2005) or
affected in eNOS KO models (Duranski et al., 2005;
Milsom et al., 2010). We now also understand that
nitrite reduction during I/R is not just a phenomenon
precipitated by acidic disproportionation, as suggested
by Zweier et al. (1995), who identified nitrite-derived
·NO generation in the ischemic heart in their seminal
findings in 1995. Over the past decade, a number of
different nitrite reductases have been implicated in
nitrite-derived ·NO formation during I/R injury, with
the role of each catalytic pathway identified being
influenced both by the site/organ of injury and the
severity of hypoxia. Much of the research focused on
identifying the key nitrite reductase involved in the I/R
injury setting has been conducted within the heart,
where it appears that the two key nitrite reductases are
XOR and Mb.
XOR has been implicated in the reduction of nitrite to
·NO in the myocardium in both animal and human
heart tissue, with the first studies being conducted in
the isolated rat heart and atrial appendage collected
from patients undergoing cardiac surgery, respectively.
In tissue supernatants, nitrite-derived ·NO generation
was profoundly attenuated (50%) after incubation with
the XOR inhibitor allopurinol (Webb et al., 2004), obser-
vations that have been replicated by others (Baker et al.,
2007; Li et al., 2008). Similarly, XOR has been implicated
as the nitrite reductase in other organs, including when
delivered topically in renal I/R injury in vivo in both rat
and mouse models (Tripatara et al., 2007; Milsom et al.,
2010). XOR also contributes to nitrite bioactivation in
other hypoxic settings, including pulmonary hyperten-
sion (Baliga et al., 2012) and vascular remodeling after
balloon injury (Alef et al., 2011), thus identifying a
widespread function of XOR as a key nitrite reductase
in hypoxic environments. This profile of activity is
not unexpected, since studies with purified bovine
enzyme demonstrate increasing XOR-dependent nitrite
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reductionwith reducingO2 tension (Li et al., 2001). This
bioactivity, as mentioned earlier, occurs at the molyb-
denum site of the enzyme and is a reaction facilitated by
at least three different reducing substrates, including
xanthine, NADH, and aldehydes (Khambata et al., 2015).
Perhaps of particular note in this respect is NADH, the
levels of which rise in ischemic environments (Sahlin,
1983), possibly suggesting why XOR-dependent nitrite
reduction predominates in such reduced O2 tension
environments and plays a much lesser role under
physiologic conditions (Dejam et al., 2007).
Mb represents the other key nitrite reductase impli-
cated in the bioactivation of nitrite during I/R injury
and, again, particularly in the heart (Rassaf et al., 2007;
Shiva et al., 2007a). Mb must be partially deoxygenated
to act as a nitrite reductase, only occurring when O2
levels fall below the p50 of Mb, as for Hb (Cosby et al.,
2003; Crawford et al., 2006). Studies in the heart
suggest that 60%–70% of nitrite-derived ·NO is due to
deoxyMb-dependent conversion, with the balance due to
XOR activity (Rassaf et al., 2007; Shiva et al., 2007a).
Accordingly, nitrite reduction was abolished in the
Mb KO mouse (Hendgen-Cotta et al., 2008), and the
beneficial effects of nitrite after coronary artery occlu-
sion were lost, including improved postischemic LV
developed pressure. These studies suggest that Mb
plays an important role in nitrite-induced regulation
of cardiac energetics and oxygen utilization under
conditions of hypoxia. To date, whether Mb is also
critical in nitrite reduction in the human heart has not
been elucidated.
3. Potential Mechanisms for Nitrite-Induced Cytopro-
tection in I/R Injury. The activity of nitrite in I/R
injury has been attributed to both direct and ·NO-
dependent actions as a consequence of chemical modi-
fications of both cellular proteins or lipids, mitigating
the injury occurring at reperfusion. Potential molecular
mechanisms for cytoprotection of the former include
the direct S-nitrosation of critical regulatory thiols
on proteins such as caspase-3, a pivotal protein of
the apoptotic pathway, leading to its inactivation and
preventing apoptotic cell death (Maejima et al., 2005),
or the L-type calcium channel, which results in reduced
cytosolic Ca21 and subsequent I/R injury (Sun et al.,
2006). There are several functional consequences of
these chemical interactions that underlie the benefits of
nitrite, with the key ones summarized below.
a. Improved mitochondrial function. ·NO, through
the activation of GC-1 and ultimately the production of
cGMP, is known to be a key regulator of mitochondrial
function as well as a stimulator of mitochondrial bio-
genesis (Clementi and Nisoli, 2005; Nisoli et al., 2005).
It is thus unsurprising that the mitochondrion has
emerged as a major subcellular target of nitrite, with
evidence demonstrating the specific targeting of key
proteins within the mitochondria organelle [for review,
see Murillo et al. (2011)]. Studies have convincingly
shown that nitrite directly inhibits complex 1 of the
electron transport chain, causing a consequent decrease
in ROS generation, a decrease in Ca21 influx, and a
reduction in cytochrome c release (Shiva et al., 2007b)
after I/R injury in both the heart and liver (Gladwin
et al., 2005). This inhibition of complex I may also in
turn prevent opening of the mitochondrial permeability
transition pore (Fontaine et al., 1998; Nadtochiy et al.,
2007), leading to an improved mitochondrial tolerance
to Ca21 overload (Nadtochiy et al., 2007). Nitrite-induced
elevations of ·NO activating cGMP, in turn, also activate
PKG, resulting in stabilization of mitochondrial big
conductance K (Frankenreiter et al., 2017) and KATP
channels (Sasaki et al., 2000), which is associated with
decreased mitochondrial Ca21 accumulation, and pre-
vention of mitochondrial permeability transition pore
opening (Takuma et al., 2001; Brown and Borutaite,
2002), properties that are likewise exhibited by ·NO
(Brookes et al., 2000; Heusch et al., 2008). A significant
component of the action of nitrite has also been
attributed to the reversible inhibition of cytochrome c
oxidase (complex IV of the electron transport chain).
·NO binds to this enzyme, in competition with O2,
resulting in a reversible inhibition of O2 consumption
(Poderoso et al., 1998). This effect in turn has conse-
quences for the preservation of high-energy phosphate
stores during I/R injury, and this effect in particular
may play a role in the phenomenon in the heart of
“hibernation,” in which the metabolic activity of the
heart is temporarily shut down during ischemia to
preserve high-energy phosphate reserves (Hendgen-
Cotta et al., 2008; Murillo et al., 2011).
As mentioned, there is also some suggestion that the
effects of nitrite are in part mediated by direct actions of
the anion and not ·NO (Mo et al., 2012; Kamga Pride
et al., 2014). Mo and colleagues, using a rat model of
carotid injury, showed that nitrite treatment reduced
the hyperproliferative smooth muscle cell response to
mechanical injury. The authors suggested that this action
was due to upregulation of peroxisome proliferator–
activated receptor-g coactivator-1 (the master regulator
of mitochondrial biogenesis) and, thus, accordingly, an
increase in the number of mitochondria in the injured
artery. In cultured rat aortic smooth muscle cells, the
authors showed that the nitrite-induced increase in
mitochondrial number was unlikely to account for the
beneficial effect profile, despite small increases in cGMP.
The authors further demonstrated that nitrite augmented
adenylate kinase activity, leading to phosphorylation of
AMPK, the consequent downstream activation of sirtuin-
1 and deacetylation of peroxisome proliferator–activated
receptor-g coactivator-1. More importantly, all of these
changes occurred independently of cGMP (Mo et al.,
2012). Kamga Pride et al. (2014) showed in cultured rat
H9c2 cardiomyocytes subjected to hypoxia and reoxyge-
nation that treatment with nitrite for only 30 minutes
under normoxic conditions substantially reduced the cell
744 Kapil et al.
death after an ensuing hypoxic episode initiated 1 hour
after the treatment. Since the treatment was conducted
in normoxia, the authors suggested that conversion of
nitrite to ·NOwas unlikely. Using purportedly selective
inhibitors, the authors provided evidence of protein
kinase A–mediated phosphorylation, and thus inhibi-
tion, of dynamin-related protein 1, leading to enhanced
mitochondrial fusion. Functionally, this augmented
mitochondrial superoxide production, which oxidized
and activated AMPK, and is an essential step in nitrite-
mediated preconditioning.
b. Antiplatelet effects. The activation and conse-
quent adhesion and aggregation of platelets is a critical
event in the lead up to an acute MI (AMI) and other
ischemic injury (Didisheim et al., 1974; Badimon et al.,
2002; Gawaz, 2004; Vorchheimer and Becker, 2006). It
is widely accepted that platelet activation is key in
the formation of thrombosis that culminates in stroke,
AMI, and other vascular events (Davì and Patrono, 2007).
As well as the obvious physical implications of thrombus
formation after an event, activated platelets release
several mediators that participate in the damage caused
by the second wave of injury, occurring as a consequence
of reperfusion, but also to the long-term consequence of
I/R injury contributing to the increased risk for second-
ary events in such patients (Badimon et al., 2002). It is
therefore unsurprising that strategies repressing plate-
let reactivity play a key role in the treatment of organ
ischemia and I/R injury as well as reducing risk for
further events. It is accepted that ·NO, in health, acts as
an important repressor of platelet activation and adhe-
sion to intact vascular endothelium (Radomski et al.,
1987; Dangel et al., 2010) as well as platelet aggregation
itself (Radomski et al., 1990), as discussed earlier, and
thus, there has been considerable interest in identifying
·NO-based strategies that might be useful in I/R injury.
Since there is substantial evidence that nitrite in vivo
modulates platelet function, it is possible that some of the
benefits in the I/R setting are derived through actions on
platelets. In particular, in our own trial,NITRITE-AMI, in
which patients received an intracoronary dose of nitrite
at the point of reperfusion after primary percutaneous
coronary intervention (PCI), we demonstrated reduc-
tions in ex vivo assessments of platelet reactivity
(aggregation and cell activation markers) acutely but
also, interestingly, up to 6 months after the interven-
tion. We speculated that the acute reduction of platelet
reactivity likely contributed to the reduced microvascu-
lar obstruction that is thought to be pathogenic and a
primary mechanism in worsening cardiac cell death
postreperfusion, which has recently been highlighted as
an important target for developing novel cardioprotec-
tion therapies in the AMI setting (Nazir et al., 2016;
Niccoli et al., 2019).
c. Anti-inflammatory effects. A key phenomenon
contributing to damage in I/R injury is inflammation,
and since several observations recently have identified
anti-inflammatory properties of nitrite, it has been
suggested that this effect may be contributing to the
beneficial actions of nitrite in the I/R setting. The
recruitment of leukocytes and their consequent proin-
flammatory effects plays a critical role in determining
the magnitude of damage induced post I/R injury
(Entman and Smith, 1994). Polymorphonuclear cells
are the major leukocytes found in necrotic tissue
immediately after ischemic injury, with neutrophils
the early cellular mediators of local microvascular
changes and parenchymal damage (Vinten-Johansen,
2004). Monocytes and macrophages infiltrate later and
extend the early injury phase (Ysebaert et al., 2000). In
addition, lymphocytes have been identified as contrib-
uting to the damage in the later stages in the response
to I/R injury in a variety of organ systems (Linfert et al.,
2009). Lymphocyte-related cytokines are upregulated
in the postischemic heart (Squadrito et al., 1999), and
leukocyte adhesion molecules and chemokines, such as
P-selectin glycoprotein ligand-1, CD11/CD18, ICAM-1,
CCL2 (Herskowitz et al., 1995; Birdsall et al., 1997),
and lymphocyte adhesion, migration, and signaling
(Loetscher et al., 1996) have been implicated in exper-
imental myocardial I/R injury.
Asmentioned, ·NOexerts anarray of anti-inflammatory
effects, and many of these have been demonstrated in
experimentalmodels of I/R injury in various vascular beds
(Kubes et al., 1991; Palazzo et al., 1998; Ahluwalia et al.,
2004). Leukocyte recruitment is a multistep process
constituting leukocyte tethering, rolling, adhesion, and
ultimately emigration from the microvasculature (Petri
et al., 2008), and ·NO has been shown to influence each
of these steps through the damping/repression of inter-
actions of the leukocyte with endothelial cells (Kubes
et al., 1991). Specifically, there is evidence showing that
·NO inhibits adhesion molecule expression and activa-
tion, including that of P-selectin, ICAM-1, vascular cell
adhesion molecule-1, and CD11b (Gauthier et al., 1994;
Lefer and Lefer, 1996; Leite et al., 2009). Accordingly,
data in humans have emerged from a phase 2 study
suggesting that nitrite, and presumably nitrite-derived
·NO, exerts anti-inflammatory effects when given during
primary PCI for AMI (Jones et al., 2015a). In these
patients, we demonstrated important reductions in neu-
trophil numbers and activation post–primary PCI
(Jones et al., 2017). In the placebo-treated patients,
we observed increases in the total circulating neutrophil
numbers and levels of high-sensitivity C-reactive protein
postreperfusion, which then decreased over time. In
contrast, in nitrite-treated patients, these changes were
suppressed up to 6 months post–primary PCI (P , 0.01).
These differences were also associated with reduced
expression of neutrophil CD11b, plasmaCXCL1,CXCL5,
and CCL2 levels (P , 0.05). Importantly, there were no
differences in the number of any other leukocyte pop-
ulation measured (monocytes and lymphocytes) or acti-
vation markers expressed by these cells between the
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treatment groups. In addition, these effects on inflam-
matorymarkers were associatedwith a reduction in both
microvascular obstruction and infarct size, suggesting
important effects of nitrite on neutrophil activation and
recruitment (Jones et al., 2017). Further study is needed
to examine these effects.
4. Nitrite as a Mediator of Remote Ischemic
Preconditioning. In the early 1990s, Przyklenk et al.
(1993) proposed the existence of signal transduction
between the local site of remote ischemia and the
myocardium. This link has been identified as underly-
ing the efficacy of remote ischemic preconditioning
(rIPC), although the exact nature of this endocrine
communication has remained uncertain. In 2014, Ras-
saf and coworkers conducted a series of experiments
suggesting that nitrite may be the elusive endocrine
factor responsible for the effects of rIPC (Rassaf et al.,
2014). Their studies demonstrated that plasma nitrite
concentration increases during reactive hyperemia in the
brachial artery of healthy volunteers as a consequence of
shear-stress triggering eNOS activation (Rassaf et al.,
2006). In mouse models of rIPC, the authors demon-
strated a similar elevation in circulating nitrite levels
and that the benefits of rIPC were blocked with C-PTIO
and absent in eNOS KO mice. In the final experiment,
the authors infused human plasma collected from indi-
viduals subjected to, or not, rIPC into isolated mouse
heart Langendorff preparations. In these experiments,
they demonstrated that nitrite accounted for the effects
of rIPC, since treatment of the transferred plasma with
acidified sulfanilamide eliminated the transfer of pro-
tection (Rassaf et al., 2014). Prior to this work, Elrod
et al. (2008), who used a transgenic mouse with cardiac
restricted overexpression of eNOS, also provided evi-
dence in support of an endocrine action of nitrite. These
mice are characterized by increased levels of nitrite and
other ·NO metabolites in the circulation, resulting in
subsequent transport and storage in organs throughout
the body, including the liver. Elrod et al. (2008) demon-
strated that this elevation of tissue nitrite provided
protection against the damaging effects of a consequent
hepatic I/R injury.
An important caveat of the above findings is that the
levels of nitrite generated in these models are approxi-
mately 10-fold lower than those typically shown to be
cytoprotective in preclinical models of I/R injury (Webb
et al., 2004; Duranski et al., 2005). This discrepancy in
efficacy implies potential differences in bioactivity/potency
of endogenously derived versus exogenously deliv-
ered nitrite and is an issue that is worthy of further
interrogation.
5. Translational Aspects.
a. I/R injury. The cytoprotective actions of nitrite
have been reproduced in a variety of animal models
by different investigators focusing on different target
organs (Webb et al., 2004; Duranski et al., 2005; Pluta
et al., 2005; Jung et al., 2006; Tripatara et al., 2007).
Our group provided the first evidence of the cytoprotec-
tive effects of nitrite (Webb et al., 2004). In this study,
we demonstrated that administration of NaNO2 (10 or
100 mmol/l) either prior to or at reperfusion in the
isolated rat Langendorff heart preparation improved
both LV function and coronary perfusion pressure as
well as decreasing infarct size after an I/R insult. Many
others have confirmed these effects in the heart using
not only in vitro (Baker et al., 2007; Hendgen-Cotta
et al., 2008) but also in vivo preclinical rodent models
of AMI (Duranski et al., 2005; Bryan et al., 2007).
Duranski et al. (2005) administered sodium nitrite via
an intraventricular injection (2.4–1920 nmol) 5 minutes
prior to reperfusion after 30 minutes of occlusion of the
left main coronary artery occlusion in mice. This group
observed a dose-dependent decrease in infarct size. The
maximum benefit was provided with a dose of 48 nmol,
although the higher dose of 1920 nmol nitrite failed to
exert any significant cardioprotective effect. Bryan et al.
(2007) used the same model and demonstrated that
dietary nitrite supplementation (50 mg/l) for 7 days
prior to ischemia caused a 48% reduction in infarct size.
In addition to rodents, the functional benefits of
nitrite have been reproduced in larger species. In a
canine model induced by ligation of the left anterior
descending coronary artery in vivo, intravenous admin-
istration of NaNO2 (0.2 mmol/min per kilogram for the
first 20 minutes and then 0.17 mmol/min per kilogram
for 40 minutes) for the last hour of a 2-hour period of
ischemia reduced infarct size by ;50% compared with
control (Gonzalez et al., 2008). The authors also consid-
ered intravenous administration of nitrite during the
last 5minutes (0.2mmol/min per kilogram) of the 2-hour
occlusion in a bid to identify an approach with greater
chance of clinical translation and showed that, with this
treatment, infarct size and apoptosis were reduced to a
similar level as with treatment of 60 minutes prior to
reperfusion. There is, however, some evidence contra-
dicting the above findings. In the multicenter preclinical
CAESAR cardioprotection initiative (Jones et al., 2015),
a lack of efficacy of nitrite was observed (Lefer et al.,
2014). However, this multicenter assessment used in-
travenous delivery of NaNO2 and not local intracoronary
administration (with higher local concentrations), as in
many of the studies described above, and still remains
unpublished in full form, therebymaking it impossible to
comment on methodological differences.
Similar protective effects of nitrite have also been
evidenced in other organs, including the liver (Duranski
et al., 2005), brain (Pluta et al., 2005), and kidney
(Tripatara et al., 2007). In a murine model of hepatic
I/R, intraperitoneal treatmentwithNaNO2(1.2–480nmol)
during the ischemic period caused dose-dependent cyto-
protective effects that resulted in reductions in hepatocel-
lular necrosis and apoptosis and reductions of serum
elevations of liver transaminases (Duranski et al., 2005).
In a rat model of cerebral I/R, 48 and 480 nmol of nitrite,
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infused intravenously at the start of reperfusion, exerted
dose-dependent neuroprotective effects, reduced cerebral
infarct volume by 33% and 77%, respectively, and pro-
moted neurologic functional recovery (Jung et al., 2006).
Similarly, topical administration of NaNO2 (0.12 nmol/g)
in a rat model of renal I/R injury 1 minute prior to
reperfusion significantly attenuated renal dysfunction,
reperfusion injury, glomerular dysfunction, and tubular
injury (Tripatara et al., 2007). It is noteworthy that, in this
study, intravenous administration of the same dose of
NaNO2 at the same time point (1 minute before reperfu-
sion) did not improve renal dysfunction or reperfusion
injury (Tripatara et al., 2007). In all of these studies, the
beneficial effects were shown to be due to the activity of
·NO and were most often specifically associated with the
local application into or on the organ of interest.
Given this robust preclinical data regarding the
cytoprotective effects of nitrite therapy, it is logical to
consider the clinical translation of nitrite-based thera-
pies for I/R injury. Clinical situations in which this may
be important include the settings of AMI, cardiac
surgery, angiogenesis, cardiac arrest, organ transplan-
tation, and cerebrovascular accidents. This rapidly
evolving field is summarized in the following sections.
b. Humans models of I/R injury: transient endothe-
lial dysfunction. A number of studies conducted in
healthy volunteers demonstrate that elevations in the
levels of circulating nitrite levels (achieved through
administration of a high dietary nitrate load) lead to a
number of beneficial effects, including prevention of
transient endothelial dysfunction in a model of I/R
injury in the forearm (Webb et al., 2008b; Kapil et al.,
2010). In this study it was shown that I/R injury
significantly reduced FMD (by ;60%) of the brachial
artery, a phenomenon that was prevented in the volun-
teers after ingestion of a dietary nitrate load (Webb et al.,
2008b). Similar beneficial effects have been demonstrated
with NaNO2 infused at a dose of 1.5 mmol/min for
20 minutes prior to I/R injury in the forearm of healthy
volunteers. In this study, the authors demonstrated that
peak FMD decreased by 43% after I/R when subjects
received saline (6.8%6 0.7% vs. 3.9%6 0.7%, P, 0.01);
however, nitrite treatment prior to ischemia prevented
this decrease (5.9% 6 0.7% vs. 5.2% 6 0.5%, P 5 N.S.).
However, the protective effects of nitrite were abolished
when the nitrite infusion was initiated during the
ischemic event (Ingram et al., 2013).
c. Organ-specific I/R injury.
i. Myocardial I/R Injury. In adults with inducible
myocardial ischemia, intravenous infusion of NaNO2
improved functional cardiac responses during dobut-
amine stress echocardiography. In this small study
(Ingram et al., 2013), 10 patients with inducible myo-
cardial ischemia were randomized to either low-dose
NaNO2 (1.5 mmol/min for 20 minutes) or placebo in a
double blind fashion. Long-axis myocardial function
was quantified by peak systolic velocity (Versus) and
strain rate (SR) responses. Comparing saline and
nitrite infusions, Versus and SR at peak dobutamine
increased in regions exhibiting ischemia (Versus from
9.56 0.5 to 12.46 0.6 cm/s, SR from22.06 0.2 to22.86
0.3 second21), whereas they did not change in normally
functioning regions (Versus from 12.6 6 0.4 to 12.6 6
0.6 cm/s, SR from 22.6 6 0.3 to 22.3 6 0.1 second21)
(P , 0.001). With nitrite treatment, Versus improved
only in those areas of the myocardium that were poorly
functioning (1122%, P , 0.001), implying that the
effects of this low-dose NaNO2 occurred primarily in
regions of ischemic myocardium, with no effect in
normoxic regions (Ingram et al., 2013).
Recently, two phase II studies have been conducted
investigating the effects of nitrite therapy for AMI.
There were many similarities between the studies,
including that both enrolled patients undergoing pri-
mary PCI for ST-elevatedMI. However, a key difference
between the studies was that the NaNO2 was delivered
via different routes, i.e., intravenous and intracoronary.
The first of these studies, by Siddiqi et al. (2014), was
based on the intravenous administration protocol
employed to good effect by Gonzalez et al. (2008) in
dogs. Siddiqi and colleagues recruited a total of 229 pa-
tients presenting with AMI who were randomized to
receive either an intravenous infusion of 70 mmol
NaNO2 (n 5 118) or matching placebo (n 5 111) over
5 minutes immediately before primary PCI (Siddiqi
et al., 2014). In this study, a prerequisite for inclusion
was that patients must have been categorized as with
thrombolysis in myocardial infarction (TIMI)#1 flow in
the infarct-related artery at the time of reperfusion. The
dose was chosen assuming a mean body weight of 70 kg,
corresponding to 1 mmol/kg. Sadly, the primary end-
point of MI size (assessed at 6–8 days by cardiac MRI)
did not differ between the groups. After adjustment for
the area at risk for infarct, diabetes, or the recruitment
center (patients were recruited at four different cen-
ters), there was still no difference between the groups. A
number of secondary outcome measures also showed no
signal, including plasma troponin I or creatine kinase
area under the curve (72-hour), LV volumes or LVEF
measured at 6–8 days, and infarct size at 6months. This
study would suggest that despite the promising pre-
clinical data, the intravenous route of nitrite adminis-
tration does not decrease infarct size after primary PCI
for AMI (Siddiqi et al., 2014).
The second study was conducted by our own group
(Jones et al., 2015) and examined the effects of intra-
coronary nitrite given prior to balloon inflation in
patients with ST-elevated MI undergoing primary
PCI. Eighty patients in total were randomized to
receive intracoronary 10 ml NaNO2 (1.8 mmol) or NaCl
(placebo) through an over-the-wire balloon positioned
distal to the occlusion in the culprit coronary artery
prior to balloon inflation. In this study, there were no
reported adverse effects of nitrite associated with a
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significant increase in circulating nitrite that was
evident 30minutes after NaNO2 administration. Again,
similarly to the above trial, the primary outcome of
creatine kinase release (P 5 0.92) was not different
between the groups, as neither was troponin T (P 5
0.85), or cardiac MRI-assessed infarct size (P 5 0.254)
in the whole patient cohort. However, in contrast,
there was an improvement in myocardial salvage
index (P 5 0.05) and reduction in major adverse
cardiac events (defined as all-cause mortality, hospi-
talization for HF, MI, or target vessel revasculariza-
tion) at 1 year (2.6% vs. 15.8%; P5 0.04) in the nitrite
group. Additionally, in a 66-patient subgroup with
TIMI #1 flow, there was a 20% reduction in serum
creatine kinase (P 5 0.030), a 19% reduction in
cardiac MRI-determined infarct size (P 5 0.034), a
48% reduction in microvascular obstruction (P 5
0.015), and a 30% increase in myocardial salvage
index (P 5 0.002) with nitrite therapy. This would
suggest that in patients with TIMI #1 flow at time of
primary PCI, intracoronary nitrite may have benefit
as an adjunctive therapy (Jones et al., 2015).
The reason for the discrepancy between the two
studies is not clear; however, a number of potential
factors could have played a role, including patient
selection, doses of nitrite, and/or mode of administra-
tion. In terms of the dose, there is a large body of
preclinical evidence indicating that nitrite is cytopro-
tective against I/R injury only when given at concen-
trations (2.5–10 mmol) that far exceed physiologic
(0.2–0.5 mmol/l) levels of circulating nitrite. In the study
by Siddiqi and colleagues, circulating nitrite with their
intervention only reached 1.4 mmol/l, a concentration
that is lower than that reported in dogs, in which the
same dosing regimen led to circulating levels of 5 mmol/l
(Gonzalez et al., 2008). However, the levels achieved
were 7.8-fold higher than in the placebo group and
consistent with levels achieved in a previous murine
periconditioning study demonstrating at least some
molecular effect of nitrite inmice at such concentrations
(Duranski et al., 2005). Indeed, raising circulating
levels of nitrite to those shown effective in most pre-
clinical studies is likely to be associated with adverse
effects, such as hypotension and methemoglobinemia,
as demonstrated in healthy volunteers (Pluta et al.,
2011). It is this possibility that underlies the advantage
of intracoronary nitrite administration in which this
route provides high local concentrations (2.5–10 mM)
within the myocardium only, thus minimizing potential
systemic side effects that may occur with systemic
nitrite administration. In the study delivering intra-
coronary nitrite, although levels of systemic nitrite were
elevated in the study patients, indicating a degree of
systemic absorption, levels achieved were approxi-
mately 0.5 mmol/l, at the upper level of physiologic
levels, which would be in keeping with the low rates of
side effects seen in the study.
The question of what is the optimal route (intrave-
nous vs. intracoronary) for nitrite therapy is an
important issue to address for future studies. The
two routes have been compared directly in the kid-
ney; in this study, the local administration of nitrite
was effective at reducing infarct size, whereas the
same dose given via the intravenous route was
not, indicating a superiority of local administration
(Tripatara et al., 2007). In contrast, the intravenous
route was effective in myocardial I/R injury in dogs
(Gonzalez et al., 2008), although as noted above, the
intracoronary route does have several advantages.
Additionally, if agents are to be delivered at reperfu-
sion, i.e., after angiography to ensure TIMI flow # 1,
the intracoronary route does not delay reperfusion.
This is compared with intravenous administration,
which may result in a delay in reperfusion while
administered and might require the establishment of
very high circulating levels to achieve sufficient levels
of nitrite. Together, these observations suggest that
nitrite may have use in the treatment of acute
ST-elevated MI in which nitrite could be delivered
locally (intracoronary) before balloon inflation at the
time of primary PCI; further studies in this area are
needed.
ii. Cardiopulmonary Surgery. The injury that oc-
curs as a consequence of ischemia and reperfusion
during cardiac surgery, such as CABG, is distinctly
different from that occurring during spontaneous AMI.
In this setting, ischemia is induced artificially by aortic
cross-clamping, and myocardial preservation strategies
are employed throughout this ischemic period. Once
surgery has been completed, the clamp is released,
and the heart is then suddenly and globally reper-
fused with anticoagulated blood. This critical process,
although necessary, does result in the immunologic
priming of leukocytes due to exposure to the cardio-
pulmonary bypass circuit, but it is also characterized
by a very high partial pressure of O2. Together, this
restoration of the circuit delivers a substantial I/R
stress. To date, assessing the role of nitrite in cardio-
protection post-CABG has not been done. There is
currently one clinical trial ongoing to investigate this
(clinical trial NCT01098409); however, the start date
for this study was 6 years ago, and few updates have
occurred, suggesting that recruitment may be difficult.
There has, however, been some reporting from a similar
study from the same institution in patients. In this study,
patients undergoing CABG were subjected to either
placebo (saline) or NaNO2 treatment (10 mg/kg per min-
ute) either 30 minutes or 24 hours before surgery. In
preischemia LV biopsies, 10 mg/kg per minute nitrite
administration 24 hours or 30 minutes before CABG
surgery was associated with statistically significant in-
creases in the expression of both total eNOS and phos-
phorylated eNOS at position Ser 1177, an effect similarly
evident in LV biopsies taken at reperfusion. These results
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intimate that some of the benefits of nitrite may relate to
improved eNOS signaling (Bailey et al., 2014).
iii. Skeletal Muscle I/R Injury (Crush Syndrome).
Skeletal muscle crush syndrome occurs after prolonged
physical compression of limb muscles (after events
such as earthquakes, road traffic accidents, etc.),
followed by the reperfusion that accompanies decom-
pression of the limbs. It is associated with significant
morbidity and mortality, and the current standard of
care is i.v. crystalloid fluid therapy. Using a rat model
of crush syndrome, muscle nitrite levels were shown
to be reduced by crush injury, suggesting some eNOS
dysfunction (Murata et al., 2012). Both bolus (200–
500 mmol/kg) and continuous infusions for 3 hours (200–
500 mmol/kg) of NaNO2 reduced lethality of the model
(Murata et al., 2012, 2017), with improvements in both local
skeletalmuscleanddistant (lung, kidney) indices ofdamage
(Murata et al., 2017), suggesting a possible therapeutic
option for this catastrophic condition.
iv. Transplantation. Since I/R injury is thought to
play a major role in graft failure in liver and lung
transplantation (Calvert and Lefer, 2010), there has
been interest in assessing the efficacy of nitrite in this.
In preclinical studies assessing hepatic I/R injury in
mice, nitrite (1.2–480 nmol) has been shown to exert
profound dose-dependent protective effects on cellular
necrosis and apoptosis, with protective effects observed
at near-physiologic nitrite concentrations (Duranski et al.,
2005). Nitrite-mediated protection of the liver was de-
pendent on ·NOgeneration and independent of eNOS and
hemoxygenase-1 enzymeactivities (Duranski et al., 2005).
In a preclinical murine model of liver transplantation,
nitrite supplementation attenuated the release of liver
enzymes, with the protective effects being even greater
with longer cold preservation times. Separately, a
reduction in apoptosis with preserved tissue morphol-
ogy was evident with histologic analysis, and liver graft
acute function post-transplantation was improved (Li
et al., 2012). Despite this promising preclinical data for
nitrite therapy, translation into clinical studies has
been slow, and so far there are no published studies of
nitrite in human organ transplantation. Interestingly,
iNO has proven beneficial in both transplantation of the
lung (Yerebakan et al., 2009) and of the liver (Lang
et al., 2007). Yerebakan et al. (2009) evaluated the
effects of treatment with iNO (starting dose 40 ppm) in
nine patients (six female, three male; mean age 42.9 6
15.8) requiring lung transplantation. Significant reduc-
tions in mean PAP (36.8 6 15.8 to 22 6 6.8 at 6–8 and
22.8 6 7.96 mm Hg at 12–14 hours) were evident with
·NO treatment in all patients except one, with improve-
ments in overall respiratory function. In patients un-
dergoing orthotopic liver transplantation, Lang et al.
(2007) demonstrated that treatment with inhaled ·NO
doubled plasma nitrite levels and that this was associ-
ated with improved liver function and reduced injury
(i.e., transaminases and coagulation studies) compared
with the control group. Importantly, these positive effects
were associated with hard outcomes for these patients,
with reduced hospital length of stay by 1.24 days (P 5
0.034). Reperfusion resulted in increased apoptosis
[indicated by terminal deoxynucleotidyl transferase–
mediated digoxigenin-deoxyuridine triphosphate nick-
end labeling staining (TUNEL)] in both the placebo and
iNO groups; however, the magnitude of increased
TUNEL staining was significantly attenuated (;75%)
with ·NO treatment. Although the authors stated
that not all effects of iNO may be mediated by
nitrite, they suggested that those benefits related
to I/R injury were likely due to the actions of nitrite.
Currently, there are ongoing clinical trials assess-
ing nitrite therapy in lung transplant recipients
(NCT01715883).
v. Global Ischemia (Cardiac Arrest). Cardiac arrest
results in significant mortality after initial resuscita-
tion due in most cases to I/R-induced brain injury and,
to a lesser degree, myocardial dysfunction (Nichol et al.,
2008; Wachelder et al., 2009). Experimental models
have suggested a protective role of intravenous nitrite
or iNO both on neurologic and cardiac function after
cardiac arrest (Dezfulian et al., 2009, 2012; Minamishima
et al., 2011). Nitrite therapy after murine cardiac arrest
improved 22-hour survival through improvements in
myocardial contractility (Dezfulian et al., 2009). These
improvements accompanied transient mitochondrial
inhibition, which reduced oxidative injury to the heart;
however, late brain injury related to cardiac arrest was
still apparent and resulted in high rates of mortality.
Further studies performed in a rat model of cardiac
arrest with prolonged survival (7 days) have subse-
quently been performed (Dezfulian et al., 2012). In this
study, cardiac arrest resulted in hippocampal CA1
delayed neuronal death, which has been well charac-
terized in human cardiac arrest survivors (Horn and
Schlote, 1992). Nitrite therapy resulted in increases in
hippocampal nitrite and S-nitrosothiol levels, but not
cGMP, shortly after therapy, with associated significant
(75%) increases in CA1 neuron survival. Based on
this promising data, one pilot clinical study has been
performed, which has demonstrated the feasibility and
safety of low-dose nitrite infusion in cardiac arrest
survivors but has, to date, not reported any improve-
ment in outcome (Dezfulian et al., 2012). In the initial
phase of this study, four patients who suffered cardiac
arrest (within 12 hours) and were successfully resusci-
tated and survived to intensive care unit admission
have been randomized in a double blind manner—3:1
ratio to NaNO2 (1 mg in 100 ml normal saline) or
100ml saline placebo infused i.v. over 5 minutes. This
initial dose of 1 mg nitrite represents 0.2 mg/kg (based
on 70 kg b.wt.). Nitrite infusion at this dose did not
appear to cause significant hypotension or tachycardia,
and mean metHB levels were 0.74% 6 0.14% over time,
with the highest recorded level of 1.1%. Nitrite infusion
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increased plasma and blood levels in three of four patients
(one received placebo), but the degree of increasewas in all
cases less than 5-fold from the patient’s baseline. Further
data from the same study have now been published in
11 patients (seven nitrite/four placebo) receiving 1 (n5 3)
or 9.6 mg (n 5 4) NaNO2 after resuscitation from out-
of-hospital cardiac arrest. Only the higher dose was
associated with significant elevation in plasma nitrite
levels, and neither dose was associated with worsening
hemodynamics, although no hard outcomes were re-
ported, and the study finished without completing its
planned third dose (14.5 mg NaNO2) and was only able
to recruit 11 patients into the study out of .450 out-of-
hospital cardiac arrests in the 5 years that the study
was open and recruiting (Dezfulian et al., 2018).
Perhaps a more pertinent time frame to start poten-
tially protective nitrite therapy is at the time of resusci-
tation by emergency services personnel rather than in
hospital. In this regard, a pilot study of paramedic-initiated
intravenous nitrite therapy (over 30 seconds) immediately
after standard advanced cardiac life support interventions
were conducted (defibrillation, intubation, epinephrine)
was performed in 120 patients. The initial dose chosen
was 25 mg nitrite but after review of pharmacokinetic
data midtrial, the dose was increased for subsequent
patients to 60mg (25mg: n5 59; 60mg: n5 61) to achieve
the desired post-bolus nitrite concentration in venous blood
of 10–20 mmol/l, probably due to hypoxic consumption of
nitrite in thearrested state.The control groupwasacquired
from contemporaneous controls in the paramedic data base
of all out-of-hospital cardiac arrests who had received
standard of care and did not receive nitrite (n 5 355)
during the period the study was open. Interestingly, there
was no difference in outcomes (return of spontaneous
circulation, rearrest, use of epinephrine, BP, survival to
discharge, neurologically favorable survival) between the
low- or high-dose nitrite groups or between patients re-
ceiving nitrite compared with control patients (Kim et al.,
2018). A larger (n 5 1500) randomized placebo-controlled
trial is underway comparing two doses of nitrite (45 or
60 mg) and placebo, which should provide a definitive
answer as to whether it is useful or not, with primary
outcomes of survival to hospital admission and rear-
rest/epinephrine use prehospital (NCT03452917).
Although there is amultitude of preclinical and early-
phase clinical studies highlighting the diverse potential
of nitrite-derived ·NO in human disease states,
particularly in the CV system, almost 20 years of
clinical studies have not yielded a positive phase III
study in any condition, and neither inorganic nitrate
nor nitrite is an established, guideline-recommended
treatment as of yet. However, with the large number
of adequately powered and mechanistically sound
studies ongoing, it is likely that the medical commu-
nity will have definitive answers as to the true
therapeutic utility of these approaches within the
next few years.
VII. Concerns Regarding Nitrite- and
Nitrate-Based Therapeutics
Over the past 30 years, there have beenmany attempts
to manipulate the L-arginine:·NO pathway through pro-
vision of substrate or cofactors to the NOS system (Zhang
et al., 2011) to facilitate greater ·NO production. The
discovery of authentic ·NO production from nitrite re-
duction (Benjamin et al., 1994; Lundberg et al., 1994;
Zweier et al., 1995) has provided a further avenue within
which to explore ·NO-based therapeutics.
A. Epidemiologic Links to Possible Benefits of
Dietary Nitrate
Vegetables are a rich source of nitrate, with high
amounts of nitrate found particularly in green leafy
vegetables, which account for up to 85% of nitrate intake
(Hord et al., 2009).Vegetarianismhas longbeenassociated
with lower BP (Donaldson, 1926; Sacks et al., 1974;
Armstrong et al., 1977, 1979; Ophir et al., 1983), and
small-scale controlled clinical trials havedemonstrated that
increasing fruit and vegetable intakes are associated with
lower BP (Rouse et al., 1983; Margetts et al., 1986; Appel
et al., 1997). Epidemiologic studies have found consistent
patterns demonstrating reduction in BP (Li et al., 2016a),
CVD (Joshipura et al., 1999, 2001; Bhupathiraju et al.,
2013; Hu et al., 2014; Gan et al., 2015), and CV and non-CV
death (Hung et al., 2004; Miller et al., 2017) associated
with increased daily vegetable intake.
The precise constituent and mechanism of cardiopro-
tection related to vegetable intake is elusive. There are
many proposed vegetable constituents that could be
responsible for beneficial CV effects, including soluble
fiber, potassium, and antioxidants. Although there are
issues with using epidemiologic data to try to identify
micronutrient intake because of issues such as dietary
recall (Naska et al., 2017) and, in the context of dietary
nitrate, seasonal nitrate variation in vegetables (https://
www.food.gov.uk/research/research-projects/nitrate-
monitoring-in-spinach-and-lettuce-surveillance-pro-
gramme), further analyses of such data have suggested
green leafy vegetables, which are the largest source of
dietary nitrate (Hord et al., 2009), appear to confer the
greatest cardioprotective effects (Joshipura et al., 1999,
2001). Such data have led to the proposal that dietary
nitrate is responsible for the beneficial effects of
vegetable-rich diets (Lundberg et al., 2006; Webb
et al., 2008b; Ralt, 2009), given the recent discoveries
of reductive pathways that can take nitrate in humans
to ·NO via nitrite as an intermediate (Lundberg et al.,
2008).
Putting questions of therapeutic efficacy in human
outcome trials aside given the lack of currently pub-
lished data, there have been additional concerns raised
about the safety of such approaches. Nitrate content of
drinking water in Europe and the US is regulated and
kept at ,50 mg/l. There is an ADI recommendation for
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dietary nitrate as well, set at 3.7 mg/kg daily, which
equates to ;4 mmol nitrate daily for an average 70-kg
person (European Food Safety Authority, 2008). How-
ever, as can be seen in particular from the section on BP
and nitrate, most of the clinical studies that have
beneficial effects have used acute or chronic dosing
that is far above this recommended level. Fruit and
vegetable–rich diets that have beneficial effects on CVD
(Joshipura et al., 1999, 2001; Hung et al., 2004) and BP,
such as the DASH diet (Appel et al., 1997), contain large
amounts of nitrate naturally, perhaps up to 10–20mmol
daily (Hord et al., 2009), far in excess of the recom-
mended ADI above. Despite this, concerns relating to
nitrite- and nitrate-based therapeutics continue largely
based on two main areas: metHB and carcinogenesis.
B. Methemoglobinemia
Infants have very low nitrite levels, as their oral
microbiome takes time to develop the right ecology for
effective oral nitrate reduction (Jones et al., 2015b), but
they are susceptible to preformed nitrite. Initial concerns
regarding the etiological role of nitrate and methemoglo-
binemiawere first reported in the early 1900s in children
treated with bismuth subnitrate (Beck, 1909). It was
recognized by these early clinician-scientists that many
people could tolerate very large doses of inorganic nitrate
with no ill effects, but that children, and those with
intestinal infections, were particularly prone to methe-
moglobinemia (Beck, 1909). It was discovered that
nitrate wasmetabolized to nitrite and that the problems
of methemoglobinemia after nitrate ingestion were
synonymous with that of nitrite ingestion, as first de-
scribed by Gamgee (1868). As described earlier, nitrite
reactswith oxyHb to formmetHB,which is incapable of O2
transport (Doyle et al., 1981), and the young are particu-
larly susceptible to the ill effects (Roe, 1933) because of
preponderant fetal Hb and immature metHB reductase
system (Gupta et al., 1999; Greer and Shannon, 2005).
In relation to this, post–World War II well-water
surveys in rural American districts with reported cases
of infant methemoglobinemia (Comly, 1945; Walton,
1951) led to the establishment of regulatory frameworks
to control the nitrate level in suchwater at levels,50mg/l
that are still in place (U.S. Public Health Service, 1962).
Contemporary analysis of dietary nitrate consumption
has re-evaluated this historical data and makes it less
likely to be a significant concern (Fewtrell, 2004). The
early reports of infantile methemoglobinemia were
commonly in children that were unwell with presumed
bacterial gastroenteritis (Cornblath and Hartmann,
1948), and therefore, the possibility of high systemic
nitrite levels from intestinal bacterial conversion of
nitrate to nitrite in vivo or in contaminated water supply
has been suggested for apparent cases of nitrate-induced
infantile methemoglobinemia (Hanukoglu and Danon,
1996;Avery, 1999). Indeed, recent data showno consistent
association between drinking water nitrate levels and
either the risk of developing clinical methemoglobinemia
or blood metHB levels themselves (Ward et al., 2005).
Importantly, in oral dietary nitrate intervention
studies, especially with beetroot juice with nitrate
concentrations far higher than those set as safety limits
for drinking water described above, there is only a modest
rise in plasma nitrite levels (commonly ,1 mmol/l, within
the physiologic realm) and chronic supplementation with
dietary nitrate that leads to long-term systemic nitrite
elevation is not associated with elevation of metHB
measured by co-oximetry (Kapil et al., 2015; Velmurugan
et al., 2016). In adults, there is no report of vegetable intake
causing clinically relevant methemoglobinemia, and cases
in children are largely thought to be related to preformed
nitrite accumulation due to bacterial contamination and
preingestion nitrate-to-nitrite conversion (Chan, 2011).
Furthermore, systemic application of nitrite in mecha-
nistic studies has achieved much higher levels of nitrite
without significant elevation of metHB. Intra-arterial
infusion of NaNO2 into the human forearm achieved
systemic nitrite levels of 16 mmol/l (Cosby et al., 2003),
far higher than that needed to achieve clinically mean-
ingful reductions in BP (Ghosh et al., 2013; Kapil et al.,
2015). In this study, metHB levels were pegged at ;1%
(Cosby et al., 2003). A more detailed pharmacokinetic
study aimed at establishing dose-limiting toxicity of
intravenous sodium nitrite as a therapeutic agent has
been conducted. Infusions of sodium nitrite for 3–9 hours
at ;7 mmol/kg per hour produced large symptomatic
reductions in BP associated to plasma nitrite levels of
1–5 mmol/l, which caused clinically insignificant, asymp-
tomatic elevation of metHB to only 2%–5% (Pluta et al.,
2011), well below the levels that are associated with
symptomatic dyspnea (Ash-Bernal et al., 2004).
C. Carcinogenesis
The potential for carcinogenesis has long been a
concern in relation to nitrite and nitrate biology. Indeed,
almost all of the works in the 1970s and 1980s looking
at oral nitrate reduction were done for the purpose of
exploring possible contributions to carcinogenesis via
N-nitrosamines (Harada et al., 1974; Tannenbaum et al.,
1974, 1976; Ishiwata et al., 1975a,b,c,d; Ishiwata,
1976a,b; Spiegelhalder et al., 1976; Eisenbrand et al.,
1980; Tannenbaum and Correa, 1985), and more re-
cently, concerns have been re-expressed relating to
cancers in the upper GI tract (Iijima et al., 2003).
It is more than 60 years since the first appreciation
that N-nitrosamines were carcinogenic. Six months of
feeding rats with dimethylnitrosamine (50 ppm) pro-
duces large, necrotic hepatocellular carcinoma (Magee
and Barnes, 1956), and long-term supplementation in
rats of other related N-nitrosamines causes malignant
tumors of othermajor organ systems, including esophagus,
stomach, liver, and kidney as well (Magee and Barnes,
1967). These effects are not limited to rats but have been
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found in ;40 other species in which N-nitrosamines are
directly carcinogenic (Bogovski and Bogovski, 1981).
The relevance ofN-nitrosamines to nitrite and nitrate
biology is apparent on understanding that they can
be formed in vitro by incubating gastric juice, nitrite,
and secondary amines (Sen et al., 1969) and in vivo in
humans after dietary ingestion of nitrite-containing
foods (Fine et al., 1977). Endogenous nitrosation reac-
tions can occur from swallowed nitrite, either from
dietary sources or from oral nitrate reduction that can
be protonated to nitrous acid, which can further yield
the powerful nitrosating agent dinitrogen trioxide,
which in turn can nitrosate secondary and tertiary
amines via the addition of nitronium cation, eventually
forming N‐nitrosamines (Leaf et al., 1989; Tricker, 1997).
Ascorbate (vitamin C) and other food-based micronu-
trients such as polyphenols and tocopherol (vitamin E)
inhibit this formation (Bartsch and Frank, 1996),
suggesting that any putative risk relating to dietary
nitrite/nitrate ingestionmay be potentially mitigated in
persons consuming whole vegetables as a source rather
than through water or nitrite-containing meat.
The US National Toxicology Program produced a
technical report studying 2-year drinking water supple-
mentation studies of high levels of nitrite (;16–65mmol/l)
in rodents and concluded that there was no evidence
of carcinogenesis (National Toxicology Program, 2001).
In contrast, the International Agency for Research on
Cancer evaluated the effects of both nitrate and nitrate
on human carcinogenesis and reported (International
Agency for Research on Cancer, 2010) the following:
• inadequate evidence linking dietary and water
sources of nitrate to cancer overall,
• limited evidence linking dietary nitrite to stom-
ach cancer risk,
• inverse risk of dietary nitrate and stomach cancer,
and
• nitrite and nitrate under conditions resulting in
endogenous nitrosation are probably carcinogenic.
In addition, additional expert reports have been
prepared that contend there is no effect. For example,
the WHO Expert Committee on Food Additives con-
cluded that there was no evidence that nitrate was
carcinogenic to humans (Speijers and van den Brandt,
2003). In subsequent large cohorts, fruit and vegetable–
richdiets that exceed theADI severalfoldarenotassociated
with any increase in cancer ormortality (Hung et al., 2004)
andmay indeed offer protection against cancer (World
Cancer Research Fund/American Institute for Cancer
Research, 2007; Boffetta et al., 2010). Epidemiologic
work in this is area is naturally hamstrung by the
methods for data collection in such works. Exposure
estimates for dietary nitrite and nitrate across differ-
ent populations are problematic because of the lack of
widely applicable dietary databases that include the
nitrate and nitrite content of common foods.
Furthermore, there are agricultural issues that alter
nitrate content found naturally in batches of plants. Plants
accumulate nitrate through the roots and use it for novel
synthesis of amino acids and proteins (Vogtmann and
Biedermann, 1985). If the plant does not use the nitrate
immediately, it is stored in vacuoles, and it remains in the
vacuoles if the plants are supplied with more nitrate than
they can use and therefore will be stored more readily in
vegetables with a low rate of photosynthesis (Martinoia
et al., 2007). Hence, vegetables harvested in winter have
higher nitrate content than those harvested in the
summer (https://www.food.gov.uk/research/research-
projects/nitrate-monitoring-in-spinach-and-lettuce-
surveillance-programme). Further variability comes
from the amount of nitrate in irrigation water, potential
use of nitrogen‐containing fertilizers, and postharvest stor-
age (Blom-Zandstra, 1989). This produces a problem when
trying to estimate dietary nitrate intake using databases of
mean nitrate content for epidemiologic purposes. These also
produce a problemwhen trying to consider dietary nitrate as
a therapeutic, though the use of inorganic nitrate salts in
capsule or tablet form (Zand et al., 2011), although excluding
the protective effects of coexistent micronutrients, or con-
centrated, fixed-dose dietary nitrate supplements, could
avoid this (Muggeridge et al., 2014).
A recent National Heart, Lung, and Blood Institute
working group reviewed all these epidemiologic data and
made some recommendations for future research, includ-
ing the addition of location-specific information relating to
nitrate content of foodstuffs; use of urine and plasma
nitrate measures as an index of exposure; addition of
drinking water exposure to dietary databases and ques-
tionnaires; and a focus on subpopulations at risk of
carcinogenesis, such as smokers or those taking supple-
ments (Ahluwalia et al., 2016).
D. Pharmacokinetic Considerations considering
Nitrite and Nitrate as ·NO-Therapeutics
Inorganic nitrate can be thought of as a prodrug for
bioactive nitrite, as it is largely thought to be inert in
mammalian systems unchanged. In almost all disease
areas studied in preclinical and clinical studies to date,
the effect of systemic nitrite elevation through nitrite
or nitrate supplementation (the latter requiring the
enterosalivary conversion to nitrite involving oral
microbiota) are synonymous.
There are possible pharmacokinetic advantages to
oral dosing with nitrate over nitrite, however. Nitrate
has amuch longer half-life in human plasma (;6 hours)
(van Velzen et al., 2008) compared with oral or intrave-
nous nitrite application (Dejam et al., 2007; Hunault
et al., 2009) and, therefore, is appropriate for dosing
with a once-daily regimen. With chronic oral nitrate
dosing, there is sustained nitrite elevation at trough
24 hours postdosing (Kapil et al., 2015; Ahluwalia
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et al., 2016) while nitrite is typically given two to three
times daily (Mohler et al., 2014; DeVan et al., 2016).
Adherence is improved in chronic medical conditions,
such as systemic and pulmonary hypertension, that
could be targeted by nitrite/nitrate therapeutics by
once-daily compared with multiple-times-daily posol-
ogy (Waxman et al., 2013; Vrijens et al., 2017). There is
the additional benefit that dietary nitrate supple-
mentation is applicable on a public health scale through
campaigns to increase vegetable intake (https://
www.nhs.uk/live-well/eat-well/why-5-a-day) and is po-
tentially low-cost and therefore applicable to con-
strained emerging health economies.
VIII. Conclusions
Until recently, the prevailing view ofmammalian ·NO
biology included the production of ·NO uniquely from
the five-electron oxidation of the amino acid L-arginine
by NOS (Stuehr, 1999). However, recent evidence has
proved the existence of an alternative or noncanonical
pathway that utilizes the sequential reduction of nitrate
to nitrite, and thence ·NO, and involves a fundamental,
symbiotic role for hitherto bystander oral microbiota
(Lundberg et al., 2008). This alternative pathway for ·NO
generation is more active in hypoxia and acidosis, a
situation in which the classic L-arginine pathway is
dysfunctional and therefore provides a backup system
for ·NO generation by re-cycling the oxidative prod-
ucts of ·NOmetabolism, with important contributions
from the diet as well. This reveals that nitrite and
nitrate are no longer end products of ·NO metabolism
but exist in a balanced ·NO cycle (Reutov and Sorokina,
1998; Reutov, 2002).
Given the protean roles that have been discovered for
·NO in physiology and pathophysiology, it is not sur-
prising that there has been a wide-ranging exploration
of the potential roles of this new biology. Translational
studies, predominantly in the realm of cardiorespira-
tory disease, have demonstrated beneficial effects with
systemic or local elevation of nitrite levels, whether
achieved directly or after nitrate supplementation and
oral reduction of nitrate to nitrite. The next few years
will see the publication of important outcome studies in
patient populations in need of additional therapeutics
and will determine whether this early evidence trans-
lates into truly beneficial outcomes and useful thera-
peutic medicines.
Or, as said almost 80 years ago by Stieglitz and
Palmer (1937):
“Because of the rapid disappearance of nitrite from
blood and the relative constancy of the level found in
freshly drawn blood, one may tentatively assume that
there is a constant production and destruction of the
nitrite going on in the body.
The source of the nitrite of the blood may be from
administration by any route, absorption of nitrites from
the bacterial reduction of food or drug nitrates in the
lower portion of the bowel or absorption of nitrates and
a subsequent reduction in the blood stream itself or a
reduction of nitrates in the tissues. Any of these sources
may be foci of a more or less constant production of
nitrite…
Nitrite… has profound effects in very small amounts
on a great many functions of the body directly by its
action of relaxing smooth muscle, especially arteriolar
muscle, and indirectly by its effects on the blood flow in
secretory organs.
The exact physiologic significance of the blood nitrite
is uncertain, but it may be that normally it aids in
maintaining those functions which are stimulated by
the administration of therapeutic doses. Clinical appli-
cation of nitrite analysis of the blood may reveal some
correlation between a disturbed nitrite metabolism and
abnormalities of the arterial tension.”
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